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ABSTRACT OF DISSERTATION 
 
 
 
 
 
EARLY EVENTS OF HUMAN METAPNEUMOVIRUS INFECTION 
 
Human metapneumovirus (HMPV) is a worldwide respiratory pathogen that belongs to 
the paramyxovirus family of enveloped viruses and affects primarily the pediatric, geriatric, and 
immunocompromised populations. Despite its prevalence and importance to human health, no 
therapies are available against this pathogen. For paramyxoviruses, it is believed that infection 
starts by attachment of the virus to the surface of the cell through the viral attachment protein 
followed by fusion between the viral and cellular membranes, a process mediated by the fusion 
(F) protein at the plasma membrane and at neutral pH. Previous work showed that HMPV 
infection can occur in the absence of the attachment protein and membrane fusion triggered by 
the F protein can be promoted by low pH. The work presented here are significant advances in 
our understanding of the entry process of HMPV. We confirmed that the F protein has receptor-
binding functions and identified the cellular binding partner to be heparan sulfate proteoglycans 
(HSPGs). Additionally, we provide evidence that electrostatic interactions at two different 
regions play important roles for the proper folding, stability, and low pH triggering of the HMPV 
F protein. We confirmed the hypothesis that protonation of H435 is important for HMPV F 
triggering and provide additional evidence that the entry of HMPV may be occurring through 
endocytosis. Therefore, we hypothesize that HMPV entry occurs through endocytosis after viral 
binding to HSPGs through the F protein and membrane fusion occurs in an acidified 
compartment. 
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Chapter 1: Introduction 
 
Paramyxoviruses: Classification and Relevance to Human Health 
The paramyxovirus family includes multiple viruses that are of importance to global 
economics and human health. Among the members of the family are well-known, highly 
infectious worldwide human pathogens such as measles virus (MeV), one of the most 
contagious human diseases known and the causative agent of an estimated 164,000 deaths in 
2008 despite aggressive eradication efforts (1); respiratory syncytial virus (RSV), the leading 
cause of lower respiratory tract infections in infants and children worldwide causing about 34 
million infections and approximately 3.4 million hospitalizations every year in children under the 
age of five (130, 229); and the more recently characterized human metapneumovirus (HMPV, 
described below). Besides causing respiratory disease, human parainfluenza virus types 2 and 3, 
like mumps virus (MuV), have also been implicated as causative agents of myopericarditis (111, 
375). Parainfluenza viruses have also been identified as a significant cause of morbidity and 
mortality in pediatric organ transplant patients (10). Furthermore, two highly pathogenic 
zoonotic paramyxoviruses, Hendra (HeV) and Nipah (NiV) virus, emerged at the turn of the 
century and cause fatal encephalitis and mortality rates that can reach 70% (379). 
Paramyxoviruses also cause disease in other species (such as parainfluenza virus 5 [PIV5] and 
Sendai virus [SeV]), some of which bring about a tremendous economic burden to society by 
causing serious, and sometimes fatal, disease in poultry (Newcastle disease virus [NDV] and 
avian metapneumovirus [AMPV]), cattle (bovine RSV [BRSV]), horses (HeV), and pigs (NiV) (68, 
127, 180, 183, 208, 225).  
While these viruses share many common characteristics, such as possessing a anti-sense 
single-stranded RNA genome and a lipid bilayer envelope (180), there are also many unique 
aspects in their lifecycles. Based on morphologic criteria, the activity of their proteins, and 
sequence homology, viruses in this family are divided into seven distinct genera, of which five 
belong to the paramyxovirinae subfamily and the remaining two are grouped in the 
pneumovirinae subfamily. Thus, viruses like RSV and HMPV are classified in the pneumovirinae 
subfamily while MeV, SeV, NDV, the henipaviruses, and the parainfluenza viruses are part of the 
paramyxovirinae subfamily (Figure 1A). Several recently discovered paramyxoviruses such as J 
virus, Mossman virus, and Salem virus have not yet been classified within a subfamily (180). 
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Human Metapneumovirus and Medical Relevance 
HMPV was discovered in 2001 in the Netherlands in nasopharyngeal aspirate samples 
from children suffering from respiratory tract infections, making it the first representative of the 
metapneumovirus genus to cause human disease and the third paramyxovirus that primarily 
infects the respiratory tract (352). Despite the relatively recent discovery of HMPV, serological 
studies confirmed that HMPV has been infecting humans for over half a century (352). 
Phylogenetic analysis divides HMPV strains into 2 major genetic lineages which can be further 
subdivided into 2 subgroups each (designated A1, A2, B1, and B2). While concurrent circulation 
of all four subtypes is common, a single, usually different, subtype usually predominates each 
year (46, 148, 195, 261).  
HMPV causes respiratory tract disease worldwide, producing yearly epidemics with a 
typical seasonal distribution in temperate climates (105, 154, 159, 196, 238, 258, 261, 352). Due 
to the ubiquitous presence of HMPV across the world, virtually all children are exposed to this 
virus by age five (252, 352). Unfortunately, this virus induces only incomplete immunity, 
increasing the chances of multiple infections throughout life (363). Thus, HMPV infection is not 
only a concern in the pediatric population but also a concern in older populations (112, 113, 
252, 363). Symptomatic and severe disease usually occurs in young children, older adults, and 
immunocompromised individuals, many times resulting in admission into the intensive care unit 
and the use of mechanical ventilation. However, HMPV can cause upper and lower respiratory 
tract infection in all age groups (38, 39, 113, 172, 252, 300, 363). Furthermore, adults with 
cardiopulmonary conditions are far more likely to require medical attention as a result of HMPV 
infection (112, 363). 
Symptoms of HMPV infection are clinically indistinguishable with those seen with RSV, 
likely contributing to mis- and under-diagnosis of the disease (93, 374). The most common signs 
and symptoms of HMPV infection include cough, rhinitis, fever, and wheezing (376). More 
severe infections can result in bronchiolitis, croup, asthma exacerbation, and pneumonia 
requiring hospitalizations (38, 87, 109, 178, 352). Febrile seizures are more common with HMPV 
than RSV (113) and acute otitis media is seen in up to one third to one half of HMPV infections 
(87). Though largely restricted to respiratory tract disease, HMPV RNA has been detected in the 
brain of a patient who suffered from a fatal case of encephalitis (294). Most studies indicate that 
between 5 and 15% of respiratory tract infections are caused by HMPV infection – second in 
frequency only behind RSV (39, 110, 112, 205, 261, 353, 354, 363). Despite the high prevalence 
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of HMPV and the burden it signifies to human health, there are currently no approved antiviral 
therapies against infection from this virus.  
 
Paramyxovirus Structure, Its Surface Glycoproteins, and Their Role in Entry 
Paramyxoviruses possess a lipid bilayer envelope that is derived from the plasma 
membrane of the host cell. The non-segmented RNA genome of paramyxoviruses, which contain 
six to ten tandemly linked genes, is contained within the helical nucleocapsid core composed of 
the nucleocapsid (N), phospho- (P), and large (L) protein. The overall morphology of the viral 
particle is thought to be regulated by the matrix protein (M), which interacts with the 
nucleocapsid core, the viral envelope, and the surface glycoproteins. Some paramyxoviruses 
also encode accessory proteins, usually as additional transcriptional units interspersed with the 
invariant genes (180). Compared to pneumoviruses like RSV, metapneumoviruses lack the non-
structural proteins NS1 and NS2 and the order of the genome is different: RSV (3’-NS1-NS2-N-P-
M-SH-G-F-M2-L-5’), HMPV (3’-N-P-M-F-M2-SH-G-L-5’) (29, 164, 352). 
Out of the six to ten genes present in the genomes of paramyxoviruses, only two or 
three of the encoded proteins are expressed at the surface of the virus (Figure 1B). For 
enveloped viruses, the surface glycoproteins are used by the virus to identify and attach to their 
cellular receptors and promote viral-cell membrane fusion, a process that allows the 
nucleocapsid to enter the cellular cytoplasm. The rest of the encoded proteins are primarily 
involved in viral genome transcription/replication or assembly. Paramyxovirus entry occurs 
through virus-cell membrane fusion and is usually mediated by the attachment protein (H, HN, 
or G) and the fusion protein (F) (180).  
In addition to the presence of the fusion and attachment glycoproteins on the viral 
surface, three of the seven genera of paramyxoviruses, including members of the 
pneumovirinae subfamily, also express a third putative viral surface glycoprotein, the small 
hydrophobic protein (SH). To date, there is no evidence to suggest that the SH protein plays a 
direct role in the virus attachment and entry steps. Interestingly, unlike the fusion and 
attachment proteins, the SH protein is much less conserved across the family; in addition to the 
low sequence conservation among members of the family, some SH proteins are type I proteins 
and some, like that of PIV5 and the pneumoviruses, are type II (31, 339). The exact function of 
the SH protein is not known and studies have shown that mutant viruses devoid of this protein 
remain infectious and retain their growth properties in vitro ((27, 31, 136)and see results). In 
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fact, it has been shown that the rate of mutation for wild type HMPV SH is the highest compared 
to the rest of the proteins in the genome (26). Even though these studies suggest that SH is not 
essential for viral infection and replication, all clinical isolates at least for HMPV (26) and mumps 
(377) contain an intact SH gene, suggesting that the SH protein must be serving an important 
function for the virus to retain this protein in its genome. Furthermore, several in vivo studies 
have shown that viruses like RSV and PIV5 (53, 137, 370), but not HMPV (31), are attenuated 
when the SH protein is absent. This difference between in vitro and in vivo studies could be due 
to the role of SH in cell signaling. Indeed, studies with RSV (117), PIV5,and mumps suggest that 
SH antagonizes the induction of apoptosis and, like HMPV (13) , may also block the activity of 
NF-κB (377). 
 
Paramyxovirus Attachment Proteins and Viral Receptor Binding 
The attachment proteins of rubulaviruses, respiroviruses, and avulaviruses have both 
hemaglutinin (sialic acid binding) and neuraminidase (sialic acid cleaving) functions and are 
called HN proteins. Viruses with an HN protein use cellular surface sialic acid as their receptors 
with various degrees of affinity (360). The attachment proteins of morbilliviruses (H) lack 
neuraminidase activity but can bind sialic acid. However, morbilliviruses use cellular proteins, 
such as CD46, CD150/SLAM, and nectin-4, in the case of MeV (223, 240, 264), as receptors for 
attachment. Henipaviruses and members of the pneumovirinae subfamily have attachment 
proteins that do not bind sialic acid and are named G (for glycoprotein). Hendra and Nipah G 
bind to cellular Ephrin B2/B3 (41, 232, 233) whereas previous reports have shown that 
pneumovirinae G proteins bind to heparan sulfate proteoglycans (174, 347). In addition to 
mediating the initial attachment of the virus to a cell, attachment proteins of most 
paramyxoviruses also have fusion promoting activity as coexpression of the homotypic 
attachment and fusion proteins is required for membrane fusion and viral spread to occur (4, 
185, 251, 264, 266, 271, 272, 330, 340, 382). The cascade of events occurring after receptor 
binding that leads to the triggering of the F protein, however, remains largely unknown. 
All paramyxovirus attachment proteins characterized to date are homotetrameric type II 
integral membrane proteins (180). They are made up of a membrane-proximal stalk and a large 
c-terminal globular head domain anchored by a single-pass N-terminal transmembrane domain 
(180). The crystal structure of the globular head domain of several paramyxovirus attachment 
proteins, including NDV HN, PIV5 HN, PIV3 HN, MeV H, HeV G, and NiV G, has been solved, 
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showing that this domain is composed of four six-blade β-propeller fold monomers arranged in a 
four-fold symmetry (43, 50, 79, 135, 184, 381, 386). Substantial evidence suggests that the stalk 
domain of paramyxovirus attachment proteins is likely a helical coiled-coil that in many cases 
interacts with and determines the specificity of the fusion protein (89, 90, 209, 264, 341). The 
latest crystal structures of NDV and PIV5 HN have, in fact, provided further evidence that the 
stalk domain is a tetrameric coiled-coil as the portion proximal to the head domain was 
observed (43, 385). For most HN attachment proteins, the binding site to sialic acid is located at 
the top of the globular head and at the center of the β-propeller fold of each monomer (386). 
However, the crystal structure of NDV HN protein shows a second sialic acid binding site located 
at the dimer interface (48, 387). Inhibitor-based studies and studies of mutant viruses also 
suggest the presence of a second sialic binding site for PIV3 HN that is important for fusion 
promotion and not for receptor avidity (250, 269, 270). Interestingly, this the second binding 
site was not detected in the crystal structure of PIV3 HN (184) and a more recent study provided 
evidence that, similar to PIV1 HN (9), this site in PIV3 HN may be covered by N-linked glycans 
(216). Thus, the importance of this second sialic acid binding site is still not fully understood. 
Though the morbillivirus H and henipavirus G proteins have adapted to bind to their 
proteinaceous receptors, a site analogous to the sialic acid binding site of HN proteins can be 
found in these H or G proteins, suggesting that they have evolved from a HN-like protein (49, 70, 
135). While the binding site for Ephrin B2/B3 in the henipaviruses is also located at the top of 
the head domain of each monomer (50, 381), the binding site in MeV H to CD46/SLAM is located 
toward the sides of the β-barrel of each monomer (70, 134).  
While multiple reports indicate that the interaction between the attachment and the 
fusion proteins regulates the fusogenic activity of paramyxovirinae virus F proteins, studies have 
shown that both RSV and HMPV are infectious in the absence of their highly glycosylated G 
protein ((27, 31, 65, 164, 346) and results). Furthermore, cell-to-cell fusion promoted by the F 
protein of HMPV occurs without coexpression of HMPV G ((65, 143, 298, 299) and results). 
Recent reports have shown that RSV F interaction with cell surface nucleolin and HMPV F 
interaction with heparan sulfate proteoglycans can mediate viral binding to target cells ((65, 80, 
342) and results). In addition, it has been shown that β1 integrin plays an important role in 
promoting HMPV infection (65, 80). These observations suggest that, unlike members of the 
paramyxovirinae subfamily, receptor binding activity for members of the pneumovirinae 
subfamily can occur through the F protein and receptor interactions with the G protein are not 
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essential. Interestingly, RSV produces a soluble form of the G protein that plays a role in 
immune evasion (306). Therefore, while the attachment protein is required for viral entry of 
members of the paramyxovirinae subfamily, more studies are needed to determine the precise 
role of the pneumovirinae G protein in viral entry. 
 
Paramyxovirus F Proteins: Structure and Function 
All paramyxoviruses discovered to date express a homotrimeric type I fusion protein. 
Like other class 1 fusion proteins such as those of influenza, Ebola and HIV, paramyxovirus F 
proteins have a hydrophobic fusion peptide (FP), two heptad repeat regions (HRA and HRB), are 
anchored at the surface by a single-pass transmembrane domain (TM), and contain a short, 20 
to 40 amino acid residue c-terminal cytoplasmic tail (180). Paramyxovirus fusion proteins are 
synthesized as a biologically inactive F0 precursor form which must then be cleaved into the 
fusogenically active F1+F2 metastable prefusion form (Figure 2A). Upon triggering, the F protein 
undergoes extensive and irreversible conformational changes that result in the repositioning of 
the heptad repeat regions to form a stable six-helix bundle (6-HB), a process intimately linked to 
membrane fusion. Due to its ability to fuse two different membranes, the expression of the F 
protein in the surface of transfected or infected cell can result in the fusion of the membranes of 
neighboring cells resulting in the formation of giant, multinucleated cells named syncytia. 
Syncytia formation is a hallmark of infection by many of these viruses and a valuable tool in the 
diagnosis and study of paramyxoviruses (144, 180, 243).  
While amino acid sequence alignment shows minimal sequence conservation, structural 
and biochemical analysis suggest a similar structure among paramyxovirus F proteins. Analysis 
of the crystal structure of the uncleaved, GCNt-stabilized PIV5 F protein in its prefusion 
conformation showed a large globular head domain connected through the HRB-linker region to 
a membrane-proximal stalk region composed of the three HRB domains forming a three-helix 
coiled-coil (Figure 2B) (384). In this metastable state, HRA (orange) is located at the top of the 
globular head domain and the fusion peptide (blue) is buried between two subunits of the 
trimer with its N-terminus exposed to the surface for cleavage. HRB (green) is located proximal 
to the lipid bilayer and is anchored by a TM domain which, in the crystal structure, was replaced 
by a GCNt trimerization domain. Though the structure of the TM domain is absent from the 
crystal structure, evidence supports a helical structure which self-interacts (36) and recent 
studies indicate that TM domains of paramyxoviruses self-associate into trimers and may help 
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stabilize the prefusion conformation ((313) and Smith, et. al, manuscript submitted for 
publication). Furthermore, several studies indicate that this domain is important for the activity 
of class 1 F proteins and serves as more than just an anchor to the lipid membrane (36, 211, 217, 
313). 
Crystal structures of the fusion protein in the more stable postfusion conformation 
obtained from NDV F (336), hPIV3 (383), and RSV F (207) revealed a strikingly different 
conformation (Figure 2B). While these proteins remained trimeric in the postfusion state, the 
extensive intersubunit contacts in the prefusion form are disrupted, HRA (orange) forms a new 
three-helix coiled-coil projecting away from the base region of the head domain, and HRB 
(green) translocates to the opposite side of the protein, packing against the HRA coiled-coil and 
creating the characteristic 6-HB. This drastic refolding of the fusion protein creates new 
intersubunit contacts and disrupts many of those found in the prefusion conformation, creating 
an overall more compact and stable structure (180). Recent studies suggest that the FP adopts a 
helical structure important for fusion (Smith, et. al. manuscript in preparation), and that the FP 
both associates with itself and with the TM domain (95). 
 
Paramyxovirus F Cleavage Activation 
To be fusogenically active, paramyxovirus F proteins must be proteolytically cleaved 
from the precursor F0 form to a disulfide-linked F1+F2 heterodimer (Figure 2A). Indeed, cleavage 
of the F protein is an essential step for pathogenicity of the virus. Cleavage activation, which 
occurs after one or more basic residues (180), creates a new N-terminus in F1, properly positions 
the fusion peptide, and may lower the activation energy barrier for triggering (100, 256, 280). 
The cleavage event for most paramyxovirus F proteins such as those of PIV3, NDV, RSV, and 
MeV occurs during transport through the trans-Golgi network, and is promoted by furin, a 
ubiquitous subtilisin-like cellular endoprotease that recognizes an R-X-K/R-R motif (40, 125, 126, 
170, 247). Cleavage by a furin protease, however, is not ubiquitous for F proteins, as not all 
paramyxovirus F proteins contain this consensus sequence. Henipavirus F proteins do not 
contain a furin cleavage site and are cleaved after a single basic residue by the cysteine-protease 
cathepsin L following an endocytic event that brings the F0 precursor protein from the surface 
back to an endosomal compartment (91, 92, 248, 249). Furthermore, some F proteins such as 
those of HMPV and Sendai virus are cleaved by an extracellular protease, a process supplanted 
in cell culture by the addition of trypsin (31, 224, 299, 352). In vivo, the F proteins of these 
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viruses are likely cleaved by exogenous proteases such as TMPRSS2 and mini-plasmin after 
budding to further promote infection (30, 224, 307). Interestingly, all paramyxovirus F proteins 
described to date are activated with a single cleavage event with the exception of RSV F protein, 
which expresses two consensus sequences for furin cleavage. Cleavage at both sites is necessary 
for fusion activity of RSV F (19, 125). 
The cleavage of the F protein may result in structural rearrangements of the F protein, 
as peptide antibodies against the heptad repeat regions of PIV5 recognized primarily the 
uncleaved form of PIV5 F (99). Furthermore, replacement of the cleavage site in Sendai F with 
the cleavage sites of RSV F rendered the F chimera capable of promoting syncytium formation in 
the absence of its homotypic HN protein (280), suggesting that alterations at the cleavage site 
can affect triggering of the F protein. While some studies with NDV F indicate that cleavage of 
the F protein is a determinant of virulence, as NDV F proteins with multibasic cleavage sites are 
more virulent than those with a single basic cleavage site (227, 228), a recent study with APMV-
2 strain Yucaipa, which lacks the furin consensus sequences but replicates in the absence of 
exogenous proteases (332), suggests that the cleavage site plays an important role for viral 
replication in vitro but does not alter the virulence of the virus (331). Therefore, the cleavage 
event may determine pathogenicity in some paramyxoviruses. 
 
Triggering of Fusion, the Role of the Attachment Protein, and Low pH 
Because the refolding of the fusion protein from the prefusion to the postfusion 
conformation is essentially irreversible, it is critical that the fusion protein is triggered at the 
right place and time. Triggering in the absence of a proper target membrane would inactivate 
the F protein (44, 57, 73). Therefore, the triggering of paramyxovirus F proteins must be 
temporally and spatially regulated. For the majority of paramyxoviruses, it is hypothesized that 
specific interactions between cell surface receptors and the viral attachment proteins trigger the 
F protein conformational changes as the expression of the homotypic attachment protein is 
required for F to promote membrane fusion (104, 180). Studies have shown that the F protein 
and the attachment protein interact for a number of paramyxoviruses and that these specific 
interactions are required for triggering (4, 34, 230, 266, 268, 272, 330, 340, 382). Interactions 
between the F protein and the attachment protein have been primarily shown to occur at the 
head region (185) of F. While many studies indicate that the stalk domain of the attachment 
protein is responsible for interactions with the F protein (33, 90, 209, 230, 271, 341), residues in 
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the TM domain (47, 206) and the globular head domain (3, 34, 215) have also been shown to 
affect F interactions. It is hypothesized that upon receptor binding, conformational changes in 
the attachment protein alter the interaction with the F protein, signaling the F protein to trigger 
(79, 230, 381, 387). However, a recent study indicates that the continuous activation of the F 
protein by the attachment protein was required throughout the fusion process (268), suggesting 
a more complex interaction.  
For some paramyxoviruses such as NDV and PIV3, it has been shown that the extent of 
fusion activity is directly proportional to the strength of the interaction between the fusion 
protein and the HN attachment protein (210, 268, 271). It is therefore hypothesized that the 
attachment protein could be acting as a molecular scaffold that facilitates the triggering of the 
fusion protein upon receptor binding (180). However, fusion activity is inversely related to the 
strength of morbillivirus H and henipavirus G interactions with their respective F protein (5, 
266), suggesting that the mechanism by which the attachment protein regulates the triggering 
of the fusion protein is different between viruses. Interestingly, previous studies have shown 
that MeV H associates with MeV F intracellularly (265). Therefore, it is hypothesized that the 
dissociation of the intracellularly-formed F-H complexes at the surface upon receptor binding 
allows the F protein of MeV to trigger (152). An intracellular interaction was not detected 
between HN and F of PIV5and hPIV3 (255), and studies detected either no interaction (191) or 
extremely low levels of interaction (330) between NDV F and HN.  In addition,  cotrafficking of 
Hendra F and G proteins was not observed (372), suggesting that the MeV model for 
intracellular association is not a universal feature for the paramyxovirus family.  
Triggering of the F protein in the absence of its homotypic attachment protein has been 
documented for some paramyxoviruses like PIV5 and SeV, although the presence of the 
attachment protein dramatically enhances fusion activity in these cases (102, 189). 
Furthermore, mutations in the NDV F, Sendai F, and PIV5 F can remove the dependency on the 
homotypic attachment protein for triggering (12, 102, 280, 301, 303). Other mutagenesis studies 
have shown that the HRB-linker region (289, 298), portions of HRA (193), and a region in F2 that 
interacts with HRA (121) are all important for the triggering of F, suggesting that multiple 
regions of the F protein regulate this process. For viruses belonging to the paramyxovirinae 
subfamily, fusion can be triggered by raising the temperature in the absence of the attachment 
protein (256, 369), suggesting that the attachment protein of these viruses helps lower the 
energy of activation for F triggering to occur. 
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Interestingly, it has been shown that the fusion protein of wild type RSV and HMPV 
alone can promote membrane fusion. Furthermore, RSV and HMPV virions remain infectious in 
the absence of their homotypic G protein (31, 160, 163, 164, 299, 343). While the majority of 
paramyxoviruses induce cell-cell fusion when their glycoproteins are expressed in cultured cells 
(17, 35, 180, 302), suggesting that the F proteins of these paramyxoviruses promote fusion 
under neutral pH conditions, low pH has been shown to trigger the F protein of some strains of 
HMPV (143, 299). Studies of viruses with better-characterized low pH-triggering fusion proteins 
such as influenza and rhabdovirus vesicular stomatitis virus (VSV) suggest that triggering of 
these fusion proteins are also regulated by multiple regions within the protein, with histidine 
residues within the protein having particularly important regulatory role in the regulation of this 
process (282, 323, 325, 348). With a pKa of 6.04, histidine residues are the amino acids most 
likely to ionize within the physiological pH range (361). However, several charged, non-histidine 
residues have also been shown to play an important part alter the pH threshold for triggering 
influenza HA (325, 348). Mutagenesis studies of low-pH dependent HMPV also suggest that the 
protonation of a critical histidine residue at position 435 plays a large role in the low pH 
dependency of the F protein (65, 203, 298). While the exact mechanism by which low pH 
triggers certain HMPV F protein is still unclear, changes in electrostatic interactions between 
residues that become protonated at low pH could provide the driving force for F protein 
triggering (56, 146, 298). The low pH dependency of certain HMPV strains and the observation 
that wild type F proteins of members of the pneumovirinae subfamily can trigger in the absence 
of the attachment protein suggest that the regulation of this process is different between the 
two subfamilies. Therefore, a precise role for the G protein of pneumovirinae viruses is still 
unknown. 
It is apparent that the regulation of F triggering is a complex process and varies between 
members of the family. For most paramyxoviruses, it is thought that receptor interactions with 
the attachment protein trigger the fusion protein. While more studies are needed to elucidate 
the details on the precise mechanism by which triggering is regulated, five models have been 
proposed for the role of attachment protein interactions on triggering of the F protein. One 
model, supported by studies of MeV (265, 266) and NDV (330), suggests that the fusion and 
attachment proteins interact at the endoplasmic reticulum during synthesis and trafficking to 
the cell surface, with the attachment protein potentially holding the fusion protein in its 
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prefusion conformation. After receptor binding, the attachment protein releases the fusion 
protein and allows it to trigger (Figure 2C, model A).  
Alternatively, the fusion and attachment proteins could travel independently to the cell 
surface, where they then interact until receptor binding disrupts this interaction and allows the 
fusion protein to trigger (Figure 2C, model B). This model is supported by studies in HeV and NiV, 
where fusion activity and F-G avidity are inversely correlated (4, 5, 34), but HeV and NiV F 
undergo a unique endocytic recycling process for cleavage (92, 248, 249), and differential rates 
of F and G folding in the ER and trafficking through the secretory pathway have been observed 
(371, 372). Recent studies with hPIV3 show that the attachment and fusion proteins associate 
before receptor engagement, and this interaction is required beyond the triggering step (268, 
272). These observations are in agreement with an earlier study showing that the extent of 
fusion promoted by hPIV3 F was dependent on the surface density of hPIV3 HN (102) and 
suggest that the attachment protein actively participates in the entire fusion process. 
A third proposed model suggests that the attachment and fusion proteins do not 
interact until after receptor attachment, with the subsequent interaction between the two 
glycoproteins allowing F to trigger (Figure 2C, model C). This model is supported by studies with 
NDV where F-HN interactions are seen only in the presence of receptor, and mutations altering 
receptor binding of HN decrease F-HN interactions and fusion (76, 210). In addition, bimolecular 
complementation studies of PIV5 F and HN showed increased association of the tagged proteins 
and corresponding increases in fusion, suggesting that much of the F protein was not normally 
associated with HN (74).  
Fusion proteins from RSV, HMPV, and other paramyxoviruses that do not require the 
expression of the attachment protein to induce membrane fusion demonstrate that interactions 
between the two glycoproteins are not absolutely required for triggering of all paramyxovirus F 
proteins (299). For these viruses, interactions between the attachment protein and cell surface 
proteins such as heparan sulfate proteoglycans (344, 347) may facilitate fusion by bringing the 
two membranes in close proximity, with F subsequently interacting with a cellular receptor 
(Figure 2C, model D). However, attachment protein interactions with cellular proteins are 
dispensable for RSV and HMPV, indicating that the F proteins of these viruses are capable of 
performing the attachment step (65, 176, 344) (Figure 2C, model E). 
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Paramyxovirus F-Induced Membrane Fusion 
For paramyxoviruses to gain access to the host cell, they must overcome two lipid 
barriers that separate the genomic contents of the virus from the cytoplasm. Therefore, 
paramyxoviruses must unite two lipid bilayers during entry, a process that is very energetically 
unfavorable. This energy barrier is thought to be surmounted in an ATP-independent manner 
through the irreversible conformational changes of the fusion protein that occur after triggering 
which provide the energy required to merge the two membranes. Refolding from the 
metastable prefusion form to the lower energy postfusion state ultimately leads to the creation 
of a fusion pore allowing the viral contents to be released into the cytosol. 
Our understanding of the mechanism of paramyxovirus F protein-mediated membrane 
fusion has increased greatly over the last decade largely due to the availability of crystal 
structures of fusion proteins in the prefusion and postfusion conformations. The postfusion F 
structures of three paramyxoviruses, hPIV3 F (383), NDV F (336), and RSV F (207), have been 
solved and show that key elements are conserved, such as the formation of a six-helix bundle 
through the juxtaposition of HRA and HRB. The prefusion structure of PIV5 F (384) is also 
available and, together with the postfusion structures, suggest that paramyxovirus fusion 
proteins undergo a “spring-loaded mechanism” of fusion similar to that of influenza HA (57, 58). 
It is hypothesized that, upon triggering, the HRB coiled-coil present in the prefusion form region 
melts, creating the open stalk form. Changes in interactions around HRA and the fusion peptide 
lead to projection of the fusion peptide towards the target membrane and refolding of HRA into 
a trimeric alpha-helical coiled-coil (pre-hairpin intermediate). Mutagenesis and peptide 
inhibition studies support the existence of both intermediates, as peptides that mimic HRA can 
block fusion at an earlier step compared to peptides that mimic HRB (256, 288, 289). More 
direct evidence of the existence of the pre-hairpin intermediate was recently obtained through 
electron microscopy and computational studies, which confirmed a distance between the 
membranes consistent with a pre-hairpin intermediate (167). Changes in the globular head then 
reposition HRB in an anti-parallel fashion with the grooves of HRA, forming a stable 6-HB and 
facilitating the opening of the fusion pore (Figure 3). The formation of the fusion pore likely 
requires the simultaneous refolding of more than one trimeric F protein, as cells expressing PIV5 
HN and very low amounts of PIV5 F were able to bind red blood cells without promoting 
membrane fusion (102). 
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The requirement for the formation of the 6-HB in paramyxovirus F proteins for 
membrane fusion underscores the importance of the HRA and HRB domains as well as the 
regions around them for the fusion activity of the protein. However, several studies suggest that 
both HRA and HRB play other important roles in addition to forming the 6-HB. Conserved 
domains in the F2 subunit and in HRA, for instance, are seen packed against each other in the 
crystal structure of the prefusion form of PIV5 F and are likely stabilizing the prefusion state 
(384). Mutations in these domains were shown to modulate the fusion activity of PIV5 F (121, 
368). Furthermore, a single mutation in the F2 subunit of PIV5 F (L22P) allowed for the triggering 
of the fusion protein in the absence of the homotypic attachment protein (256). Residues 
around the HRB domain have also been implicated in modulating the fusogenic activity of PIV5 
F. Mutagenesis studies showed that changes in residues located in the HRB-linker region led to 
an increase or decrease in fusion depending on the side chain substituted (289). Furthermore, 
the mutation S433P, located just N-terminal of HRB, led to an increase in the rate and the extent 
of fusion promoted by PIV5 F (256). 
While the importance of HRA and HRB in promoting membrane fusion has clearly been 
established, a substantial amount of evidence recently obtained also suggests a regulatory role 
for the cytoplasmic tails of paramyxovirus glycoproteins. It is thought that cytoplasmic tails 
transmit a signal to the ectodomain that regulates the conformational changes during 
membrane fusion, as changes in both the length and sequence of the cytoplasmic tail have been 
reported to alter the fusogenic activity of the F protein (267, 366). Furthermore, deletion of the 
cytoplasmic tail of PIV5 F affects fusion pore expansion (103), and F protein chimeras with 
cytoplasmic tails from other paramyxoviruses also led to changes in F protein expression and 
activity indicating that the correct sequence needs to be in place for fusion to occur (391). 
Interestingly, truncation of the MeV H tail also alters fusogenic activity, suggesting that the 
cytoplasmic tails of attachment proteins also play a regulatory role in membrane fusion (219). 
Recent work on fusion peptides has also shed light on the importance of these 
membrane-interacting regions in the refolding of paramyxovirus fusion proteins. Evidence to 
date indicates that fusion peptides are highly conserved between paramyxoviruses and adopt an 
alpha-helical structure upon contact with membranes (95). Analytical ultracentrifugation studies 
have determined that fusion peptides assemble cooperatively into hexamers in a lipid 
environment (95). Indeed, mutations affecting the alpha-helical nature of the peptide decrease 
the efficiency of HeV F protein-promoted membrane fusion (Smith, et al, manuscript submitted 
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for publication). Interestingly, alanine substitution of conserved glycine residues in the fusion 
peptide of PIV5 F resulted in an increase in fusion activity and a loss of dependency on the HN 
protein. However, mutations of the same glycine residues in hPIV3 F and NDV F did not allow 
the fusion protein to promote fusion in the absence of the attachment protein (287). 
Furthermore, mutation of the conserved glycine residues altered the expression and processing 
of HeV F (Smith, et al, manuscript submitted for publication). These observations suggest that 
these residues may be important in providing stability to the prefusion form and in regulating 
the kinetic barrier of F protein activation. 
More than serving as mere anchors for the ectodomains of paramyxovirus F proteins, 
TM domains have been shown to play an important role in regulating F triggering and fusion. A 
glycophosphatidylinositol (GPI) anchored influenza HA protein, another class I fusion protein, 
does not promote aqueous content mixing in fusion assays, indicating that, for a class I fusion 
protein, a proteinaceous TM domain is required to promote membrane fusion (165, 200). 
Interestingly, membrane fusion was abolished when the TM domain of NDV F was replaced with 
that of MeV F or SeV F even though these mutant proteins were transported to the cell surface 
and proteolytically cleaved (128), suggesting that either the TM domain is important in 
triggering, or alterations in the TM affect F ectodomain conformations, resulting in fusion 
defects. Though structures of paramyxovirus fusion protein TM domains are not available, 
current evidence suggests that they are composed of interacting alpha-helices (36). 
Furthermore, recent sedimentation equilibrium studies showed that the TM domains of several 
paramyxovirus F proteins self-associate into trimers and that mutations in the GxxxG motif of 
the HeV F TM domain, known to mediate helix-helix association (286), altered this association 
leading to a decrease in fusogenic activity (Smith, et. al., manuscript submitted for publication). 
Interestingly, the addition of the HRB domain to the isolated HeV F TM domain destabilized the 
trimeric interactions between TM domains suggesting that interactions in the head domain and 
in the TM domain are important for stabilizing the prefusion coiled-coil formed by HRB (313). 
 
Endocytosis and Viral Entry into Cells 
Viruses have evolved a variety of mechanisms to gain access to host cells and ensure 
their survival despite the complex protective machinery implemented by the host. In general, 
after receptor binding, enveloped viruses enter the target cell either through direct penetration 
at the plasma membrane or by receptor-mediated endocytosis. Endocytosis is a process utilized 
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by cells to internalize molecules from the extracellular environment. Undoubtedly, the most 
studied pathway is that of clathrin-dependent endocytosis (20), a process that is orchestrated by 
the AP-2 complex, which, aided by Eps15, allows clathrin to form a network around an area that 
invaginates and becomes a vesicle. The final formation of the clathrin-coated vesicle, however, 
is dependent on the GTPase activity of dynamin (20). Influenza, VSV, and dengue virus are 
among the many viruses that use this pathway for entry (81, 201, 355). 
A second characterized pathway is caveolin-dependent endocytosis (204, 260), where 
the small invaginations of the plasma membrane (caveolae) are rich in cholesterol, lined with 
the protein caveolin-1, and regulated by cavin-1 (145, 260). While cargo uptake through this 
pathway has been difficult to study due to its infrequent budding, the pathway also requires 
dynamin to form the final vesicle (204, 253, 260). BK virus and echovirus-1 are examples of 
viruses that have been proposed to enter in a caveolin-dependent manner (98, 201, 234). 
Pathways independent of clathrin and caveolin also exist (204) and viruses like HIV and the 
human papilloma virus (HPV) are hypothesized to use some of those pathways for entry (319, 
357). These pathways, however, are not well understood and their players have yet to be 
elucidated.  
Regardless of the initial endocytic pathway used for cargo uptake, it appears that these 
vesicles transport cargo into acidified endosomes (259), where cargo is subsequently sorted and 
delivered to their target compartment. Much of this intracellular trafficking is regulated by Rab 
GTPases (Figure 5) (326). For instance, Rab5 is required for the formation of early endosomes 
while Rab7 is needed for early to late endosomal trafficking. Rab9 and Rab11 are both needed 
for trafficking to the trans-Golgi network. Rab11 is also needed for recycling endosomal 
trafficking (326). Many viruses need to reach different stages in the endocytic pathway before 
triggering membrane fusion. HIV-1, for instance, needs Rab5 and Rab7 but not Rab11 for 
infection indicating that HIV-1 likely needs to reach the late endosomal stage but not the 
recycling endosomes for fusion (358). HPV-31, on the other hand, requires Rab5 but not Rab7, 
which suggests that this virus escapes the endosomal pathway at an early stage (317). 
A significant amount of knowledge has been obtained on the route of entry for viruses 
with low-pH dependent fusion proteins such as influenza and VSV. These viruses take advantage 
of the increased acidity of the endocytic pathway to trigger their fusion proteins and deliver 
their genomic content to the cytoplasm of the cell (37, 81, 116, 311). Some of these viruses, 
however, still require prior receptor binding to trigger fusion (221, 316). Additionally, some 
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viruses like Ebola exploit the presence of cellular proteases in these low-pH environments to 
activate their fusion proteins (62). 
In contrast to viruses with low-pH dependent fusion proteins, viruses that have pH-
independent fusion proteins such as most paramyxoviruses, herpesviruses, and retroviruses 
have been thought to enter cells at the plasma membrane, where the pH is neutral (Figure 4A) 
(35, 144, 179). This hypothesis is substantiated by the ability of their fusion proteins to promote 
syncytium formation when expressed at the cell surface under neutral pH and by infectivity 
studies in the presence of agents that prevent the acidification of endosomes (bafilomycin and 
ammonium chloride among others) (203, 320). However, direct evidence of viral entry at the cell 
surface has not been obtained. Indeed, low pH does not inhibit the activity of the fusion 
proteins of paramyxoviruses like PIV5 (35), HeV (A. Chang and R.E. Dutch, unpublished results), 
RSV (320), NDV (54, 292), and pH-independent strains of HMPV (203). Furthermore, RSV and 
NDV fusion, as assessed by a R18 dequenching assay, is enhanced in acidic environments (54, 
292, 320). Therefore, the pH requirement for fusion does not necessarily clarify the location of 
the fusion reaction. 
Recent studies suggest a more complex mechanism of cell entry for viruses with pH-
insensitive fusion proteins. Using sophisticated imaging techniques, it was shown that HIV entry 
occurs through a dynamin-dependent pathway and blockage of this step prevented HIV particles 
from attaining complete fusion at the plasma membrane (85, 218). Furthermore, entry of HSV-1 
can also occur through endocytosis in a dynamin-dependent manner (235, 277). Image 
correlation spectroscopy studies showed that SeV fusion can occur in the plasma membrane or 
in intracellular membranes (279). Other studies using chemical inhibitors, microscopy, and RNAi-
mediated knockdown of proteins involved in endocytosis have shown that multiple 
paramyxoviruses (54, 92, 171, 262, 298) could at least be partially using endocytic pathways to 
establish infection (Figure 4B). NDV infection was significantly inhibited by agents that sequester 
cholesterol, and NDV particles were found to colocalize with early endosomal markers, 
suggesting that NDV may be using the caveolae-dependent endocytic pathway (54). Despite 
being largely insensitive to traditional lysosomotropic agents such as bafilomycin A1 and 
ammonium chloride, RSV infection was significantly decreased when clathrin light chain, AP1B1, 
dynamin 3, and Rab5A among others players of the clathrin-mediated endocytosis pathway 
were knocked down (171). Disruptions of the cellular endocytic and macropinocytic pathways 
through chemical inhibitors and the expression of dominant negative proteins have been shown 
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to inhibit NiV infection (Figure 4C) (92, 262). Furthermore, we recently reported that infection 
with the low-pH dependent HMPV strain CAN97-83 was significantly inhibited by treatment with 
lysosomotropic agents, with the inhibitor of clathrin-mediated endocytosis chlorpromazine, or 
with the dynamin inhibitor dynasore (298). Interestingly, the extent of the effects of 
lysosomotropic agents on HMPV infection appears to be strain dependent (203). Therefore, 
more studies are needed to determine the exact entry pathway for most paramyxoviruses. 
 
Glycosaminoglycans and Their Importance in Viral Infection 
Most cells express a broad array of different carbohydrates which are linked to lipids 
(glycolipids) or proteins (glycoproteins). These glycoconjugates have important functions 
including cell adhesion, growth, and signaling (284). The glycan synthesis of glycoproteins is 
based on two main processes: N-glycosylation, which consists of the addition of two molecules 
of N-acetylGlucosamine (GlcNac) to the nitrogen atom of an aspargine residue, or O-
glycosylation, which involves the addition of N-acetylGalactosamine (GalNac) or xylose (xyl) to 
the oxygen atom of a serine or a threonine residue. O-glycosylation involving GalNac addition 
leads to the synthesis of mucins, whereas xylose addition, with the exception of keratin sulfate, 
leads to synthesis of glycosaminoglycans (GAGs) (273). The addition of two molecules of 
galactose and one molecule of glucuronic acid to xylose forms the core on which linear chains of 
disaccharides branch off to form GAGs. The disaccharide is composed of two alternate 
monosaccharides: one aminosugar (usually GalNac or GlcNac) plus a molecule of glucuronic or 
iduronic acid. As these GAG chains are synthesized, they undergo various degrees of 
epimerization and sulfation which, coupled with variations in the lengths of the GAG chains, 
result in molecules with very high degrees of structural heterogeneity (284). Due to the 
extensive network of sugar residues and the high degree of sulfation of some GAG chains, 
proteoglycans, proteins modified by GAGs, have a very high negative charge (273). The 
biosynthesis of GAGs is very a complex process and is catalyzed by many specific enzymes both 
in the Golgi as well as in the extracellular compartment (11). While GAGs are considered to be 
the most complex biological polymer (246), as it is estimated that 1036 potential structures can 
be formed by heparan sulfate alone (11), they can be classified into six different groups based 
on their composition: heparan sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, 
hyaluran, and heparin (24, 273, 334).  
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Proteoglycans can be found in intracellular granules (like serclycin, and chromogranin 
A), the extracellular matrix and basement membranes (like aggrecan, versican, decorin, biglycan, 
fibromodulin, and Type IV collagen), and on the cell surface (like fibroglycan, betaglycan, 
thrombomodulin, CD44, NG2, and the syndecan and glypican families of proteins) (106, 190, 
284). While some proteoglycans such as NG2, glypicans, and thrombomodulin are modified by 
one specific type of glycan chain, others such as syndecan and serglycin contain more than one 
type of GAG chain (106, 284). Additionally, some proteoglycans like CD44 and chromogranin A 
exist in GAG free forms (106). The tremendous variability in proteoglycan structure and 
expression allow these proteins to interact with different binding sites of different proteins 
(291). 
Because GAGs are expressed ubiquitously, they are frequently implicated in host-
pathogen interactions. Bacteria, parasites, fungi, and viruses have all been shown to exploit 
GAGs to facilitate infection (11). It is thought that many pathogens use GAGs as initial, lower 
affinity attachment sites to facilitate a subsequent interaction with a higher affinity receptor 
that would mediate tissue tropism and facilitate internalization (11, 284, 318). Of the many 
GAG-modified proteins known, those modified with heparan sulfate (HS), or heparan sulfate 
proteoglycans (HSPGs), are the ones most often implicated in virus-cell interactions. HS has 
been described as a receptor for multiple herpesviruses and is also necessary during the first 
step of adhesion of other viruses such as adenoviruses, HIV, dengue, several hepatitis viruses, 
and influenza (reviewed in (318) and (11)). Furthermore, it has previously been shown that HS 
also has an important role in the initial steps of PIV3 (42) and RSV entry, the closest related 
human pathogen to HMPV (45, 131, 132, 174). This interaction, however, appears to be largely 
mediated by RSV G, and viruses lacking G show a significant decrease in binding to CHO-K1 cells 
(344). A recent study showed that the HMPV G protein also has the ability to bind GAGs and 
suggested that this interaction might be a significant factor for virus-cell interactions (347). 
Even though virus-GAG interactions are generally thought to be low-affinity and 
relatively non-specific, some viruses recognize a specific HSPG as cellular receptors. It has been 
shown, for instance, that HSV-1 can bind to HSPGs through its surface glycoproteins gB and gC 
(182), likely facilitating the interaction between gD and HVEM, nectin-1, or nectin-2 that 
promotes internalization (138). However, studies have shown that HSV-1 gD can bind directly to 
3-O-sulfated HSPGs and mediate internalization (241, 308) and peptides that bind to these 
HSPGs were capable of blocking HSV-1 infection in vivo (349). HSV-1 binding to HS enhances the 
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formation of filopodia which is then used by the virus for internalization (244). Furthermore, the 
nonenveloped hepatitis E virus (HEV) targets primarily the HS present in syndecan-1 through the 
major capsid protein pORF2 (161). Different papillomaviruses also show preferential binding to 
different HSPGs (157). Thus, these studies indicate that the preference of one HSPG over 
another likely results from sulfation differences between different HSPGs and suggest that, for 
some viruses, attachment to HSPGs may be a more than mere nonspecific electrostatic 
interactions. 
Previous studies have also shown that pathogens can use GAGs as scaffolds to alter 
virulence factors or to facilitate transmission and systemic dissemination. Binding of HS by the 
capsid protein L1 of the papillomavirus HPV16, for instance, induces a conformational change in 
the capsid protein L2 that exposes the binding site for the internalization receptor (11, 157). 
Interestingly, HPV appears to bind first to basement membrane HSPGs that are exposed after 
tissue injury (168). The conformational change of L2 likely involves the activity of furin and 
cyclophilin B, a protein isomerase that colocalizes with HSPGs (32, 157). Additionally, viruses like 
foot-and-mouth disease virus (FMDV) hijack different endocytic pathways for entry depending 
whether it binds to HS or to other receptors (11, 242). It has also been shown that HIV binds to 
HS in several cell types including dendritic cells, prolonging the infectivity of the virus and its 
transmission to T cells (11). Thus, viruses have evolved a wide array of mechanisms to take 
advantage of GAGs in their infectious lifecycle. 
 
Integrins and Their Multiple Roles in Viral Infection 
Integrins are a superfamily of cell adhesion proteins that are expressed in all cell types 
and have critical roles in the regulation of cell-to-cell, cell-to-matrix adhesion, tissue growth, 
differentiation, attachment, migration, thrombus formation, and apoptosis (reviewed in (15, 
151)). These transmembrane heterodimers, composed of at least 18 different α and 10 different 
β subunits, contain several domains important for binding to a myriad of proteins including 
some HSPGs, and proteins that express the amino acid sequence Arg-Gly-Asp (RGD) (285, 338). 
At least nine different α subunits contain an I or A domain, a conserved metal-ion-dependent 
adhesion site (MIDAS) that, under physiological conditions, binds Mg+2 or Ca+2 and, when 
present, is usually the ligand binding site (328). The binding site of integrins that lack the I 
domain is typically formed by the β-propeller domain of the α subunit and the I domain of the β 
subunit and recognizes RGD peptides. Some integrins are known to be promiscuous and bind a 
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variety of ligands like laminin, collagen, connective tissue growth factor, fibrillin, ICAM-4, L1, 
HSPGs, ADAM family members, and those with LDV and SVVYGLR motifs (150). Structural details 
of many of these interactions, including the binding sites in integrins, remain to be elucidated. 
In addition to mediating cell attachment to the extracellular matrix, integrins also serve 
an important role by conveying signals from the outside to the inside of cells and vice versa (61, 
328). This is achieved through interactions between the cytoplasmic domains of the α and β 
integrin subunits with a variety of intracellular proteins including kinases and cytoskeletal 
proteins like talin. Importantly, it has been shown that integrins play an important role in the 
regulation of cell signaling through receptor-mediated endocytosis and the recycling of many 
surface proteins. Integrins α5β1, for instance, can retain phosphorylated caveolin-1 in focal 
adhesions, inhibiting lipid raft endocytosis and keeping active Rac at the surface of adherent 
cells. Upon cell detachment, phosphorylated caveolin-1 is recruited to lipid rafts and 
endocytosis ensues (88). 
It has been shown that integrin heterodimers are endocytosed by clathrin-dependent 
and clathrin-independent pathways including caveolin-dependent endocytosis (61). The integrin 
β subunits contain a conserved NXXY motif in their cytoplasmic tails, which is known to interact 
with endocytic adaptor proteins like AP2 in clathrin-coated pits (61). It is, however, likely that 
integrins can enter cells through several endocytic pathways as both clathrin and caveolar 
uptake of α5β1 and αvβ3 integrins has been documented (61). Following endocytosis, integrins 
travel to the early endosomes and are usually recycled to the plasma membrane in a Rab4- 
and/or Rab11-dependent route (61). The internalization and recycling of integrins also allows 
them to direct the traffic of receptors and other cargo through the several intracellular 
compartments. Thus, it has been shown that integrins regulate the recycling and degradation of 
receptor tyrosine kinases like VEGFR2 (281) and EGFR1 (60). The presence of αvβ3 blocking 
agents, for instance, promotes the recycling of VEGFR2, rescuing it from its usual rapid 
internalization and degradation (281). Thus, ligand association with integrins can initiate 
multiple signaling events that facilitate cellular uptake and dictate the trafficking pathway of the 
ligand.  
Given the importance of integrins in signaling, their promiscuity in ligand binding, and 
their broad distribution on cell surfaces of many cell types, it is not surprising that several 
viruses have evolved to take advantage integrins for infection. Indeed, studies indicate that 
integrins are receptors for some picornaviruses, papillomaviruses, adenoviruses, and 
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hantaviruses (194, 222, 328). Certain strains of adenoviruses can use αv integrins in the absence 
of their primary receptor coxsackie adenovirus receptor (CAR) (194, 278). Interestingly, while 
the picornavirus echovirus-1 recognizes the human α2β1 integrin as its receptor, the virus is also 
able to infect cells and rodents expressing human α2 and rodent β1 integrin but cannot infect 
cells expressing either the rodent α2 subunit or other β1 integrins (21, 140, 149). Furthermore, 
pathogenic strains of hantaviruses bind to the inactive conformation of β3 coupled either to an 
αIIb or an αV subunit in an RGD-independent manner (328). Thus, even though integrins are 
expressed as heterodimers, in many cases a certain integrin subunit seems to play a more 
prominent role in viral cell invasion. The integrin that a particular virus recognizes can also be a 
determinant for the pathogenicity of the virus. Pathogenic strains of hantaviruses, for instance, 
recognize β3 integrins as their receptors while nonpathogenic strains recognize β1 integrins 
(122, 328). 
In addition to using integrins as initial cellular receptors, studies have shown that many 
viruses including adeno-associated virus, ebola virus, β and γ herpesviruses, reoviruses, and, 
more recently, paramyxoviruses exploit integrin signaling and trafficking processes for cell entry 
and infection (80, 84, 222, 297, 328). Proper regulation of expression and activity of endosomal 
cathepsins by integrins, for instance, is required for ebola virus infection (297). Furthermore, 
after initially binding to CAR (22) or CD46 (119), several adenoviruses interact through a RGD 
loop on the viral surface with αv and β1 integrins for internalization by clathrin-mediated 
endocytosis (373). Through the activation of focal adhesion kinase (FAK) and phosphoinositide 
3-kinase (PI3K), the interaction of adenovirus with integrins also promotes actin polymerization 
and increases the survival of the host cell, facilitating viral internalization and the production of 
progeny virions (328). Rotaviruses and other reoviruses also associate with integrins after 
cellular attachment to promote internalization (84, 328). 
Integrins also play an important role in host cell invasion for enveloped viruses. While 
human cytomegalovirus (CMV) and Kaposi’s sarcoma virus (HHV-8 or KSHV), both members of 
the herpesvirus family binds to host cells via association with HSPGs, efficient cell entry and 
infection requires interactions between the viral gB protein and integrins, particularly β1 and β3 
(7, 114). Interestingly, studies indicate that CMV interacts with integrins through a RX6-8DLXXF 
motif present in the gB protein (114) and also through a RGD motif in the gH protein (365), 
suggesting that viruses can use different proteins and different motifs to interact with integrins. 
Interactions with integrins have also been shown to be important for efficient infection by other 
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enveloped viruses such as members of the retrovirus (69) and togavirus (177) families. While 
very little is known about integrin interactions with members of the paramyxovirus family, it has 
recently been reported the αvβ1 integrin is a major component for HMPV infection (80). 
 
Dissertation Overview 
HMPV is a recently discovered paramyxoviruses that causes widespread disease 
worldwide. Despite the relevance of this virus to human health, very little is known about the 
infectious cycle of the virus. Therefore, the goal of this dissertation was to add knowledge about 
the attachment and fusion steps in the viral entry cycle of HMPV. A few reports have provided 
information about the lifecycle of the virus and the mechanism that HMPV uses for cell entry. 
These studies, nonetheless, highlighted the uniqueness of this respiratory pathogen compared 
to other members of the family. Indeed, studies have shown that the fusion protein needs an 
exogenous protease for proteolytic activation in vitro (352), can be triggered at low pH (299), 
and viruses devoid of the other putative surface glycoproteins besides F remain infectious (31). 
At the time I started my studies, the mechanism by which low pH triggers HMPV F and the 
implication of low pH triggering on entry was being studied by Dr. Rachel Schowalter. She 
identified a histidine residue at position 435 in the HMPV F protein to be important for low pH-
mediated fusion and we worked together to complete the work showing initial data that HMPV 
infection requires a low pH environment in cells and that entry requires the activity of dynamin, 
a protein that is required for the formation of endocytic vesicles (298). This work led us to 
hypothesize that HMPV entry occurs through endocytosis and that protonation of H435 under 
acidic environments was responsible for the triggering of HMPV F. I performed more studies 
with mutants at position H435 to test whether the presence of a constant positive charge at this 
position could rescue the fusogenic activity of the protein at neutral pH. My results indicate that 
a positive charge at this position is required but not sufficient for low pH-mediated fusion and 
that substitution with residues bearing negative charges abolished fusion. The inability to rescue 
fusion activity by placing a positive charge at position 435 suggested that changes at more than 
one site are required for low pH triggering.  Thus, with the help of Brent Hackett, a second area 
with a high concentration of charged residues located between the HRA domain and the F2 
portion of the F protein was identified. Studies with HMPV F proteins carrying mutations in this 
region showed that electrostatic interactions across different regions of the protein play 
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important roles in stabilizing the metastable prefusion form and in allowing for proper folding 
and triggering of HMPV F.  
In order for viral infection to occur, the virus must first bind to a cellular receptor to gain 
entry into cells. Before my studies began, the receptor for HMPV was not known and, in 
collaboration with Dr. Cyril Masante, we developed techniques to assess viral binding and 
infection in different cell types in the hopes of identifying the receptor(s) and the cellular factors 
that mediate the initial attachment of the virus to cells. Shortly after our studies began, a report 
was published showing an important role for the integrin αvβ1 in promoting HMPV infection 
(80). My studies indicate that interactions between the RGD motif of HMPV F and β1 integrins 
are not essential for fusion activity. Furthermore, we learned that HMPV binding and infection 
was greatly dependent on the presence of GAGs in the target cell surface. Through enzymatic 
cleavage of different GAGs and studies with cells carrying different mutations that prevented 
them from synthesizing certain GAGs, we discovered that heparan sulfate was the GAG required 
for HMPV infection. The use of recombinant viruses lacking the G and SH proteins allowed us to 
confirm that the initial interaction between GAGs and the virus is mediated by the F protein. Our 
studies therefore conclude that the initial binding of HMPV to cells is mediated by an interaction 
between HSPGs present in the cell surface and the HMPV F protein. We hypothesize that 
integrins play an important role to promote efficient infection at a step downstream of the 
initial binding to HSPGs. The work presented here is an important step forward in our 
understanding of the lifecycle of this important human pathogen. Further investigations on the 
early events leading to HMPV infection will provide valuable information that could be 
translated into the development of therapeutics. 
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Figure 1. Paramyxovirus family and structural organization of the virus (64). 
A. Classification of representative members of the paramyxovirus family. B. Schematic of a 
paramyxovirus. Genomic RNA is wrapped by nucleocapsid core proteins (brown), which are 
connected to the viral envelope (red) by the matrix protein (blue). The attachment (green), 
small hydrophobic (present only in certain paramyxoviruses, orange), and fusion proteins (cyan) 
are depicted at the virus surface. 
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Figure 2. Paramyxovirus fusion protein: structure and triggering (64). 
A. Schematic of the cleaved, disulfide-linked paramyxovirus fusion protein. B. Structure of the 
uncleaved form of PIV5 F in its prefusion conformation (384) and structure of the hPIV3 F in its 
postfusion conformation (383). C. Schematic of the different models of paramyxovirus 
triggering. (a) The attachment and F proteins could interact while trafficking through the 
different biosynthetic compartments and dissociate upon receptor interaction with the 
attachment protein, allowing the F protein to trigger. (b) Alternatively, the attachment and F 
proteins could travel separately through the biosynthetic pathway, associate at the cell surface, 
and dissociate after attachment protein interaction with receptor, triggering the F protein. (c) 
The attachment and F proteins could also travel separately and not associate until the 
attachment protein interacts with its receptor. The association between the attachment protein 
and the F protein allows the latter to trigger. (d) Direct interaction between the attachment and 
F proteins may not be required for some viruses as receptor binding by the attachment protein 
could facilitate binding of another receptor (illustrated as a brown pentagon) by the F protein, 
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allowing the F protein to trigger. (e) Finally, some paramyxoviruses do not require the 
expression of an attachment protein. For these viruses, the F protein binds to its receptor and 
then promotes membrane fusion, which in some cases can be triggered by low pH. For all 
images, the fusion peptide is represented in blue, heptad repeat A (HRA) in orange, heptad 
repeat B (HRB) in green, the transmembrane (TM) domain in red, and brown represents the 
cytoplasmic tail. 
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Figure 3. Schematic of membrane fusion mediated by paramyxovirus fusion proteins (64).  
After the prefusion form of the fusion protein A. is triggered, the coiled-coil HRB domain melts 
leading to the formation of the open stalk form B. The FP is then projected towards the target 
membrane and HRA refolds to a trimeric coiled coil (pre-hairpin intermediate, C. HRB then 
translocates toward HRA, forcing the viral membrane and the target membrane into a 
hemifusion state D. The complete refolding of HRB around HRA forms the stable 6HB and allows 
for the formation of the fusion pore E. Blue: FP, Orange: HRA, Green: HRB, Red: TM. 
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Figure 4. Schematic of different pathways of viral entry (64).  
A. Viral-cell membrane fusion of pH-independent viruses could occur at the plasma membrane 
under neutral pH after binding to receptor. B. A viral particle could enter the cell through an 
endocytic pathway after receptor binding. Viral-cell membrane fusion could then occur in an 
intracellular compartment. Low pH may or may not be required for membrane fusion to occur. 
C. Viruses could enter cells through macropinocytosis, where the viral particle is engulfed by the 
cell after receptor binding. Fusion between the viral and cellular membranes would then take 
place at an intracellular compartment. 
  
29 
 
 
Figure 5. Representation of intracellular trafficking pathways and selected Rab GTPases.  
Rab 5 controls cargo delivery to the early endosome (EE) and recycling endosome (RE) while Rab 
7 is responsible for delivering cargo from the EE to the late endosomal (LE) and lysosomal 
compartments. Rab 11 is required for cargo recycling and transport to the trans-Golgi network 
(TGN). 
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Chapter 2: Materials and Methods 
 
Cell Lines 
Vero, BSR T7/5 (provided by Karl-Klaus Conzelmann, Max Pettenkofer Institut) (51), 
GD25 and β1GD25 cells (provided by Deane Mosher, University of Wisconsin, Madison, WI) 
(367), MEF cells (provided by Terence Dermody, Vanderbilt University, Nashville, TN), and HeLa 
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Invitrogen, Carlsbad, 
CA), supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA) 
and 1% penicillin and streptomycin (P/S, Invitrogen). CHO-K1, pgsA745 (108) and Lec1 (322), 
which were obtained from ATCC, IdIDLec1 (107, 321), which were derived from ldlD cells (169) 
(provided by Craig Vander Kooi, University of Kentucky), and pgsD677 cells (192) (provided by 
Jeff Esko, University of California, San Diego, CA) were grown in HyClone Ham’s F-12, Kaighn’s 
Modification Medium (Thermo Scientific, Waltham, MA) supplemented with 10% FBS and 1% 
P/S. A-549 cells (provided by Tianyan Gao, University of Kentucky) were grown in RPMI-1640 
media supplemented with 10% FBS and 1% P/S. BEAS-2B cells (obtained from ATCC) were grown 
in BEBM media supplemented with the supplied additives (Lonza, Walkersville, MD) and plated 
in flasks and dishes precoated with a mixture of 10µg/mL fibronectin from human plasma 
(Sigma, Saint Louis, MO), 30µg/mL bovine collagen type I (Invitrogen), and 10µg/mL bovine 
serum albumin (Sigma). BSR cells were selected for T7 polymerase-expressing cells every third 
passage with 0.5 mg/ml G-418 sulfate (Gibco Invitrogen). The media of β1GD25 cells was 
supplemented with 10µg/mL puromycin (Gibco Invitrogen) every third passage to select for the 
β1-expressing cells.  
 
Plasmids and Antibodies 
The HMPV F gene within the pGEM-3Zf(+) vector was provided by Ursula J. Buchholz and 
Peter Collins (NIAID, Bethesda, MD) with permission from Dr. Guy Boivin (Centre Hospitalier 
Universitaire de Québec, Quebec City, Quebec, Canada). The HMPV F H435R, H435K, H435D, 
H435E, D331A (F RGA), E51A, D54A, E56A, R163A, R166A, E51K, E51K/H435R, D54A/E56A, 
D54A/E56A/H435R, D54A/H435R, E56A/H435R, D54N/E56Q, and D54N/E56Q/H435R protein 
mutants were created using QuikChange site-directed mutagenesis (Stratagene, La Jolla, CA). 
The HMPV F wild type (WT) and mutant genes were released from pGEM-3Zf(+) and ligated into 
the pCAGGS mammalian expression vector following digestion with EcoR1 and Sph1. All mutants 
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were sequenced in their entirety after ligation. The wild type and K44A dominant negative 
mutant dynamin-2 fused with mCherry plasmid was a generous gift from Gregory Melikyan 
(Emory University, Atlanta, GA) (218). The wild type and the GTP-bound constitutively active 
Rab5a Q79L mutant fused with mRFP plasmid was a generous gift from Emilia Galperin 
(University of Kentucky, Lexington, KY). 
Antipeptide antibodies against HMPV F (Genemed Synthesis, San Francisco, CA) were 
generated using amino acids 524-538 of HMPV F. The monoclonal antibody 23H12 against VSV 
M was a generous gift from Michael Whitt (University of Tennessee Health Science Center, 
Memphis, TN) (188). 9EG7 anti-mouse-β1-integrin was purchased from BD-Pharmigen (San 
Diego, CA). MAB2021Z anti-αv-integrin was purchased from Milipore (Billerica, MA). NBP1-
21631 anti-HMPV N monoclonal antibody was purchased from Novus Biologicals (Littleton, CO). 
R4654 anti-Rab5 and R4779 anti-Rab 7 polyclonal antibodies were purchased from Sigma. Anti-
heparan sulfate 10E4 antibody was purchased from US Biologicals (Swampscott, MA). Goat anti-
mouse DyLight649 secondary antibody was purchased from KPL Inc. (Gaithersburg, MD). 
 
Generation of GFP-tagged HMPV G and HMPV M 
The HMPV G gene was amplified by PCR from the HMPV G-pCAGGS plasmid using 
primers that contain 5’ BglII and EcoR1 and 3’ Kpn1 and BamH1 restriction sites 
(AAAAGATCTGAATTCTATGGAGGTGAAAGTAGAG and TTTTGGATCCGGTACCGCGTTTTGCATTGTG 
for C-terminal tagging of HMPV G; AAAAGATCTGAATTCAATATGGAGGTGAAAGTAGAG and 
TTTGGATCCGGTACCCTAGTTTTGCATTGTG for N-terminal tagging of HMPV G). The resulting DNA 
fragments were digested with EcoR1 and Kpn1-HF (New England Biolabs, Ipswich, MA) and 
ligated into pEGFP-C1 or pEGFP-N1 (for N- and C-terminal tagging respectively) plasmid.  
The HMPV M gene was amplified by RT-PCR from the HMPV genome using primers 
containing 5’ BamH1 and 3’ NheI restriction sites (TATATAGGATCCGAGTCCTATCTGGTAGACACC 
and TATATAGCTAGCTTATCTGGACTTCAGCACATATCTTGTTCC). The resulting DNA fragment was 
digested with BamH1 and Nhe1 and ligated onto pEGFP-C1 plasmid. Inserts were sequenced and 
GFP expression was confirmed by microscopy following transfection of Vero cells with these 
plasmids. 
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Viruses 
Recombinant, GFP-expressing HMPV (rgHMPV) strain CAN97-83 (genotype group A2) 
and the mutant viruses HMPV ΔG and HMPV ΔG/ΔSH with a codon stabilized SH gene (25) were 
kindly provided by Peter L. Collins and Ursula J. Buchholz (NIAID, Bethesda, MD). Recombinant 
WT, ΔG, and ΔG/ΔSH HMPV were propagated in Vero cells (starting MOI of 0.01 to 0.03) 
incubated at 32˚C with Opti-MEM, 200 mM L-glutamine, and 0.3 μg/ml TPCK-trypsin replenished 
every day. On the seventh day, cells and media were collected and frozen at -80°C. The virus-
containing suspension was thawed at 37°C the next day and subjected to centrifugation at 2500 
g for 20 min at 4°C on a Sorvall RT7 tabletop centrifuge. The supernatant was then subjected to 
centrifugation on a 20% sucrose cushion for 2 hours and fifteen minutes at 27,000 x g 4°C using 
a SW28 swinging bucket rotor on a Beckman Optima L90-K ultracentrifuge. The resulting pellet 
was resuspended in 300 µL of Opti-MEM and left at 4°C overnight. Aliquots of the samples were 
made the next morning and stored at -80°C. Recombinant GFP-expressing HMPV with the F 
protein mutations K295A, R396A, H435A, H435N, and K438A were generated from cDNA. First, 
adapters containing the HMPV G-F and F-M2 intergenic regions were added to the specific 
mutant HMPV F genes by PCR; PCR fragments were cloned into pCAGGS and sequenced. Then, a 
1653 bp NheI/PacI DNA fragment containing the wild type HMPV F gene was removed from the 
pgHMPV full length cDNA plasmid, and replaced by the individual mutant HMPV F genes. 
Recombinant GFP-expressing HMPV with mutant F genes were recovered from cDNA as 
described previously (6).  rgHMPV with F protein mutations K295A, R396A, H435A, H435R, and 
K438A were propagated under the same conditions as wild type virus; virus stocks were 
harvested either when cell death became prominent or when GFP expression was seen in all 
cells. Mutant viruses were either harvested as described above or by addition of SPG (218 mM 
sucrose, 0.0049 M L-glutamic acid, 0.0038 M KH2PO4, 0.0072 M K2HPO4) from a 10X solution 
after collecting the cells and media. Aliquots of viruses in SPG solution were then made, frozen 
in dry ice/methanol, and thawed twice before storage at -80°C.  
Recombinant GFP-expressing PIV5 was kindly provided by Robert Lamb (Howard Hughes 
Medical Institute, Northwestern University) and Jessica Robach (Northwestern University, 
Evanston, IL). GFP was inserted between the P/V and M genes with a duplicate of the EIS 
(End/Intergenic/Start) sequence that precedes M. PIV5 was propagated in MDBK cells as 
described (254) and stored in 1 x SPG. Aliquots were frozen in a dry ice/methanol mix and 
thawed twice prior to storage at -80˚C. Recombinant VSV, kindly provided by Michael A. Whitt 
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(University of Tennessee Health Science Center, Memphis, TN) in which the G envelope gene 
was replaced with the GFP gene and pseudotyped with the VSV G glycoprotein was propagated 
as previously described (337). 
 
Virus Titering 
Viral titers were determined by titration of the viral samples on either a 24-well or a 96-
well plate and counting the number of GFP-expressing cells the following day. For non-GFP 
expressing viruses, (rHMPV), a control rgHMPV was used as a reference. Five hundred thousand 
Vero cells plated the day before were infected with the nonfluorescent virus and control 
rgHMPV by serial dilution. Infected cells were suspended the following day, fixed in 4% 
formaldehyde, permeabilized in 0.02% Triton X-100 at 4°C, and labeled with 70µL of anti-HMPV 
N antibody for 90 minutes after resuspending the cells in 70µL FBS. Samples were analyzed by 
FACS following incubation with a DyLight649-conjugated goat anti-mouse secondary antibody. 
The ratio of rHMPV to rgHMPV at the same dilution was used to calculate the titer for the non-
GFP expressing HMPV. 
 
Syncytia Assay in Transfected Cells 
Subconfluent monolayers of Vero cells plated in 6-well plates were transiently 
transfected with a total of 0.5 µg of DNA consisting of pCAGGS-HMPV F WT, F protein mutant, or 
the empty pCAGGS vector (control) using Lipofectamine and Plus reagents (Invitrogen) 
according to the manufacturer’s instructions. The next morning, confluent cell monolayers were 
washed twice with phosphate saline buffer (PBS) and incubated at 37˚C in 1 mL Opti-MEM with 
0.3 µg/ml TPCK-trypsin for 1.5 hours. Afterwards, cells were rinsed once with PBS (pH 7.3) 
before adding 1 mL of PBS of the indicated pH buffered with 10 mM HEPES and 10 mM MES. 
Cells were incubated for 4 minutes at 37˚C under the indicated pH conditions. Media (1 mL Opti-
MEM with 0.3µg/ml TPCK-trypsin) was replaced and cells were incubated at 32°C until the next 
pH pulse. The pH pulse was repeated for a total of four times (2-3 hours apart) throughout the 
day and cells were incubated overnight at 32˚C in order to allow final cellular rearrangements to 
take place. Digital photographs of syncytia were taken the next morning with a Spot Insight 
Firewire digital camera mounted on a Carl-Zeiss Axiovert 100 inverted microscope using a 10x 
objective (Thornwood, NY). 
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Reporter Gene Fusion Assay 
Vero cells in 60-millimeter dishes were transfected with 0.55 μg pCAGGS- HMPV F wild-
type or mutant F protein and 0.55 μg T7 plasmid containing luciferase cDNA under control of the 
T7 promoter (Promega, Madison, WI) using Lipofectamine and Plus reagents (Invitrogen) 
according to the manufacturer’s instructions. The following day, Vero cells in one 60-millimeter 
dish were lifted from the plate surface with 1 mL of trypsin, resuspended in 2 mL of DMEM plus 
10% FBS and 1% P/S, and subjected to centrifugation at 400 x g, 4°C in a Sorval RT7 tabletop 
centrifuge for 5 minutes. Pelleted cells were resuspended in 2 mL of DMEM plus 10% FBS and 
1% P/S and overlaid onto two 35-millimeter dishes of confluent BSR T7/5 cells, which 
constitutively express the T7 polymerase (1 mL of Vero cells per 35-millimeter dish). Cells were 
incubated at 32°C for 1.5 hours to allow Vero cells to attach. Afterwards, cells were rinsed once 
with PBS before adding 1 mL of PBS of the indicated pH (one 35-millimeter dish per pH) buffered 
with 10 mM HEPES and 10 mM MES and incubated for 4 minutes at 37˚C. Buffered PBS was 
replaced by 1 mL of Opti-MEM with 0.3 µg/ml TPCK-trypsin after the pH pulse and cells were 
incubated at 37˚C for one hour. Treatment with low pH was repeated one more time and cells 
were incubated afterwards in 2 mL DMEM plus 10% FBS and 1% P/S at 37°C for 4 hours to allow 
for luciferase production. Finally, cell lysates were analyzed for luciferase activity using a 
luciferase assay system (Promega) according to manufacturer’s protocol. Light emission was 
measured using an Lmax luminometer (Molecular Devices, Sunnyvale, CA) for five seconds with 
a 1.6 second delay between each measurement. Student-T tests or ANOVA tests were used to 
determine statistically significant differences. 
 
Expression, Metabolic Labeling, and Biotinylation of Surface Proteins 
Cells in sixty-millimeter dishes were transfected with 1.10 µg pCAGGS-HMPV F wild-
type, mutants, or empty pCAGGS as control using Lipofectamine and Plus reagents (Invitrogen) 
according to manufacturers’ protocol. At 18-24 h post-transfection, cells were starved in 
methionine- and cysteine-deficient DMEM for 1 hour and then metabolically labeled with media 
containing Tran[35S] label (100 μCi/ml; Perkin Elmer, Waltham, MA) and 0.3 μg/ml TPCK-trypsin 
for 4 hrs. Following radiolabeling, cells were washed three times with ice-cold pH 8 PBS and 
incubated with 1 mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce, Rockford, IL) diluted in pH 8 PBS for 30 
min rocking at 4˚C, then 20 min at room temperature. Cells were washed three times again with 
pH 8 PBS and then lysed in 1 mL RIPA buffer containing 100 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
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0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 1% deoxycholic acid, protease inhibitors (1 
KalliKrein inhibitory unit of aprotinin [Calbiochem, San Diego, CA], 1 mM phenylmethylsulfonyl 
fluoride [Sigma]), and 25 mM iodoacetamide (Sigma). The lysates were subjected to 
centrifugation at 136,500 × g for 15 minutes at 4°C. The supernatants were collected and the F 
proteins were immunoprecipitated using 6 µL anti-HMPV F polyclonal antibody followed by 
30µL of protein A-conjugated sepharose beads (Amersham, Piscataway, NJ) as previously 
described (254). Immunoprecipitated protein was released from the beads by boiling using a 
total of 100µL of 10% SDS (40µL for first boil and 60µL for second boil). Fifteen percent of total 
protein collected was removed for total expression analysis and the remaining 85% was diluted 
in 500µL biotinylation dilution buffer (20 mM pH 8 Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% 
Triton X-100, 0.2% bovine serum albumin) and incubated with immobilized streptavidin (Pierce) 
for 1 hour at 4°C. Samples were washed, resolved by SDS-15% polyacrylamide gel 
electrophoresis (SDS-PAGE), and visualized using the Typhoon imaging system (GE Healthcare, 
Waukesha, WI) after 7 – 10 days of exposure to a phosphor screen. The intensities of the bands 
were obtained using ImageQuant software, background corrected, and normalized to 
expression of HMPV F WT. Student-T tests or ANOVA tests were used to determine statistically 
significant differences. 
 
Flow Cytometry Analysis of rgHMPV Infection 
One hundred thousand cells plated in a 24-well plate the day before (except for 
β1GD25, for which 50 thousand cells were plated instead to account for the difference in growth 
rate) were infected with different multiplicities of infection (MOI) of rgHMPV diluted to a final 
volume of 200µL/well. The cells were exposed to the virus for a total of 4 hours at 37°C. 
Following an overnight incubation, cells were resuspended, fixed in 1% formaldehyde diluted in 
PBS with 50mM EDTA, and analyzed either with a BD FACSCalibur or a BD LSR II flow cytometer 
(BD, Franklin Lakes, NJ) for which GFP expression and intensity of at least 10,000 cells were 
determined. Data analysis was performed using FCS Express V3 (De Novo Software, Los Angeles, 
CA), and data presented in graphs represent the percentage of GFP-expressing cells in the total 
percentage population or as a percentage of control. Student-T tests or ANOVA tests were used 
to determine statistically significant differences. 
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ELISA for HMPV Binding 
Varying amounts of rHMPV were added to a confluent monolayer of cells plated in a 96-
well plate at 4°C and spinoculated at 1000 x g, 4°C in a Beckman Coulter Allegra X-15R (Brea, CA) 
tabletop centrifuge for one hour to allow virus binding. Immediately after binding, cells were 
thoroughly washed with ice-cold PBS, fixed with 4% paraformaldehyde, and permeabilized with 
1% Triton X-100 at 4°C. Following fixing and permeabilization, cells were blocked in 1% normal 
goat serum for 1 hour and blotted with 50µL of mouse anti-HMPV N monoclonal antibody 
diluted 1:1500 for 1 hour. Cells were thoroughly washed with PBS and then blotted with 50µL of 
HRP-conjugated goat anti-mouse monoclonal antibody diluted 1:500 for 1 hour. Cells were 
thoroughly washed with PBS and assayed using a TMB 2-component microwell peroxidase 
substrate kit (KPL Inc.) according to manufacturer’s protocol. Absorbance of each well was read 
at 460nm using a µQuant microplate reader (Bio-Tek Instruments Inc., Winooski, VT) and values 
normalized to the number of cells in a well which was obtained using a Beckman Coulter Z1 
Coulter Particle Counter. Student-T tests or ANOVA tests were used to determine statistically 
significant differences. 
 
Western Blot Binding Assay 
A constant number of cells (4x104 for β1GD25 and 6x104 for the other cell types to 
account for differences in growth rate) were plated in a 24-well plate and exposed to rHMPV, 
ΔG, or ΔG/ΔSH HMPV at an MOI of 10, 15, or 100 for 1.5 hours at 4°C to prevent internalization. 
Cells were lysed in 45 µL of 20 mM Tris pH 7.9, 0.15 M NaCl, 1 mM Na2HPO4, 1 mM PMSF, 0.5 % 
sodium deoxycholate, and 0.5% NP-40. The lysate was collected and subjected to centrifugation 
at 14,000 x g for 10 mins. The supernatant was transferred to a tube containing 6 µL of 6X 
loading buffer and a volume corresponding to 6 x 104 cells were loaded onto a 10% SDS-PAGE 
gel. The proteins were transferred onto a PVDF membrane and the membrane was blocked at 
4°C overnight in TBS containing 5% milk, 0.02% sodium azide, and 0.05% Tween 20. The gel was 
analyzed using a rabbit anti-HMPV F antiserum followed by a IRDye680 conjugated goat anti-
rabbit antibody and visualized using the Odyssey Infrared Imagining System (Li-Cor 
Biotechnology, Lincoln, NE). Signal intensities were quantified using the Odyssey Application 
Software, corrected for background, and normalized to WT binding to Vero cells. Student-T tests 
or ANOVA tests were used to determine statistically significant differences. 
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Protease Treatment 
Cells plated the day before (2.4 x 105 cells for trypsin treatment and 6 x 105 for 
proteinase K treatment) were resuspended with 50 mM PBS EDTA (pH 8) and treated with 
different concentrations of trypsin for 10 minutes or 1.25% trypsin combined with 90 µL of FBS 
as control (0% trypsin). Following trypsin neutralization by addition of 90µL of FBS, the cells 
were transferred into a 15 mL conical tube, washed with 13 mL PBS, and exposed to virus 
(rgPIV5 at an MOI of 20, and rgHMPV at an MOI of 5) for 1 hour at 4°C. Cells were then washed 
with 14 mL PBS and plated in 35 mm dishes. The cells were detached the following day, fixed in 
1% formaldehyde, and analyzed by flow cytometry. For proteinase K treatment, cells were 
detached from the plate either with 2.5 mM EDTA PBS (pH8) or with 300 µL of 300 µg/mL 
proteinase K in TBS 3 mM CaI2. For control cells (0 µg/mL proteinase K), 1 mL of PBS 2.5 mM 
EDTA/1% phenylmethylsulfonyl fluoride (PMSF) and 300 µL of 300 µg/mL proteinase K were 
added simultaneously. Proteinase K was neutralized by the addition of 1% PMSF before being 
exposed to virus (at an MOI of 10, 50, and 50 for HMPV, PIV5, and VSV G* ΔG respectively). Cells 
were incubated with the virus for 45 minutes at 4°C before being plated in a 12-well plate 
overnight. The cells were detached, fixed in 1% formaldehyde, and analyzed by flow cytometry 
the following day. Student-T tests or ANOVA tests were used to determine statistically 
significant differences. 
 
Heparinase Treatment 
Cells plated the day before were treated with 2mIU/mL of heparinase 1, heparinase 3, 
both (Sigma), or 20mIU/mL chondroitinase ABC as control for 1 hour at 37°C followed by the 
standard protocol for binding or infection assays (described above).  
 
Homology Modeling 
A model of the prefusion conformation of the HMPV F protein from the molecular 
coordinates (mmdbId: 37132) determined from the crystal structure of the prefusion form of 
PIV5 F (384) was generated using DeepView/Swiss-PdbViewer v4.0.1 (www.expasy.org/spdbv/). 
The HMPV F sequence was loaded and fitted to model each monomer of PIV5 F. The modeled 
HMPV F monomers were merged, and structure was energy minimized with 100 steps of 
steepest descent. For the postfusion HMPV F protein model, the F1 and F2 sequences of HMPV 
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F were loaded to model the F1 and F2 domains of each NDV F monomer (mmdbId: 82359) (336), 
fitted onto the structure, and then merged. 
 
Isolation of Cell Surface Proteins for Receptor Identification 
Cell surface proteins of different cell types were isolated using the Biotinylation Kit from 
Pierce (Cat. 89881) according to manufacturer’s protocol. Briefly, the surface proteins of cells 
from four T-75 flasks were biotinylated at 4˚C for 30 minutes. Cells were then transferred to a 50 
mL conical tube and lysed in the presence of protease inhibitors. Complete lysis was achieved by 
sonicating the samples with five 1-second bursts at low power followed by a 30-min incubation 
on ice with occasional vortexing. The lysates were subjected to centrifugation at 10,000 x g for 2 
mins at 4˚C and the clarified lysates were transferred to a capped column with 500 µL of 
resuspended neutravidin beads previously washed with the supplied wash buffer. The lysates 
were incubated for 1 hr at room temperature in a rotator. The samples were washed and then 
incubated in a rotator for 1 hr at room temperature in 400 µL of SDS sample buffer 
supplemented with DTT and without bromophenol blue. A280 readings were performed on each 
sample following collection and then stored at -20˚C. 
 
Virus Overlay Protein Binding Assay 
Thirty microliters of isolated cells surface proteins were heated at 70˚C for 15 mins and 
subjected to centrifugation at 2000 x g for 5 mins. Two sets of 15 µL sample/well were loaded 
symmetrically into a 4-12 % NuPage Bis-Tris gel (Invitrogen) and migrated at 200 V for 40 mins. 
One sample set was fixed with 50 % methanol and 10 % acetic acid for 30 mins, washed, and 
stored at 4˚C in 10 mM Tris pH 8.8. The other sample set was transferred onto a PDVF 
membrane, blocked with 5 % milk dissolved in TBS for 1 hour at room temperature, and 
incubated with 1.6 x 107 PFU of rgHMPV diluted in 2 mL of 2.5 % milk in TBS for 4 hours. The 
PDVF membrane was washed twice with TBS and one more time with t-TBS to permeabilize the 
viral membrane before an overnight incubation at 4˚C with an anti-HMPV F polyclonal antibody 
diluted 1:1000 in 2.5 % milk. The sample was then washed and incubated for 2 hours at 4˚C in 
goat anti-rabbit conjugated with IRDye700 and developed using the Odyssey (Licor). The image 
was placed under a glass plate and the fixed gel was aligned on top of the glass to excise the 
bands of interest. The protein content of the samples of interest were determined by mass 
spectrometry by the University of Kentucky Proteomics core. 
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Immunofluorescence 
Vero cells grown in coverslips transfected with either WT or DN forms of dynamin or 
Rab5 fused with mCherry and mRFP respectively were infected with either rgHMPV or PIV5 for 
three hours. Following an overnight incubation, cells were fixed with 4 % paraformaldehyde at 
4˚C for 15 mins and mounted on slides with Vectashield + DAPI. Cell imaging was performed 
using a 20X objective on a Nikon A1 spinning disk confocal microscope. For viral particle 
colocalization studies, HMPV or VSV were bound to Vero cells grown in coverslips at 4˚C for 1 hr. 
After extensive washing, cells were either incubated in media prewarmed to 37˚C for 5 mins to 
allow viral entry before fixing or fixed right away (t = 0 mins) and then stained with Alexa Fluor 
647-conjugated wheat germ agglutinin (Invitrogen) according to manufacturer’s protocol. Cells 
were then permeabilized with 0.05 % Tween-20 in PBS for 10 mins at room temperature and 
blocked with 4 % normal goat serum diluted in PBS supplemented with 0.02 % sodium azide 
(PBSN) for 1 hr at room temperature and incubated overnight at 4˚C with primary antibodies 
against EEA-1, Rab5, Rab7, or HS and HMPV N or HMPV F in a humidified chamber. Cells were 
washed five times with PBSN the following morning, incubated in secondary antibodies (goat 
anti-mouse and goat anti-rabbit) for 3 hours, and mounted on slides with Vectashield + DAPI. 
Cell imaging was performed using a 60X objective on a Nikon A1 spinning disk confocal 
microscope. 
 
siRNA Electroporation 
A549 cells were resuspended at a concentration of 3 x 106 cells / 400 µL in RPMI media, 
transferred to an electroporation cuvette (Biorad, Hercules, CA), and incubated with 200mM 
siRNA (purchased from Sigma) at room temperature for 10 mins. Cells were subjected to 
electroporation in a Gene Pulser Xcell System (Biorad) at 400 V and 500 µF capacitance, 
incubated for 10 mins at room temperature, and diluted by adding 600 µL of RPMI media 
supplemented with 10 % FBS and 1 % P/S. Cells were then plated in 24- or 6-well plates (40 µL or 
150 µL of cells per well respectively) and incubated at 37˚C for 72 hours before assaying.  
 
RNA Isolation and Quantitative PCR 
A549 cells were collected in 1.5 mL Eppendorf tubes and subjected to centrifugation at 
1000 x g for 10 mins. The supernatant was discarded and the pellet resuspended in 800 µL 
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Tripure Isolation Reagent (Roche Diagnostics, Indianapolis, IN). After incubating the samples at 
room temperature for 5 mins, 200 µL of chloroform (Fisher) was added. Each sample was 
shaken vigorously for 15 secs followed by a 15 min incubation at room temperature. The 
solution was subjected to centrifugation at 12,000 x g for 15 mins at 4˚C and the colorless layer 
was transferred to another tube. The RNA was precipitated with 500 µL of isopropanol for 10 
mins at room temperature followed by centrifugation at 12,000 x g for 10 mins at 4˚C. The 
precipitated RNA was washed once with 1 mL of 75 % ethanol and air-dried overnight. The 
samples were then resuspended in DEPC-treated water (Ambion) the following morning and 
stored at -20˚C. For quantitative PCR (qPCR), 3 µg of RNA diluted in 8 µL was treated with 1 µL of 
DNAse 1 (Sigma) for 15 mins. DNAse activity was stopped with the addition of 1 µL of Stop 
Solution (supplied by the manufacturer) and by incubation of the sample at 70˚C for 10 mins. 
cDNAs from the RNA samples were made using qScript cDNA SuperMix kit (Quanta Biosciences, 
Gaithersburg, MD) according to manufacturer’s protocol. The amount of cDNA was then 
quantified with Brilliant II SYBR Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA) 
using a Stratagene Mx4000 Multiplex Quantitative PCR cycler. 
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Chapter 3: Potential Electrostatic Interactions in Multiple Regions Affect HMPV F-Mediated 
Membrane Fusion 
 
* This work was completed with the help of Brent Hackett, who contributed intellectually to this 
work and performed the initial mutagenesis reactions for the HMPV F E51A, D54A, E56A, R163A, 
R166A, D54A/E56A, D54A/H435R, E56A/H435R, D54N/E56Q, and D54N/E56Q/H435R protein 
mutants. Insertion of the mutant F proteins into the HMPV full length cDNA plasmid and the 
initial rescue of mutant viruses were performed by Christine Winter and Ursula Buchholz. The 
rest of the HMPV F protein mutants, the generation of plasmids with mutant HMPV F flanked by 
intergenic regions, and the subsequent propagation of mutant viruses were performed by me. 
Furthermore, I also performed all the experiments shown in the figures related to this chapter. 
 
Introduction 
Human metapneumovirus (HMPV) is a recently discovered paramyxovirus that is a 
major cause of upper and lower respiratory tract disease worldwide in all age groups (38, 39, 
252, 363). Numerous studies have shown that, in addition to exacerbating underlying diseases 
such as COPD, HMPV can cause significant morbidity, and some mortality, especially in infants, 
the elderly, and people with compromised immune systems (38, 112, 113). Indeed, studies have 
estimated that HMPV is the second or third most common cause of severe acute respiratory 
tract infection in children (252). Despite its widespread human pathogenicity, there is currently 
no approved antiviral medication or vaccine against HMPV. 
HMPV expresses three surface glycoproteins: the putative attachment protein, G, the 
fusion protein, F, and the small hydrophobic protein, SH (180). The F proteins of 
paramyxoviruses, including that of HMPV, are trimeric, type I fusion proteins. The membrane 
fusion event is intimately linked to final formation of a six helix bundle in the F protein, after 
extensive conformational changes bring two heptad repeat (HR) regions—HRA and HRB—into 
close proximity (315). For paramyxovirus, the triggering event that drives these conformational 
changes is hypothesized to occur following attachment of the virus to its receptor. This 
triggering must be carefully regulated as the subsequent conformational change of the F protein 
from its metastable prefusion form to its stable postfusion form is irreversible. Before a 
paramyxovirus F protein can be triggered to promote membrane fusion, it must undergo one or 
more proteolytic cleavage events, which cut the precursor form of the protein (F0) into an 
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active, disulfide-linked form (F1+F2) (180, 315). Unlike most paramyxovirus F proteins, which are 
processed by proteases present in the host cell, HMPV F requires exogenous protease cleavage 
to be fusogenically active. Thus, for infection to occur, HMPV requires proteolytic activation 
after budding. In vitro, the cleavage of HMPV F can be achieved by artificially adding a low 
concentration of trypsin to the system (299). 
Despite being classified as a paramyxovirus, HMPV is novel in several aspects. While 
most other paramyxoviruses require the expression of an attachment protein to be infectious, 
HMPV, like its near relative RSV, is infectious in vitro when devoid of the G protein (31, 164, 
180). However, unlike RSV, HMPV lacking the G protein was also infectious in animals, including 
non-human primates (27, 31). Additionally, the HMPV F protein alone was able to promote cell-
cell fusion in the absence of the G protein (299). These observations suggest that HMPV F can 
promote both attachment and efficient membrane fusion. 
Another distinguishing feature of HMPV is that, at least for some strains of the virus, low 
pH can trigger the fusion activity of the F protein (143, 299) while most paramyxovirus F 
proteins are triggered at neutral pH (180). Our laboratory has shown that low pH treatment of 
Vero cells transfected with the F protein of HMPV strain CAN97-83 (Clade A2) leads to F 
triggering and subsequent syncytia formation (299). Furthermore, inhibitors of endosomal 
acidification such as bafilomycin A and concanamycin were able to confer partial protection 
against infection with a recombinant GFP-expressing HMPV CAN97-83 as well as a B1 strain of 
the virus (203, 298). Certain strains of HMPV Clade A1 also show low pH-promoted fusion (143). 
While low pH triggering is unusual for paramyxoviruses, several viruses from other virus 
families require low pH for membrane fusion. A classic example of a type I fusion protein 
triggered by low pH is influenza HA, which has a triggering threshold of approximately pH 5.4 
(276). Mechanistically, it is thought that electrostatic repulsive forces that arise between 
residues that become protonated at low pH and their neighboring residues are responsible for 
destabilizing the prefusion form and allowing it to trigger and refold into its postfusion 
conformation (133, 147). The effects of electrostatic interactions on the stability of a protein 
vary dramatically depending on the location of the interaction and the surrounding 
environment. For instance, modeling studies showed a strong attraction between the positively 
charged HA1 subunits and the negatively charged HA2 subunits of influenza HA. At low pH, 
however, the HA1 subunits become protonated, increasing the repulsive force between 
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neighboring HA1 subunits in the trimeric protein. This results in protein destabilization, which 
aids in facilitating the transition to the postfusion structure (146). 
Previous studies have emphasized the role of histidine residues in the influenza HA 
triggering event as well as for other fusion proteins (162). These moieties, with a side chain pKa 
value of 6.04 in solution, can undergo protonation under physiological conditions. Interestingly, 
sequence analysis of different influenza serotypes showed that a number of histidine residues 
are conserved across strains, highlighting the potential role of these residues for the function of 
the fusion protein (162). Analysis of a homology model of the prefusion form of the HMPV F 
protein showed the presence of a region in the HRB-linker domain consisting of a central 
histidine, H435, that is surrounded by several basic residues, most notably K295, R396 and K438 
(Figure 6 and (298)). Previous studies indicate that the HRB-linker domain is important for 
modulating fusion in the F protein of PIV5 (289). Mutagenesis studies confirmed the importance 
of this region for the low pH-dependent trigger of HMPV F as alanine substitutions to the 
abovementioned basic residues resulted in a dramatic decrease in fusion activity (298). Thus the 
electrostatic repulsion forces that arise upon protonation of H435 at low pH could be a driving 
force for fusion triggering of HMPV F. 
In this study, we tested the hypothesis that changes in the ionization state of H435 
provide the driving force to trigger fusion. While the introduction of a negatively-charged 
residue stabilized the protein, preventing it from triggering, a positive charge at this position 
restored triggering at pH5 but not at a higher pH. These results indicate a positive charge in this 
region is required but not sufficient for triggering. Further analysis of the HMPV F protein 
revealed a second unique, highly-charged region located in F2. We therefore performed 
mutagenesis studies in this region and report that residues E51, D54 and E56 are also important 
in the triggering and stability of HMPV F. The results reported in this study shed new light on the 
potential roles of electrostatic interactions for HMPV F-mediated membrane fusion and suggest 
that interactions in multiple regions drive F conformational changes. 
 
Results  
A Positive Charge at Residue 435 is Required but not Sufficient for Efficient Triggering of HMPV F 
We have previously reported that the histidine at position 435 (H435), located at the 
HRB-linker domain (289), and the basic residues K295, R396 and K438 that surround it (Figure 
6A) are important for low pH triggering of HMPV F (298). Because estimating the position of the 
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side chains from a homology model is less accurate than estimating that of the protein 
backbone, the distance between the β-carbons of H435 and K295, R396 and K438 were 
measured and were estimated to be less than 15 Å apart (Table 1). Therefore, the side chains of 
these residues could be positioned such that addition of another positive charge through the 
protonation of H435 at pH 5 could destabilize the metastable prefusion form, causing it to 
trigger. To test this, a positive charge at position 435 was introduced by making arginine and 
lysine substitutions (HMPV F H435R and H435K). Additionally, HMPV F H435D and H435E 
mutants were created to introduce a negative charge in the region. 
Surface biotinylation was performed using an antibody against the cytoplasmic tail of 
HMPV F to examine surface expression and proteolytic cleavage of the mutant proteins. For all 
mutant proteins, the inactive F0 precursor form and the cleaved, active F1 form were expressed 
at the cell surface (Figures 7A-B), suggesting that these proteins are properly folded. Total and 
surface expression levels of the F1 form of HMPV F H435D, H435K and H435E mutants were 
decreased by 30-50% compared to wild type (WT) whereas the HMPV F H435R mutant was 
expressed at WT levels. The percentage of cleaved protein varied from 54 to 59% for the wt and 
mutant F proteins, a difference that was not statistically significant. 
Fusogenic activity of these mutants was determined using a syncytia assay, where cells 
expressing the mutant proteins were exposed to four 4-minute low pH pulses (Figure 7C). Both 
the HMPV F H435R and H435K mutants were capable of promoting cell-to-cell fusion when 
exposed to pH 5 pulses, and formed syncytia at a number equivalent to or slightly higher than 
WT. Like WT, however, these mutants did not show significant fusion activity at pH 6 or pH 7 
(data not shown). These data indicate that a positive charge at position 435 is not sufficient to 
drive membrane fusion, though our results suggest a positive charge at this position is necessary 
for triggering. Similar to the previously published HMPV F H435A and H435N protein mutants 
(298) and in agreement with results shown by Mas, et. al. (203), fusion activity was not detected 
for the HMPV F H435D or H435E mutants, potentially because the positive charge involved in 
triggering was replaced by a negative charge that stabilized the prefusion form of the protein.  
To confirm the findings from the syncytia assay and quantify fusogenic activity, a firefly 
luciferase reporter gene assay was employed. Briefly, Vero cells co-transfected with the 
different HMPV F proteins and a T7-luciferase plasmid were overlaid onto T7 polymerase-
expressing BSR cells. Upon membrane fusion of the two cell lines, luciferase production occurs, 
allowing quantification of fusion. Consistent with the syncytia assay, the HMPV F H435R and 
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H435K mutants were fusogenically active at pH 5 but not at pH 6 or pH 7 (Figure 7D). 
Interestingly, luciferase production of cells expressing the HMPV F H435R mutant increased by 
25% compared to WT. Despite a 45% decrease in surface expression for the HMPV F H435K 
mutant, cells transfected with this mutant F protein retained 84% of fusion activity compared to 
WT, suggesting that HMPV F H435K may have a hyperfusogenic phenotype, as previous studies 
with other paramyxovirus F proteins indicate that fusogenic activity correlates with levels of 
surface expression of F (101, 289, 314). Fusion levels above background at pH 6 or 7 were not 
detected for any of the mutants tested and, as seen in the syncytia assay, HMPV F 435D and 
H435E mutants did not show any fusion above background at pH 5 (Figure 7D, p > 0.05, ANOVA). 
Together, these results suggest that a positive charge at position 435, likely present after 
protonation at low pH, is necessary but not sufficient for the triggering of HMPV F. 
 
Mutations in H435 and the Surrounding Basic Residues Impair Viral Growth 
Our previous studies showed that H435 and its surrounding basic residues are important 
for low pH-dependent cell-cell fusion activity of HMPV F (298). To determine if these changes in 
fusion activity translated into changes in viral growth, recombinant GFP-expressing HMPV 
carrying the mutations HMPV F H435A, H435N, K295A, R396A or K438A were created by 
replacing the HMPV F WT gene in the rgHMPV full length cDNA plasmid (30) with the mutant 
HMPV F genes. Mutant viruses were recovered by transfection of BSR cells (30), sequenced to 
confirm the presence of the desired mutation and the absence of other mutations in the F 
protein, and used subsequently to generate later passages. Viruses were then titered to ensure 
that cells were infected at an equal MOI of 0.01. Compared to WT, all mutant viruses exhibited 
at least a 100-fold reduced viral growth. On day six after infection with WT rgHMPV, 100% of the 
cells in a plate were infected, resulting in high GFP expression levels and a titer between 106 and 
107pfu/mL, while the rate of infection and growth of the mutant viruses was dramatically less 
(Figure 8). Consequently, propagation of these viruses required a much longer incubation period 
to achieve workable viral titers (data not shown). Interestingly, viruses carrying the mutations 
K295A and R396A were more impaired relative to HMPV carrying the mutations H435A and 
H435N in their F protein, producing titers of less than 102pfu/mL. These results confirm that 
alterations of H435 and the region surrounding it are deleterious for HMPV growth, verifying 
that this region is important for the fusion activity of HMPV F and the overall fitness of the virus. 
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An Electrostatic-rich Region in F2 Modulates HMPV F Low pH-dependent Fusion 
As our results suggested that a positive charge at position 435 was necessary but not 
sufficient to trigger HMPV F, the homology model was further examined for additional regions 
where changes in charge-charge interactions could potentially contribute to low pH triggering. 
When the amino acid sequence of HMPV F was aligned against those of other paramyxovirus 
fusion proteins, a distinct stretch of negatively-charged residues, including E51, D54 and E56, 
was identified in the HMPV F2 domain that was not present in other paramyxovirus F proteins. 
This region is homologous to the CBF2 region shown to modulate fusion of PIV5 F (121). 
Structural analysis of PIV5 F indicated that a portion of CBF2 interacts with sections of the 
heptad repeat A (HRA) to form a 3-strand β-sheet that is hypothesized to stabilize the F protein 
structure in its prefusion conformation (121, 384). Interestingly, the homology model of HMPV F 
predicts these CBF2 residues to be positioned in proximity to two positively-charged moieties 
from the HRA region—R163 and K166 (Figure 6B). Measurements from our homology model 
estimate the distance between β-carbons of these residues to be between 4 and 11 Å (Table 2), 
a distance permissible for the formation of salt bridges between side chains at neutral pH, 
potentially stabilizing the overall structure of HMPV F. For salt bridges to form, the charged 
groups of the side chain need to be less than 4 Å apart (16, 175). The highly charged local 
environment in this region could theoretically alter the pKa of the side chains such that a drop in 
pH from 7 to 5 could lead to changes in the protonation state of E51, D54 and/or E56, resulting 
in destabilization and facilitating triggering. To determine if these amino acids play a role in low 
pH-dependent fusion activity, the HMPV F mutants E51A, D54A and E56A (F2 mutants) as well as 
R163A and K166A (HRA mutants) were created and tested for proper expression and fusogenic 
activity at various pH. 
With the exception of the E51A mutant, for which surface F1 expression was 66% of WT, 
all F2 and HRA mutants were expressed close to or above WT levels on the surface of transfected 
Vero cells (Figure 9A-B). The fusogenic activity of the mutant proteins was determined with 
syncytia and reporter gene fusion assays. All the mutants were able to promote efficient 
syncytia formation at pH 5 except HMPV F E51A (Figure 9C). Cells transfected with HMPV F 
D54A, E56A, R163A and K166A mutants produced more numerous and larger size syncytia 
compared to WT at pH 5. In contrast syncytia formation was not detected in cells transfected 
with HMPV F E51A despite a significant amount of protein being expressed at the cell surface 
(Figure 9A-C). To our surprise, all the mutants except HMPV F E51A also showed syncytia at pH 
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6, albeit smaller (Figure 9C). However, compared to pH 5, syncytia formation was significantly 
lower at pH 6 and undetectable at pH 7 (data not shown). 
In agreement with the syncytia assay, all the mutant HMPV F proteins with the 
exception of E51A were able to efficiently promote fusion at pH 5 in the reporter gene assay 
(Figure 9D). In fact, the D54A, E56A and K166A mutants promoted fusion by at least 25% above 
WT. The HMPV F R163A mutant exhibited similar fusogenic activity as WT while fusion activity 
for HMPV F E51A was diminished to near background levels. The HMPV F D54A, E56A and K166A 
mutants also promoted fusion above WT levels at pH 5.5 though, as seen with WT, the fusogenic 
activity was reduced by more than 50% compared at pH 5. Fusion levels for HMPV F R163A were 
similar to WT and no fusion above background was observed for HMPV F E51A at pH 5.5. 
Interestingly, no fusion activity above background was detected at pH 6 or above for any of the 
mutants. The disparate results between the syncytia and the reporter gene assays at pH 6 may 
be due to differences in the kinetics of the fusion process triggered at this pH as well as by 
different amounts of activate F present at the surface. While luciferase production was assessed 
after two pulses spaced one hour apart, syncytia formation was induced by a total of four pH 
pulses given every two hours. Additionally, for the luciferase reporter to be synthesized, a pore 
large enough to transfer plasmid DNA or the T7 polymerase must be formed between the time 
of the pH pulse and cell lysis (4 hours). Syncytia formation, on the other hand, was assessed 
after an overnight incubation, which allows sufficient time for slower proteins to undergo the 
conformational changes needed to enlarge the fusion pore (103). 
 
E51 is Required for the Proper Local Folding and Cleavage Activation of HMPV F 
The results from the F2 and HRA mutants suggest that this region plays two important 
yet different roles in the stability and triggering of HMPV F. E51 appears to be involved in the 
overall fusion activity of HMPV F and could potentially serve as another pH sensor. Therefore, to 
test whether E51 acts similarly to H435, expression and fusion of the HMPV F E51K mutant was 
assessed. 
Replacement of E51 with a lysine (E51K) decreased the surface expression levels of the 
F1 form of HMPV F by nearly 50% (Figure 10A-B). The reduction in surface expression observed 
for both the E51A and E51K mutants suggests that the negative charge at this position is 
important for stability and expression of the protein at the cell surface. The importance of this 
residue is underscored by the fact that the portion of the HMPV F E51K mutant that remained 
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on the surface also failed to promote cell-to-cell membrane fusion at any pH, as assessed by our 
reporter gene and syncytia assays. 
To test whether there is crosstalk between E51 and H435, the mutation E51K/H435R 
was also made and analyzed. Like HMPV F E51K, surface expression of E51K/H435R was 
reduced. Furthermore, cell-to-cell fusion activity was not detected at any pH despite the 
introduction of the hyperfusogenic mutation H435R (Figure 10C-D). These results suggest that 
the E51K mutation is dominant over H435R and confirms that residue E51 plays a key role in the 
overall function of F. 
Even though the HMPV F E51A, E51K AND E51K/H435R mutants showed a lower surface 
expression, a significant amount of the mutant F reached the cell surface, suggesting that the 
effect of these mutations on the overall structure is not severe enough to result in complete ER 
retention due to gross misfolding. Since E51 is near the cleavage site of HMPV F, electrostatic 
interactions involving this moiety may be important for the proper folding and positioning of the 
proteolytic processing site. To test this, surface expression of HMPV F E51A and E51K was 
examined in the absence of trypsin. Though HMPV F strains or mutants have been identified in 
which some processing to the mature F1+F2 is observed in the absence of exogenous trypsin (28, 
293), wt HMPV CAN97-83 F protein cleavage in vitro has been shown in our laboratory and 
others to require trypsin treatment (29, 299, 352). Fitting with this, WT HMPV F protein was 
observed in the mature, cleaved F1 form only after addition of trypsin (Figure 11A-B). 
Interestingly, more than 30% of the E51A and E51K mutants were cleaved in the absence of 
trypsin (Figure 11A-B), suggesting that the removal of the negative charge at position 51 caused 
local misfolding that exposed a cleavage site normally not accessible to an endogenous 
protease. Indeed, analysis of the sequence of HMPV F revealed the presence of an arginine 
residue located two residues upstream of the putative cleavage site that could be utilized by an 
endogenous trypsin-like protease. This aberrant cleavage event, however, did not result in a 
fusogenically active F protein (Figure 10C-D). These results therefore suggest that E51 is 
important for positioning of the fusion peptide for proper proteolytic processing. 
 
Charged Residues in F2 are Important for HMPV F Prefusion and Postfusion Stability 
The hyperfusogenic phenotype of HMPV F D54A and E56A suggests that these residues 
are involved in modulating the stability of the protein, potentially through salt bridge 
interactions with R163 and K166 in the prefusion state. At low pH, neutralization of D54 and/or 
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E56 could disrupt these salt bridges, allowing F to trigger. HMPV F double mutants D54A/E56A 
and D54N/E56Q were created and analyzed to determine the effects of disrupting these 
potential interactions. The latter mutation, D54N/E56Q, is a more conservative, isosteric 
substitution that removes the charged residues while maintaining polarity at these residues. 
Analysis of the R163 and K166 mutations was not pursued further due to the location of these 
residues in HRA, as their potential role in six-helix bundle formation means fusion changes may 
not be directly attributed to triggering. Additionally, HMPV F D54A/H435R, E56A/H435R, 
D54A/E56A/H435R and D54N/E56Q/H435R mutants were made to test whether changes in one 
region influence the other. 
Though the HMPV F D54A or E56A mutants expressed at or above WT levels (Figure 9A), 
surface expression of the F1 form of the double alanine mutant (D54A/E56A) decreased by more 
than 40%. Consistent with a decrease in surface expression levels, a reduction in fusion activity 
was also observed for the HMPV F D54A/E56A mutant. The more conservative polar 
substitutions (D54N/E56Q), however, restored the surface expression to WT levels (Figure 10A-
B), suggesting that either polar residues or steric similarity is needed to stabilize the prefusion 
form of the protein. 
According to our reporter gene fusion assay, fusion activity is significantly enhanced for 
HMPV F D54N/E56Q at pH 5 (Figure 10C) to levels equivalent to E56A. However, the effect of 
these mutations on the stability and fusogenic activity of the protein is different. D54N/E56Q is 
more hyperfusogenic at pH 5.5 compared to E56A and, while the addition of the H435R 
mutation to D54N/E56Q (D54N/E56Q/H435R) had a modest effect on fusion at pH 5.5, 
E56A/H435R exhibited a dramatic increase in fusion activity at the same pH. More importantly, 
analysis of the syncytia assay revealed that cells expressing the HMPV F D54N/E56Q and 
D54N/E56Q/H435R mutants produced numerous syncytia but significantly smaller in size 
compared to WT, E56A and E56A/H435R when triggered at pH 5 (Figure 10D). The greater 
amount of smaller syncytia agree with the hyperfusogenic phenotype observed in the reporter 
gene fusion assay as this would result more cells fusing and increased luciferase production. No 
syncytium formation was detected at pH 6 or pH 7 (data not shown). Thus, our data indicate 
that the replacement of the negative charges at positions 54 and 56 leads to changes in the 
stability of the fusion protein that can be seen by changes in surface expression and fusogenic 
activity. 
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The addition of the hyperfusogenic mutation H435R (D54A/H435R, E56A/H435R, 
D54A/E56A/H435R AND D54N/E56Q/H435R) did not significantly alter the fusion levels of the 
mutant proteins at pH 5 (Figure 9A and D, Figure 10C-D). However, the presence of the H435R 
mutation led to a modest increase in fusion activity at pH 5.5 with the notable exceptions of 
D54A/H435R and E65A/H435R, where the increase in fusion was significantly more pronounced. 
Together with a minor decrease in F1 surface expression (Figure 9A and Figure 10A), our data 
suggest that H435R also affects the stability of the protein, allowing it to trigger at a higher pH. 
The destabilizing force of adding a basic residue to an already positively charged region can 
indeed be responsible for the hyperfusogenic phenotype of H435R, as disruptions of charge-
charge interactions has been shown to alter the triggering threshold of influenza HA (83, 276). 
The pH dependency of HMPV F-mediated membrane fusion, however, was not abolished by 
mutations at positions 54 and/or 56. Therefore, while H435 mediates the stability of the HRB-
linker region to behave as a pH sensor, the stability effect conferred by residues D54 and E56 is 
not involved in sensing low pH. 
 
Discussion 
The results presented in this study present new insights into the multiple roles that 
electrostatic interactions play in the folding, stability, and triggering of HMPV F. We 
demonstrated that a positive charge at position 435 is necessary but not sufficient to trigger 
HMPV F, with this charge most likely arising though protonation of H435 upon its exposure to a 
low pH environment. This conclusion is supported by a recent report in which this histidine 
residue was mutated in the F protein of phylogenetically distinct HMPV with similar results 
(203). Furthermore, our mutagenesis studies revealed that the novel enrichment of charged 
residues present in the F2 and HRA domains of HMPV F are important for proper local folding 
and the overall stability of the protein. Removal of the negative charge at position 51 affected 
proteolytic processing and led to an inactive protein on the cell surface, consistent with an 
alteration to local conformation. Loss of charge at positions 54, 56, 163 and/or 166 also affected 
stability and fusogenic activity of HMPV F. 
Several reports have shown important differences between members of the 
pneumovirinae subfamily and their paramyxovirinae counterparts. While viruses in the 
paramyxovirinae subfamily require the expression of the attachment protein for membrane 
fusion and infection to occur, both RSV and HMPV remain infectious in vitro in the absence of 
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their putative attachment proteins (31, 164). Further, our laboratory has shown that triggering 
of HMPV F can occur in the absence of the HMPV G protein (299). Indeed, recent studies suggest 
that the protein responsible for the primary attachment step for both of these viruses is F (65, 
342). The possibility of triggering the F protein of certain clades of HMPV by low pH further 
distinguishes this virus from the rest of the family (143, 299). Close examination of the sequence 
alignment of HMPV F against other paramyxovirus F proteins and a homology model based on 
the prefusion form of PIV5 F (384) reveal areas rich in charged residues that are absent in other 
F proteins. Therefore changes in the ionization state of these residues could explain the 
triggering of HMPV F by low pH, as seen in influenza HA (276, 290, 348). 
The first highly-charge region identified is located at the HRB-linker domain and is 
centered at H435 (298). Based on mutagenesis studies, we and others determined that H435 
and the neighboring K295, R396 and K438 in addition to G294 are important for low-pH 
mediated fusion (143, 298) and the severe attenuation of recombinant HMPV bearing the 
mutations H435A, H435N, K295A, R396A or K438A in their F protein (Figure 8) highlights the 
importance of this region for the virus. Furthermore, analysis of HMPV F H435R and H435K 
mutants presented here and elsewhere strongly suggests that a positive charge in this region is 
required though not sufficient for low-pH triggering of HMPV F. Both the H435D and H435E 
mutants were not fusogenically active, likely due to the presence of a negative charge. Such a 
phenotype, we hypothesize, is due to stabilization of the prefusion form via electrostatic 
attraction in contrast to the hyperfusogenic profile observed when a positive charge is present 
at position 435. 
Despite the dramatic reduction in cell-to-cell fusion observed when the charged 
residues around HMPV F H435 were removed (298), we were able to rescue infectious HMPV 
particles bearing mutations in these residues (Figure 8). Interestingly, while viral titers from all 
mutant viruses were reduced by three or more logarithmic units compared to wild type, titers 
from recombinant viruses expressing the H435A and H435N mutations were higher compared to 
those bearing the K295A and R396A mutations. Our homology model of the HMPV F protein in 
its prefusion conformation indicates that K295 and R396 are freely exposed at the surface of the 
protein (Figure 6). It is possible that these residues have other important roles in the lifecycle of 
the virus, thereby increasing the selective pressure and making these mutations more difficult to 
overcome. We have shown that HMPV entry is initially mediated by interactions between the F 
protein and heparan sulfate (65). Therefore, one possibility is that the positively charged 
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residues K295 and R396 are needed for interactions with the negatively charged heparan sulfate 
during virus entry. Even though the residues around H435 are located at the base of the head 
domain, interactions could take place at an intermediate step or with longer branches of 
heparan sulfate. 
Protonation of H368 was recently suggested by Mas et al. to also be important for low 
pH-dependent F proteins (203). Our homology model predicts this residue to be more than 20Å 
apart from H435 (data not shown), and is predicted to lie adjacent to and interacting with the 
fusion peptide (298). Alanine and asparagine mutations of H368 in HMPV F CAN97-83 suggest 
that protonation of this residue is not essential for low-pH mediated fusion of this F protein 
(298). Furthermore, with the exception of H368A, for which fusion activity was not detected, 
none of the mutations to H368 reported for CAN97-83 (298) or NL/1/00 (203) showed a pH-
independent triggering unless it was paired with a positively charged residue at position 435. 
These results further emphasize the importance of a positive charge at position 435 and support 
our previous hypothesis that side chain packing around the fusion peptide modulate the fusion 
efficiency and stability of the F protein (298, 314). 
Another unique region in HMPV F CAN97-83 where charged residues are predicted to be 
concentrated in our homology model is the interface between the F2 and HRA domains of the 
protein. While the charged residues are novel relative to other paramyxovirus F proteins, 
sequence alignments indicate this enrichment is conserved across different HMPV clades (data 
not shown). This region has been shown to be important in modulating fusion for PIV5 F (121) 
and structural analysis of PIV5 F in its prefusion conformation (384) indicates that residues in 
this area form a three-strand β-sheet with two of the three strands derived from HRA residues 
and the remaining strand by residues from F2. Though HMPV and PIV5 belong to different 
subfamilies, the importance of this region for the proper folding of F and the promotion of 
membrane fusion is preserved. Interestingly, there are striking differences between the F2 
region of PIV5 F and that of HMPV F. This region in PIV5 F is composed primarily of non-polar 
residues while polar and charged moieties are more predominant in this region of HMPV F. 
Mechanistically, the way this region modulates folding and fusion in PIV5 F is still unclear. 
However, because these charged residues in the F2 domain of HMPV F are predicted to lie near 
those in HRA, we suggest that potential electrostatic interactions between HRA and this region 
in F2 are involved in the folding and fusion of HMPV F. 
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The results shown in this study identify several areas where electrostatic interactions, 
including salt bridges, may play important roles in HMPV F function. We found that a positive 
charge at the previously identified residue H435 (298) results in a hyperfusogenic state but is 
not sufficient alone to cause pH-independent fusion while a negative charge in this position 
blocks F fusogenic activity. Furthermore, we show a charged region in F2 to be important for 
proper proteolytic activation and the overall stability of HMPV F. We have previously shown that 
HMPV infection can be partially inhibited by agents that raise endosomal pH. Additionally, 
HMPV infection was greatly reduced after inhibition of clathrin-mediated endocytosis and 
dynamin by chlorpromazine and dynasore respectively (298). A recent report found  variable 
inhibition of  infectivity of other strains of HMPV by concanamycin A, without a clear link 
between a pH triggered F protein and inhibition by the drug, and no inhibition by  ammonium 
chloride of any tested HMPV strain (203). While our previous results using chlorpromazine and 
dynasore suggest a role for endocytosis on HMPV entry, the correlation between viral entry by 
endocytosis and the requirement for low pH remains unclear. Electrostatic interactions may also 
play a role in viral binding, as we have recently shown that an interaction between HMPV F and 
heparan sulfate plays a critical role in initial binding (31, 65), suggesting that a cascade of 
electrostatic interactions occur to drive HMPV F binding and fusion promotion. 
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Table 1. Estimated distance between β - carbons of H435 and surrounding basic residues in the 
HMPV F homology model. 
From To Å 
H435 K295 10 
H435 R396 13 
H435 K438 6 
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Table 2. Estimated distance between β - carbons of selected amino acid residues in F2 in the 
HMPV F homology model. 
From To Å 
E51 R163 4 
D54 R163 5 
E56 R163 10 
E51 K166 8 
D54 K166 5 
E56 K166 10 
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Figure 6. Homology model of HMPV F in its prefusion conformation highlighting residues 
around H435 and the F2 region.  
The amino acid sequence of HMPV F was threaded onto the crystal structure of the PIV5 F in its 
metastable prefusion form (384). A. HRB-linker domain showing H435 (yellow) at close distance 
to K295, R396, and K438 (cyan). B. The amino acid residues E51, D54, and E56 (red) lie at close 
proximity allowing potential salt bridge interactions with R163 and K166 (green). 
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Figure 7. A positive charge at position H435 is required but not sufficient for HMPV F-
mediated membrane fusion.  
A. Quantification of the total and surface expression of the F1 form of metabolically labeled Vero 
cells expressing HMPV F WT, H435R, H435K, H435D, and H435E in the presence of TPCK-trypsin. 
Data represented as percent WT HMPV F set to 100% (n = 4). MCS = multiple cloning site, empty 
vector control. B. Representative gel of surface proteins used for quantification in A. C. 
Representative images of syncytium formation of cells expressing the H435 mutants after pH 5 
pulses (n = 4). D. Luciferase reporter gene assay of Vero cells transfected with mutant HMPV F 
that were overlaid onto BSR cells and subjected to two pH pulses. Data presented as percent of 
WT luminosity (fusion) at pH 5 (n=5). Error bars = SEM. 
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Figure 8. Recombinant HMPV carrying mutations in the HRB-linker domain of HMPV F show a 
drastic decrease in infectivity.  
GFP expression of WT and mutant HMPV-infected plates 6 days post-infection of passage 2 virus 
grown in Opti-MEM with 200mM L-glutamine and 0.3µg/mL TPCK-trypsin. Values in parenthesis 
are representative titers obtained as described in materials and methods after a six-day 
incubation. 
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Figure 9. Charged residues in F2 and HRA regions of HMPV F are important for the stability and 
fusogenic activity of the protein.  
A. Quantification of total and surface expression levels of the cleaved F1 form of mutant proteins 
HMPV F E51A, D54A, E56A, R163A, and K166A expressed in Vero cells (n=4). Data represented 
as percent of WT HMPV F set to 100%. Asterisk indicates significant difference compared to WT 
control at the same pH (p < 0.05). Error bars = SEM. MCS = multiple cloning site, empty vector 
control. B. Representative surface biotinylation of mutant HMPV F used for quantification in A. 
C. Representative pictures of syncytia assay of HMPV F mutants at pH 5 and pH 6 (n=4). Arrows 
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point to small syncytia seen at pH 6. Area limited by the black squares in D54A and E56A at pH 6 
were enlarged and shown in below (D54A 2x and E56A 2x respectively). D. Luciferase reporter 
gene assay of mutant F tested in A, B, and C (n=3) presented as percent of WT luminosity 
(fusion) at pH 5. Asterisks indicate significant differences compared to WT control (p < 0.05). 
Error bars = SEM. 
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Figure 10. Different charged residues in F2 are responsible for the stability and local folding of 
HMPV F.  
A. Quantification of total and surface expression of the F1 form of HMPV F E51K, E51K/H435R, 
D54A/H435R, E56A/H435R, D54A/E56A, D54A/E56A/H435R, D54N/E56Q, and 
D54N/E56Q/H435R mutant protein as previously described (n=5). Data represented as percent 
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of WT HMPV F set to 100%. Error bars = SEM. B. Representative gel used for quantification in A. 
C. Luciferase reporter gene assay of HMPV F mutant protein mentioned in A. Data presented as 
percent of WT luminosity (fusion) at pH 5 (n=6). Error bars = SEM. D. Representative 
photographs of syncytium formation of HMPV F mutants at pH 5 using Vero cells (n=4). Arrows 
point at smaller syncytia. 
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Figure 11. E51 is important for the proper folding on the HMPV F cleavage site.  
A. Representative gel of the surface expression levels of HMPV F WT and HMPV F E51A and 
E51K mutants in the presence or absence of 0.3µg/mL of TPCK-trypsin. B. Quantification of 
percent cleavage for HMPV F WT and HMPV F E51A and E51K mutant calculated from gels 
shown in A. Percent cleavage = F1/(F1+F0) (n=3). Error bars = SEM. 
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Chapter 4: Human Metapneumovirus Binding and Infection is Mediated by Interactions 
between the HMPV Fusion Protein and Heparan Sulfate 
 
* This work was made in collaboration with Cyril Masante, who made an equal intellectual 
contribution to this work. In addition, he performed the experiments shown in Figure 13C – E, 
Figure 15A – D, and Figure 16D – E, and collaborated in the generation of the data shown in 
Figure 15E – F and Figure 18A – B.  
 
Introduction 
Human metapneumovirus (HMPV) is a major worldwide respiratory pathogen first 
isolated in 2001 from children with respiratory syncytial virus (RSV)-like symptoms (352). Several 
studies since have confirmed the importance of HMPV, generally placing it as the second or 
third most common cause of severe acute upper and lower respiratory tract disease in children. 
Though children and infants, the elderly, people with underlying cardiopulmonary conditions, 
and immunocompromised individuals are more susceptible to severe disease from this virus, 
HMPV affects people in all age groups (reviewed in (252)). Seroprevalence studies have shown 
that most individuals have been exposed to this virus by the age of five though reinfections with 
this virus are frequent (352). HMPV infection results in a range of disease severities from mild 
cold-like symptoms to bronchiolitis, pneumonia, and febrile seizures, and can potentially lead to 
death (159, 252). 
Most paramyxoviruses express two major surface glycoproteins: an attachment protein 
and a fusion (F) protein. Some paramyxoviruses, including HMPV, express an additional putative 
membrane-spanning protein: the small hydrophobic (SH) protein (180). For a paramyxovirus to 
infect a cell, the virus must attach to a cellular receptor, usually through the attachment protein, 
and then fuse the viral and cellular membranes, a process driven by the F protein (180). 
Paramyxovirus F proteins are synthesized as a precursor (F0) form which is then proteolytically 
cleaved to the fusogenically active F1+F2 form (180). For HMPV, this cleavage is accomplished by 
an exogenous protease (299, 307). This proteolytic cleavage primes the F protein for triggering, 
which, for some clades of HMPV, is driven by low pH (143, 299). There is no evidence that the 
SH protein plays a role in viral entry. In fact, HMPV SH protein is dispensable for virus growth in 
vitro and in vivo (26).  
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The paramyxovirus attachment protein is a type II integral membrane protein called 
either HN, H, or G (180). Paramyxoviruses with a G protein do not bind sialic acid but instead 
bind to cellular factors such as Ephrin B2 for the henipaviruses (41, 232). Members of the 
pneumovirinae subfamily express a functionally different G protein which has been shown to 
interact with cell surface proteoglycans in the case of RSV and HMPV (174, 347). Although it has 
been shown that most paramyxoviruses require the attachment protein for binding and 
infection, a role for HMPV G protein in receptor binding has not been confirmed. 
Interestingly, while the attachment protein is essential for virus attachment and 
subsequent membrane fusion in the paramyxovirinae subfamily, studies have shown that some 
members of the pneumovirinae subfamily can be infectious in the absence of the attachment 
protein. RSV lacking G can be propagated in vitro but could not replicate efficiently in vivo (115, 
344) and bovine respiratory syncytial virus (BRSV) lacking G can still infect its host (295). 
Similarly, a recombinant avian metapneumovirus (AMPV), the closest relative of HMPV, lacking 
the SH and G proteins was able to grow, albeit slower than wild-type AMPV, in cell culture (231). 
Studies from our laboratory and others indicate that the G protein of HMPV is also dispensable 
for attachment and fusion, as cell-cell fusion can be accomplished in the absence of G and 
recombinant HMPV particles lacking G are infectious in vitro (299). Furthermore, a mutant virus 
devoid of the G protein can efficiently infect African green monkeys (27) suggesting that the F 
protein of HMPV is capable of performing both the attachment and fusion steps in vivo. Indeed, 
the HMPV F protein has been shown to be an important marker of human infection (257). 
Most cells express a large number of different surface carbohydrates that mediate 
multiple functions such as adhesion, growth and signaling (284). The glycan synthesis of 
glycoproteins is based on two main processes: N-glycosylation, which involves an addition of N-
acetylglucosamine (GlcNAc) to the nitrogen atom of an aspargine residue, or O-glycosylation, 
which is the addition of N-acetylgalactosamine (GalNAc) or xylose to the oxygen atom of a 
serine or a threonine residue. GalNAc addition leads to the synthesis of mucins, whereas xylose 
addition leads to synthesis of glycosaminoglycans (GAG). GAGs can be classified into six different 
groups based on their composition: chondroitin sulfate, heparan sulfate, dermatan sulfate, 
keratan sulfate, hyaluran, and heparin (24, 273, 334).  
Heparan sulfate (HS) is the most often implicated GAG in virus-cell interactions. HS has 
been described as a receptor for multiple herpesviruses and is also necessary during the first 
step of adhesion of other viruses such as HIV and influenza (reviewed in (318)). HS plays an 
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important role in the initial steps of RSV entry, the closest related human pathogen to HMPV 
(45, 131, 132, 174). This interaction, however, appears to be largely mediated by RSV G, and 
viruses lacking G show a significant decrease in binding to CHO-K1 cells (344). A recent study 
showed that the HMPV G protein also has the ability to bind GAGs and suggested that this 
interaction might be a significant factor for virus-cell interactions (347). 
Integrins are extracellular matrix binding proteins expressed in nearly all cell types and 
play multiple roles including the regulation of cell adhesion, tissue growth, and migration 
(reviewed in (15)). These heterodimers, composed of at least 18 different α and 10 different β 
subunits, bind to a myriad of proteins including HS proteoglycans (HSPG), and many proteins 
that express the amino acid sequence Arg-Gly-Asp (RGD) (285). Due to their broad distribution 
on the surfaces of many cell types, several integrins have been implicated in viral entry. 
Integrins are part of the receptor complex of some picornaviruses, hantaviruses, and 
papillomaviruses, and are also involved in adeno-associated virus, Ebola virus, and reovirus 
entry, though not as cellular receptors (84, 222, 297, 328). Furthermore, it has recently been 
reported that the αvβ1 integrin plays a major role in promoting HMPV infection (80). 
In this study, we investigated the role of GAGs and the integrin αvβ1 in HMPV infection 
using wild-type HMPV, a mutant virus lacking the G protein, and a mutant virus devoid of G and 
SH (27). We show that the αvβ1 integrin is not essential for HMPV F-mediated fusion or for the 
initial binding step. Rather, our data indicate that integrins promote infection at a step 
downstream of the initial binding. Additionally, we demonstrate that the G and SH proteins do 
not play a major role in viral attachment, making F the main viral determinant for HMPV 
binding. Finally, we show that HMPV F interacts specifically with heparan sulfate and that HS is 
an indispensable component of the HMPV binding receptor complex. 
 
Results 
The RGD Motif in HMPV F is not Required for Cell-to-cell Membrane Fusion 
Integrin αvβ1 has been shown to play a role in promoting HMPV infection, potentially by 
interacting with the RGD-motif of HMPV F (80). To determine whether RGD-dependent binding 
of HMPV F to αvβ1 integrin is required for fusion activity of HMPV F, we mutated the aspartic 
acid residue in the RGD motif of HMPV F to alanine (F RGA, D331A) using site directed 
mutagenesis. Since the RGD-integrin interaction is dependent on the presence of all three 
residues (285), an RGA mutation should abolish interactions between HMPV F and αvβ1 integrin 
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through this motif. To verify that this mutation did not affect protein folding and expression, the 
cell surface expression and proteolytic processing of wild-type F (F WT) and mutant HMPV F RGA 
was determined. Vero cells were transiently transfected with the pCAGGS expression vector 
(239) encoding the genes for the HMPV F WT or HMPV F RGA mutant. After metabolic labeling 
in media with TPCK-treated trypsin to proteolytically cleave the F protein (299), the surface 
proteins were labeled covalently with biotin. The F proteins were immunoprecipitated with a F-
specific antisera following cell lysis, the surface population separated with streptavidin beads, 
and samples were analyzed by SDS-PAGE electrophoresis. Both HMPV F WT and HMPV F RGA 
mutant were expressed at the cell surface (Figure 12A-B) and the addition of trypsin to HMPV F 
RGA produced the lower molecular weight F1 form. Although the total and surface expression of 
the inactive F0 precursor form of HMPV F RGA mutant was slightly greater than WT, the 
fusogenically active, cleaved F1 form was expressed at WT levels. The proper surface expression 
of the both F0 and F1 forms of HMPV F RGA indicate that this mutant adopts an intracellular 
transport-competent conformation and the cleavage site remains accessible to trypsin, 
suggesting that HMPV F RGA mutant adopts a similar conformation as HMPV F WT.  
To assess the fusogenic activity of HMPV F RGA, syncytia assays were performed (299). 
Briefly, Vero cells expressing HMPV F WT or HMPV F RGA were subjected to four – 4-minute pH 
5 pulses (pH 7 as control) to trigger the trypsin-activated F protein; pictures of syncytia 
formation were then taken the next day. Our laboratory has previously shown that expression of 
HMPV F alone is sufficient for promoting syncytia formation (299). Both HMPV F WT and the 
HMPV F RGA mutant were triggered by pH 5 treatment, leading to the formation of an similar 
number and size of syncytia (Figure 12C). Neither HMPV F WT nor the HMPV F RGA mutant were 
fusogenically active at neutral pH. These results confirm that the RGA mutation does not affect 
the pH dependency of the fusion protein, and that expression of the HMPV F RGA mutant is still 
sufficient to induce membrane fusion in the absence of HMPV G (299).  
The fusogenic activity of the RGA mutant was quantified using a firefly luciferase 
reporter gene assay. Vero cells expressing a luciferase plasmid under the control of the T7 
promoter and either HMPV F WT or HMPV F RGA mutant were overlaid onto BSR cells that 
constitutively express the T7 polymerase (51). Luciferase activity of the cell lysates was assayed 
following two 4-minute pH pulses (299). Luciferase expression directly correlates to fusion 
activity as production of luciferase occurs only after Vero cells carrying a luciferase plasmid and 
expressing a fusogenically active F protein fuse with BSR cells. The HMPV F RGA mutant 
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efficiently promoted membrane fusion at levels approximately 80% of wild-type at pH 5 (Figure 
12D). As in our syncytia assay, both HMPV F WT and the HMPV F RGA mutant did not promote 
fusion at neutral pH, and the HMPV G protein was not required for promotion of cell-to-cell 
membrane fusion. These results indicate that the RGD motif in HMPV F is not essential for the 
promotion of cell-to-cell membrane fusion. 
 
β1 – Integrin is Required for Efficient Infection by HMPV but not for the Initial Binding Step 
To determine whether interaction of HMPV F with αvβ1 integrin is necessary for initial 
virus-cell binding, we directly analyzed virus binding to cells lacking β1 integrin. GD25 cells are 
mouse embryonic fibroblasts deficient in β1 integrin expression due to the introduction of a null 
mutation within the β1 integrin gene. Expression of β1 integrin was rescued by stable 
transfection of a wild-type β1 integrin gene (β1GD25 cells) (367). The expression levels of αv and 
β1-integrins for GD25 and β1GD25, were confirmed using fluorescence automated cell sorting 
(Figure 13A). GD25 and β1GD25 cells were spinoculated with different multiplicities of infection 
(MOI, between 0.5 and 50) of HMPV at 4°C to prevent internalization. After thorough washes, 
cell-bound viruses were labeled with an anti-HMPV N monoclonal antibody followed by an HRP-
conjugated secondary antibody. Binding efficiency of HMPV to GD25 cells and β1GD25 cells did 
not vary significantly, indicating that the expression of β1 integrin does not play a critical role in 
the initial virus-cell binding (Figure 13B). HMPV bound to GD25 and β1GD25 cells at similar 
levels compared to Chinese Hamster Ovary (CHO-K1) cells, which express β1 integrin but non-
detectable levels of αv integrin.  
The results from the first binding assay were verified with a different binding assay using 
western blots (Figure 13C-D). In addition to WT-HMPV, binding efficiency of recombinant 
mutant viruses lacking the putative attachment protein HMPV G (ΔG) or both HMPV G and the 
small hydrophobic protein HMPV SH (ΔG/ΔSH) (27) was also assessed to determine which viral 
surface glycoprotein is involved in the initial binding step. Gene deletions for each virus were 
verified by RT-PCR and the quantity of HMPV F incorporated into the mutant viruses compared 
to WT was similar (Figure 13E). As previously reported (31), infectivity of these mutant viruses 
was similar to WT HMPV (data not shown). HMPV WT, ΔG, and ΔGΔSH viral particles at an MOI 
of 7 were then added to cells and incubated at 4°C for binding. After thorough washes, the cells 
were lysed and a volume corresponding to 6 x 104 cells for each cell line was loaded onto an 
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SDS-PAGE gel, analyzed by western blot, and the band intensities quantified using the Odyssey 
application software. 
While WT HMPV binding to Vero cells was 5 times higher than binding in β1GD25 and 
GD25 cells, the amount of HMPV bound to GD25 did not significantly differ from the quantity of 
virus bound to β1GD25 (Figure 13D, black). The absence of G alone or both G and SH did not 
significantly affect the binding efficiency of HMPV (Figure 13D, gray and white respectively, p > 
0.05), providing direct evidence that the initial binding step of HMPV to the cell is predominantly 
mediated by the fusion protein. Similar results were obtained when cells were treated with an 
MOI of 100 (data not shown). These observations were further supported by a binding assay 
using biotinylated HMPV and quantified with streptavidin-FITC by flow cytometry (data not 
shown). These results strongly indicate that the initial binding step for HMPV does not require 
β1-integrin.  
As β1 integrin had been reported to play a role in HMPV infection but did not 
significantly alter HMPV binding or HMPV F-promoted membrane fusion, we assessed whether 
β1 integrin expression promotes infection by HMPV. A recombinant HMPV, strain CAN97-83, 
expressing the green fluorescent protein (rgHMPV) was used to infect the various cell lines at 
different MOIs. Both β1GD25 and GD25 cells were permissive to HMPV infection, though a 
much higher MOI was required to achieve significant infection levels in cells lacking β1 integrin 
(Figure 14). Approximately 70% of Vero and β1GD25 cells were infected at an MOI of 10 
whereas only approximately 20% of GD25 cells were infected with the same MOI. Increasing the 
MOI to 50 resulted in an additional 10% increase in the number of GD25 cells infected by 
rgHMPV. Taken together, our results confirm that β1-integrin expression is indeed important for 
HMPV infection though the initial binding step does not require expression of β1-integrin. 
 
Productive HMPV Infection is Dependent on a Proteinaceous Receptor 
Our data clearly show that HMPV binding is primarily driven by HMPV F and does not 
require β1 integrin, but the nature of the cellular receptor is still unclear. To test whether a 
proteinaceous receptor is needed for HMPV infection, Vero and CHO-K1 cells pretreated with 
trypsin (Figure 15A and C) or proteinase K (Figure 15B and D) were infected with control 
parainfluenza virus 5 (Figure 15A-B) or rgHMPV (Figure 15C-D). Cellular binding of PIV5 occurs 
through the interactions of the PIV5 attachment protein HN with sialic acid moieties at the cell 
surface. Consistent with this, pretreatment of cells with trypsin or proteinase K did not 
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significantly affect PIV5 infection (Figure 15A-B). However, rgHMPV infectivity was decreased by 
50% or more after trypsin treatment. Proteinase K treatment resulted in a more drastic 
reduction of infection (Figure 15D), likely due to the more efficient digestion of proteins 
compared to trypsin. Cell surface integrins have been reported to be insensitive to protease 
treatment (142). Therefore, to verify that αvβ1 integrin was not the protease sensitive 
component involved in HMPV infection, the amounts of αv- and β1-integrin on the cell surface 
were measured after trypsin or proteinase K treatment. As expected, protease treatments did 
not remove the antibody epitopes from the cell surface (Figures 15E-4F). Together these results 
indicate that efficient HMPV infection requires the proper expression of a trypsin- and 
proteinase K-sensitive proteinaceous receptor. 
 
Heparan Sulfate is Important for HMPV F-dependent Virus-cell Binding 
Glycoconjugates, including glycosaminoglycans (GAGs), are involved in many virus-cell 
interactions (318), and a previous report showed that the HMPV G protein interacts with GAGs 
(347). Since our results indicated that HMPV F is the major viral binding protein, we directly 
analyzed the role of GAGs in virus binding and infection to the mutant CHO cell lines pgsA745, 
Lec1, and ldlDLec1 (Table 3). pgsA745 cells carry a mutation in the xylosyltransferase gene 
abolishing expression of any GAG. Lec1 cells carry a mutation in the N-acetylglucosamine 
transferase 1 (GlcNAc Transferase 1) resulting in the inability of these cells to express complex 
N-linked glycans whereas the ldlDLec1 cells carry an additional mutation (4-epimerase) 
preventing them from expressing complex N-linked glycans, mucins, and GAGs in the absence of 
galactose and GalNAc (169). However, because ldlDLec1 cells were cultured with serum, these 
cells produce heparan sulfate as their only GAG (Table 3) (66, 107).  
WT HMPV was unable to bind pgsA745 cells as efficiently as binding to CHO-K1 cells 
(Figure 16A). Surprisingly, binding to ldlDLec1 and CHO-K1 cells was similar (Figure 16A). The 
binding profile of HMPV was similar for the HMPV ΔG (Figure 16B) and the HMPV ΔG/ΔSH 
mutants (Figure 16C), confirming that the primary viral binding factor is HMPV F. The binding 
profile of HMPV to the different cell lines was confirmed by the western blots. While binding of 
WT and mutant HMPV to pgsA745 decreased by 90 percent compared to Vero cells, binding to 
Lec1 and ldlDLec1 cells was not significantly decreased (Figure 16D-E). The differences in binding 
efficiencies between Lec1 and ldlDLec1 cells in the two binding assays could be due at least in 
part to the spinoculation step performed only in the ELISA-based assay as ldlDLec1 cells have a 
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higher tendency to aggregate, resulting in artificially higher normalized values in an ELISA-based 
assay, where the initial number of cells employed is already small. Nonetheless, our data 
confirm that HMPV F is the predominant viral protein involved in the initial binding step for 
HMPV, and that cellular binding of HMPV depends on the proper synthesis of GAGs.  
The need for proper GAG synthesis for HMPV binding and infection was confirmed by 
the inability of wild-type rgHMPV to infect pgsA745 even at high MOIs despite a high degree of 
infectivity of CHO-K1, Lec1, and ldlDLec1 cells (Figure 17). At an MOI of 10, for instance, nearly 
100 percent of CHO-K1, Lec1, and ldlDLec1 cells were infected whereas only 3 percent of 
pgsA745 were infected. The infectivity of pgsA745 did not significantly increase even at an MOI 
of 50. Importantly, the absence of GAGs did not affect PIV5 infection as this virus was able to 
infect pgsA745 and CHO-K1 cells with similar efficiency (Figure 18C), indicating that not all 
paramyxoviruses require proper synthesis of GAGs for binding and infection. These data 
demonstrate that HMPV F – GAG interaction is specific for HMPV and that this interaction is 
essential for infection.  
The fact that ldlDLec1 cells were permissive for binding and infection at levels 
equivalent to CHO-K1 cells suggested that the primary GAG involved in these processes is 
heparan sulfate. To confirm that heparan sulfate is indeed the specific GAG required for HMPV 
binding and infection, pgsD677 cells were exposed to HMPV at different MOI and assessed for 
binding and infectivity. pgsD677 cells are unable to synthesize heparan sulfate, but chondroitin 
sulfate synthesis is enhanced 3 to 4 fold due to a deficiency in N-acetylglucosaminyltransferase 
and glucuronyltransferase (192). Wild-type HMPV binding efficiency to pgsD677 cells, using both 
our ELISA and western blot analyses, was comparable to that of pgsA745 (data not shown). 
Importantly, ΔG HMPV (data not shown) and ΔG/ΔSH HMPV (Figure 18A-B) also showed a 
drastic decrease in binding efficiency to these cells, providing additional evidence that F is the 
primary binding factor for HMPV. As expected, HMPV was unable to infect pgsD677 cells since 
the virus cannot bind to these cells (Figure 18C). Importantly, no significant differences in the 
levels of control PIV5 infectivity were seen in pgsA745 and pgsD677 cells (Figure 18C). Since PIV5 
is known to bind to sialic acid, our results suggest that binding to HS is an event specific for 
HMPV.  
To further confirm that heparan sulfate is indeed the primary binding partner for HMPV 
F, CHO-K1, ldlDLec1, pgsD677, and pgsA745 were treated with either a mixture of 2mIU/mL of 
heparinase 1 and 3 or with 20mIU/mL of chondroitinase ABC for 2 hours prior to analysis of 
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binding for both wild-type HMPV and ΔG/ΔSH HMPV. Binding efficiency for wild-type HMPV was 
greatly reduced after pretreatment with heparinase 1 and 3, but not after pretreatment with 
chondroitinase ABC (data not shown). This drastic reduction in binding efficiency after 
treatment with heparinase 1 and 3 was reproduced using ΔG/ΔSH HMPV (Figure 18A-B) and was 
also seen after heparinase treatment of Vero cells (data not shown), whereas pretreatment with 
chondroitinase ABC did not have an effect on binding. As seen in Figure 18B, treatment with a 
combination of heparinase 1 and 3 decreased HMPV binding to both CHO-K1 and ldlDLec1 cells 
to levels equivalent to pgsD677 and pgsA745 cells. Similarly, HMPV infection was drastically 
reduced below 5% for CHO-K1 cells after pretreatment with either 2mIU/mL heparinase 1 or 
heparinase 3 for 1 hr, but not after treatment with 20mIU/mL chondroitinase ABC (Figure 18D). 
Importantly, PIV5 infection was unaffected by heparinase 1, heparinase 3, or chondroitinase 
ABC treatment, confirming that the interaction between HS and HMPV F is specific to HMPV. 
Additionally, the lack of HMPV binding and infection of heparinase-treated β1 integrin-
expressing CHO-K1 cells further confirms that the initial binding step of productive infection is 
dependent on heparan sulfate, and that the F-heparan sulfate interaction cannot be replaced 
with integrins. 
 
Discussion 
The results presented in this study indicate that the initial interaction between HMPV 
and its target cell occurs through heparan sulfate moieties expressed at cell surface. 
Importantly, we provide direct evidence that the critical virus-cell attachment step is 
predominantly mediated by the fusion protein of a paramyxovirus. Furthermore, our results 
support the report from Cseke, et. al. that αvβ1 integrin is important for HMPV infection, 
though our studies suggest that the role of this integrin is not as the initial binding receptor. 
Rather, our results indicate that β1 integrin promotes efficient HMPV infection after the virus 
binds to cell surface heparan sulfate. 
In this study, we confirmed that the fusion protein of HMPV is the primary entry factor 
of the virus, promoting both virus-cell binding and membrane fusion. No differences in binding 
or infectivity were observed between the WT virus and the mutant viruses lacking HMPV G or 
both HMPV G and SH (Figures 13 and 16). A recent report showed that cell surface nucleolin is a 
functional receptor for RSV F (342). This interaction, however, is likely preceded by interactions 
between GAGs and RSV G, as G expression is still required for efficient growth in vivo (164, 174, 
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342, 344). Our previous observation that HMPV F-mediated cell-to-cell fusion occurs in the 
absence of HMPV G ((299) and Figure 12) and our current study indicating that HMPV binding is 
very different from other paramyxoviruses, both support the idea that the HMPV F protein is the 
major factor driving both viral attachment and entry. We cannot, however, rule out the 
possibility that the HMPV G could confer a selective advantage for viral attachment in some 
tissues as it has been demonstrated previously that the HMPV ΔG mutant is less efficient at 
infecting the lower respiratory tract (31).  
It has been reported that all strains of HMPV isolated clinically have a conserved Arg-
Gly-Asp (RGD) sequence in their F protein, raising the possibility of an interaction between F and 
integrins (80). Indeed αvβ1 integrin has been shown to be a major factor promoting HMPV 
infection (80). A direct interaction between αvβ1 integrin and the prefusion conformation of 
HMPV F, however, has not been confirmed. In this study, we investigated the role of β1 integrin 
and the RGD sequence in HMPV F by performing functional studies with an HMPV F RGA mutant 
and assessing the binding and infectivity of recombinant HMPV in cells lacking β1 integrin. Our 
data show that the RGD motif of HMPV F is not necessary for cell-to-cell membrane fusion 
(Figure 12), suggesting that this motif is not needed for F-mediated membrane fusion. 
Additionally, three independent approaches to assess virus binding clearly indicate that 
expression of β1 integrin, or lack thereof, does not significantly affect binding (Figure 13). Cells 
lacking β1 integrin, however, are significantly more resistant to HMPV infection. Interestingly, 
infectivity of CHO-K1 is equivalent to that of Vero (Figure 14) and LLC-MK2 cells (data not 
shown) even though there were no detectable levels of αv integrin in CHO-K1 cells. This suggests 
that the β1 integrin subunit plays a more important role in HMPV infection than the αv subunit. 
Thus, our data show that β1 integrin expression dramatically enhances the infectivity of HMPV, 
but is not required for the initial binding of the virus.  
It is not clear what role β1 integrin plays in HMPV entry, especially since a HMPV 
carrying an RGA mutation in its F protein is currently not available, but our data suggest that β1 
integrin is involved after initial binding and not as a direct initial cellular receptor for the virus. 
Analysis of a homology model of HMPV F in its prefusion and postfusion conformations, based 
on the crystal structure of the prefusion form of PIV5 F (384) and postfusion form of Newcastle 
disease virus F respectively (336), suggests that the RGD motif in HMPV F is covered by other 
stretches of the protein in its prefusion form (Figure 19A, RGD shown in red). Although partially 
buried, the RGD motif appears to be more accessible for protein-protein interaction in its post-
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fusion conformation (Figure 19B), suggesting that an RGD-dependent integrin interaction is 
more likely to occur in an intermediate step of the viral entry process, after a change in 
conformation from the prefusion form of F that exposes the RGD motif (15, 328). Integrins are 
well-known for their signaling capabilities and their ability to orchestrate a myriad of cellular 
processes. Indeed, the involvement of integrins in these processes has been shown to influence 
viral infectivity. The regulation of endosomal cathepsins by the α5β1-integrin, for instance, 
mediates Ebola virus entry (297) and the presence of a cellular receptor is presumably 
dependent on membrane trafficking of proteins mediating cell adhesion (96, 97). Since HMPV 
infectivity is decreased without changes in cell binding when β1 integrin expression is altered, it 
is possible that, after a conformational change that results from the initial binding step, HMPV F 
interacts with αvβ1 integrin, triggering a signal that increases cell permissiveness. Alternatively, 
αvβ1 integrin could direct HMPV to a more efficient route of entry without necessarily 
interacting with the virus, as it has been hypothesized for HSV (123).  
We report that the primary cellular binding partner for HMPV is proteinaceous in 
nature, as infection is decreased by protease treatment (Figure 15). Importantly, integrins, 
including β1, are known to be trypsin resistant (142), and we confirmed that neither αv nor β1 
are sensitive to cleavage by trypsin or proteinase K since the antibody epitope was not affected 
by the proteases (Figure 15). Since pre-treatment of Vero or CHO cells at trypsin concentrations 
higher than 0.0625% does not further reduce HMPV infectivity (Figure 15 and data not shown), 
HMPV entry appears to involve more than one component of which at least one is trypsin 
sensitive and at least another is trypsin resistant. While the antibody epitopes were unaffected 
by protease treatment, there remains a possibility that the interaction sites with HMPV F were 
destroyed. 
Our analysis of HMPV binding and infectivity of mutant cell lines derived from the CHO-
K1 indicate that binding and infectivity are highly dependent on the presence of GAGs, 
especially heparan sulfate. The drastic reduction of binding and infectivity of pgsA745 and 
pgsD677 cells compared to WT suggests that HMPV specifically interacts with HS (Figure 16-18). 
Importantly, this robust reduction in binding and infection was reproduced by treating the 
parental, β1 integrin-expressing CHO-K1 cells with heparinases (Figure 13A and 18). Since β1 
integrin is not an HSPG, it should not be affected by heparinase treatment. The dramatic loss in 
both binding and infection of CHO cells after treatment with heparinase confirms that the 
heparin sulfate-F interactions are needed for productive infection, and cannot be replaced by 
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the presence of integrins.  Altogether our data strongly suggest that the inhibition of HMPV 
infection with heparin treatment reported by Wyde, et. al. (380) was due to a direct and specific 
interaction of the virus with HS. Importantly, our data show that the dependence on HS for 
infection is driven by HS interactions with the F protein rather than the G protein as previously 
hypothesized (380). The use of the F protein as the primary viral protein for cellular attachment 
highlights the uniqueness of HMPV among the paramyxoviruses, as other human pathogens in 
this family use the attachment protein for this step.  
Carbohydrates play an important role in entry for many viruses including RSV, the 
closest human pneumovirus related to HMPV (132, 174, 202). Indeed, earlier studies have 
suggested that both RSV F but primarily RSV G are capable of binding GAGs (115, 174, 176). Here 
we report that, unlike RSV, the fusion protein of HMPV is the main GAG-binding protein. It has 
been reported that a recombinant HMPV G protein has the ability to bind GAGs (347). In light of 
our findings, this interaction is not required for the initial viral attachment step. Nonetheless, 
since HMPV G is present in all clinical isolates sequenced so far (27, 31) and studies by Biacchesi, 
et. al. demonstrated that HMPV lacking the G protein is significantly attenuated for infection in 
the upper respiratory tract of hamsters (31), this protein could confer an advantage for the virus 
to grow in vivo by either facilitating infection of certain cells with a specific GAG (or a specific 
protein) recognized by G at a higher affinity or by providing a protective mechanism against the 
host immune defenses (27, 31, 346).  
Since the sequence of the F protein from the virus used in this study was verified to be 
identical to the original CAN97-83 sequence directly isolated from the patient, the interaction 
between HS and the HMPV F protein is likely relevant in vivo. Some studies have shown that cell 
surface HS is located primarily on the basolateral side of differentiated ciliated airway epithelial 
cells (52, 226, 389). Thus, binding to HSPG may be used to infect non-ciliated cells in the 
respiratory tract, or to promote cell-to-cell spreading from the basolateral side. Moreover, the 
small amount of HSPG present on the apical side (52, 75) could be enough for HMPV to establish 
an initial infection in the upper respiratory tract. Since apical levels of HSPG are upregulated 
upon injury and basolateral HSPGs can be exposed when the monolayer is disrupted (including 
during tissue regeneration) (52), this initial infection would in turn increase the accessibility of 
HSPGs to the virus. 
By examination of viruses using HS as their first attachment factor (245, 390), it is 
possible to distinguish three potential mechanisms leading to infection (Figure 20). Like most 
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viruses that bind HS, HMPV could attach to this specific GAG to concentrate at the cell surface 
and facilitate a subsequent interaction with a more specific secondary receptor, which could be 
another HSPG (Figure 20A) (2, 120, 181, 220). Alternatively, HMPV could interact with a specific 
chemical modification of HS which then directly triggers fusion, as it has been reported as one of 
the entry pathways for HSV-1 (Figure 20C) (241, 308, 349). While not reported yet, the high 
affinity attachment and promotion of fusion could also be carried out by one specific HSPG 
(Figure 20B). Like HSV (72), HMPV could also be interacting with different cellular proteins and 
using different entry pathways depending on the cell type. While the data reported in this study 
indicate that HMPV binds to HS, whether HS alone is sufficient to trigger fusion remains 
unknown. 
In this study, we demonstrated that the F protein is the major protein driving 
attachment of HMPV. We also showed that αvβ1 integrin is not responsible for viral attachment, 
but instead that the cell-virus interaction is highly dependent on the presence of HS. Several 
HSPGs have been identified to date with a wide range of function including basement 
membrane barrier organization, cell signaling, and cellular crosstalk (78). Interestingly, some of 
HSPGs have the ability to interact with integrins. Since interactions with integrins enhance 
HMPV infection and HMPV binds to HS, a specific HSPG could mediate the interaction between 
the virus and integrins, allowing the virus to efficiently infect its target cell.  
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Table 3. Cell lines used in this study. 
Name Mutation 
Phenotype under culture conditions 
Complex N-
linked glycans 
O-linked Glycans 
Mucins GAGs 
Vero N/A Yes Yes Yes 
CHO-K1 N/A Yes Yes Yes 
pgsA745 Xylosyltransferase Yes Yes No 
pgsD677 
N-acetylglucosaminyltransferase 
and glucuronyltransferase-deficient 
CHO mutant 
Yes Yes No HS 
Lec1 
GlcNAC Transferase 1-deficient 
CHO mutant 
No Yes Yes 
ldlD.Lec1 
GlcNAC Transferase 1 and 4-
Epimerase-deficient CHO mutant 
No No Only HS 
GD25 
β1 integrin null mouse embryonic 
fibroblast 
   
β1GD25 
GD25 cells stably transfected with 
human β1 integrin 
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Figure 12. HMPV F RGA mutant promotes cell-to-cell membrane fusion at levels similar to 
HMPV F WT. 
 A. Representative SDS-PAGE gel of lysates from metabolically labeled and biotinylated Vero 
cells transfected with F WT vs F RGA. The total amount of F was immunoprecipitated with an F-
specific antisera and the surface population separated using streptavidin beads. Slower 
migrating bands represent higher oligomeric forms of HMPV F. B. Quantification of SDS-PAGE 
bands (n=3) corresponding to total (black column) and surface (white column) expression of 
HMPV F WT and RGA mutant. Data represented as percent of surface or total WT F0 or F1 
expression. C. Representative pictures (n=4) of syncytia assays in Vero cells transfected with F 
WT or the HMPV F RGA mutant are shown. D. Luciferase reporter gene assay (n=3) used to 
compare fusion activity between HMPV F WT (black) and HMPV F RGA mutant (gray). MCS 
(white) = multiple cloning site, empty vector pCAGGS control. Error bars = mean ± standard 
error of the mean. 
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Figure 13. Initial HMPV binding is independent of β1 integrin expression.  
A. Expression levels of αv and β1 integrins in Vero, GD25, β1GD25, and CHO-K1 cells assessed by 
flow cytometry. Control (gray) = secondary antibody only. B. Different MOIs (0.5, 1, 2, 5, 10, 25, 
and 50) of HMPV were bound to GD25 (close circle), β1GD25 (close square), and CHO-K1 (open 
circle) cells. HMPV binding was assessed by HRP activity following immunolabeling of the HMPV 
N protein. Data were normalized to virus bound to Vero cells at an MOI of 10. Results shown are 
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average of duplicate wells for 3 independent experiments. Error bars = mean ± standard error of 
the mean. C. Representative western blots used for quantification in D.  WT rgHMPV (lanes 2, 6, 
and 10), ΔG mutant HMPV (lanes 3, 7, and 11), and ΔG/ΔSH mutant HMPV (lanes 4, 8, and 12) at 
an MOI of 7 were bound to Vero (1-4), GD25 (5-8), and β1GD25 (9-12). Lysates of virus bound to 
cells were collected and a volume corresponding to an equal number of cells was analyzed with 
an anti-HMPV F antibody. The control cell lane without virus is shown in lanes 1, 5, and 9. D. The 
signal intensity of specific bands for HMPV F protein on the western blot was quantified for WT 
(black), ΔG (gray), and ΔGΔSH HMPV (white) bound to the different cell lines and normalized to 
WT Vero cell binding efficiency (n=6). Error bars = mean ± standard error of the mean. Brackets 
= p > 0.05, ANOVA. E. an equal number of WT, ΔG, and ΔGΔSH viral particles concentrated by a 
sucrose cushion were lysed, and blotted for HMPV F using anti-HMPV F antisera. Figure shows 
quantification of the signal of the specific bands on the western blot (n=10). Data were 
normalized to control WT GFP-expressing HMPV. Error bars = mean ± standard error of the 
mean. 
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Figure 14. HMPV infection is enhanced by the expression of β1 integrin.  
Vero (close circle), GD25 (close square), β1GD25 (open circle), and CHO-K1 (open square) cells 
were infected with different amounts of WT rgHMPV. GFP-expression of at least 10,000 cells 
was analyzed by FACS the following day. Results shown are average for 3 independent 
experiments done in duplicate. No statistical significance was seen between CHO-K1 and Vero 
infectivity. Error bars = mean ± standard error of the mean. Significant difference was observed 
in infectivity between GD25 cells and β1GD25 cells. 
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Figure 15. Effective HMPV infection requires the expression of a trypsin- and proteinase K-
sensitive cellular surface protein.  
Vero or CHO-K1 cells were treated with 0% (black), 0.0625% (gray), or 0.125% (white) of trypsin 
(A, C, and E) or 0µg/mL (black) or 300µg/mL (white) of proteinase K (B, D, and F) prior to either 
infection by control rgPIV5 (A and B) or rgHMPV (C and D), or analysis of αv and β1 integrin 
expression (E and F, n=3). GFP-expression or FITC fluorescent intensity of at least 10,000 cells 
were analyzed by FACS the following day (n=5 for trypsin and n=6 for proteinase K treatment). 
Data in A and B are expressed as percent of total infected cells whereas data in C and D are 
expressed as percent of cells infected normalized to Vero cells not treated with proteinase K. 
Error bars = mean ± standard error of the mean. 
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Figure 16. Initial HMPV binding is dependent on GAG expression and is mediated by the F 
protein.  
A-C. CHO-K1 (close circle), pgsA745 (close square), Lec1 (open circle), and ldlDLec1 (open 
square) cells were exposed to different MOIs (0, 1, 10, and 50) of HMPV WT (A), ΔG (B), or 
ΔG/ΔSH (C) at 4°C. Results shown are average of 6 independent experiments done in duplicate. 
D. Representative western blot used for quantification in E. WT rgHMPV (lanes 2, 6, 10, and 14), 
ΔG HMPV (lanes 3, 7, 11, and 15),  and ΔG/ΔSH HMPV (lanes 4, 8, 12, and 16) at an MOI of 7 
were bound to Lec1 (1-4), ldlDLec1 (5-8), pgsA745 (9-12), and control CHO-K1 cells (13-16). 
Lysates of virus bound to cells were collected and a volume corresponding to an equal number 
of cells was analyzed with an anti-HMPV antibody. The control cell line without virus is shown in 
lanes 1, 5, 9, and 13. E. Quantification of western blots signal showing binding activity of the WT 
(black), ΔG mutant (gray), and ΔG/ΔSH mutant HMPV (white). Data were normalized to WT Vero 
binding efficiency (n=10). Error bars = mean ± standard error of the mean. Asterisks p < 0.001 
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Figure 17. HMPV infection is greatly reduced in the absence of GAGs.  
CHO-K1 (close circle), pgsA745 (close square), Lec1 (open circle), and ldlDLec1 (open square) 
cells were infected with different MOIs (0, 1, 10, and 50) of rgHMPV, and GFP-expression of at 
least 10,000 cells was analyzed by FACS the following day. Results shown are average of 3 
independent experiments done in duplicate. Error bars = mean ± standard error of the mean. 
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Figure 18. HMPV binding and infection is decreased in the absence of heparan sulfate.  
A and B. HMPV ΔG/ΔSH binding to CHO-K1 (1 – 4), ldlDLec1 (5 – 8), pgsD677 (9 – 12), and 
pgsA745 (13 – 16) cells was assessed after a 2 hr treatment with heparinase 1 and 3 (lanes 4, 8, 
12, and 16, white), chondroitinase ABC (lanes 3, 7, 11, and 15, gray) or mock (lanes 2, 6, 10, and 
14, black). The control cell line without virus is shown in columns 1, 5, 9, and 13. The signal for 
the specific bands on the western blots represented in A (n = 3) were quantified and shown in B. 
C. pgsD677 cells were exposed to HMPV (black) or PIV5 (white) at an MOI of 10. Data shown is 
normalized to infectivity of CHO-K1 cells and represents the average of 3 independent 
experiments done in duplicate (n=3). D. CHO-K1 cells treated for 1 hr at 37°C with 2mIU/mL of 
Heparinase 1, Heparinase 3, or 20mIU/mL of Chondroitinase ABC (mock treatment as control) 
were exposed to 1 MOI of either HMPV (black) or PIV5 (white) at 4°C followed by normal 
incubation to allow for infection to occur. pgsA745 infection is shown as control. Data shown are 
normalized to infectivity of CHO-K1 cells in the absence of any treatments and represents the 
average of 3 independent experiments done in duplicate (n=3). Error bars = mean ± standard 
error of the mean. 
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Figure 19. Homology model of the prefusion and postfusion form of HMPV F.  
A. The amino acid sequence of HMPV F was threaded onto the crystal structure of the prefusion 
form of PIV5 F (384) using Deepview Swiss-PDV Viewer v4.0.1. The RGD sequence of HMPV (red) 
is covered by two stretches of amino acid (yellow and green in insert). B. Individual sequences of 
the F1 and F2 subunits of HMPV F were threaded onto the crystal structure of the postfusion 
form of NDV F (336). 
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Figure 20. Potential mechanisms for the initial steps of HMPV infection via HSPG interactions.  
A. HMPV could bind to any heparan sulfate proteoglycan, or any specific modification in the HS 
moiety, through HMPV F, concentrating the virus and allowing HMPV F to interact with a more 
specific viral receptor or coreceptor, which could also be an HSPG. This interaction in turn, could 
allow the virus to interact with a potential fusion receptor that will activate HMPV F. B. HMPV 
could bind to a specific HSPG, or any specific modification in the HS moiety, through HMPV F 
and that interaction could be sufficient for HMPV F triggering and viral entry. C. HMPV could 
bind to any HSPG, or any specific modification in the HS moiety, through HMPV F and that 
interaction could be sufficient for HMPV F triggering and viral entry. Integrin αvβ1 expression 
renders the cell to be more permissive to HMPV infection. 
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Chapter 5: Studies to Identify a High Affinity Receptor for HMPV 
 
Introduction 
We have shown that the initial attachment of HMPV occurs through interactions 
between the fusion protein of the virus and cellular HSPGs (65). HMPV binding and infection 
decreased to background levels after enzymatic removal of HS and cells without the ability to 
synthesize HS were largely protected from HMPV infection. It has also been shown that RSV 
interacts with cell surface HS during entry (45, 115, 174, 176). Our studies have also shown that 
binding and infection of PIV5, a member of the paramyxovirinae subfamily, is independent of 
HSPGs (65). Thus, differences in the requirement for HSPGs appear to be present between 
members of different subfamilies. It has been proposed, however, that the interaction between 
RSV and HSPGs occurs only in vitro as RSV grown in tissue culture expresses an altered 
attachment protein (176). While interactions between GAGs and the HMPV G have been 
documented (347), our studies and others indicate that the HMPV G glycoprotein is dispensable 
for HMPV infection (31, 65, 312) and that interactions between the HMPV F protein and HSPGs 
are necessary for infection to occur (65). Since the sequence of the F protein used in our studies 
is identical to the sequence of the original viral strain, we hypothesize that the interaction 
between HMPV F and HSPGs are likely to be important in vivo.  
Even though HSPGs are ubiquitously expressed and can be found in intracellular 
vesicles, at the cell surface, or as component of the basement membrane, only a small subset of 
proteins are actually modified by GAGs. To date, only a few proteins expressed at the cell 
surface have been found to be HSPGs. These proteins include the four members of the syndecan 
family of transmembrane proteins and the six members of the glypican family of GPI-anchored 
proteins (78, 190). Syndecans usually possess three to five HS chains located near the 
extracellular tips and occasionally also present chondroitin/dermatan sulfate chains near the cell 
surface. Three of the four syndecans are tissue specific: syndecan-1 (CD 138) is present in many 
epithelial tissues and some plasma cells, syndecan-2 is present in mesencyhymal cell types 
(those that differentiate into chondrocytes and adipocytes among others), and syndecan-3 is 
specific to neural tissue and in developing musculoskeletal system. Syndecan-4, however, is 
widely distributed among many cell types (78). Glypicans usually carry several HS chains near 
the surface of the cell and can have an additional chain near the tip of the ectodomain (190). In 
addition to syndecans and glypicans, there are three unrelated transmembrane proteins that 
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may or may not be present as HS-modified proteins: betaglycan (a.k.a. transforming growth 
factor β receptor type III), neuropilin-1, and CD44. Furthermore, glycan forms of betaglycan and 
neuropilin-1 can present with HS or chondroitin/dermatan sulfate (78). 
While progress has been made toward understanding the early events that promote 
HMPV infection, there are several aspects that remain to be understood. Importantly, our 
studies indicating that HMPV binding to HSPGs is essential for infection paves the way towards 
better understanding the early events that mediate viral entry. Based on studies of other viral 
systems, it is possible to distinguish three distinct mechanisms by which HMPV binding to HSPGs 
could lead to infection. Like many other pathogens, HMPV could use HSPGs as lower affinity 
attachment sites to concentrate the virus at the cell surface and facilitate a subsequent 
interaction with a higher affinity receptor that would dictate tissue tropism and facilitate 
internalization (Figure 20A) (11, 138, 284, 318). As shown for HTLV-1, this secondary, high 
affinity receptor could also be a HSPG (181). Alternatively, HMPV could bind directly to a specific 
modification of HS, regardless of the protein HS is attached to, that also mediates internalization 
(Figure 20C), as has been reported for HSV-1 (72, 308). Finally, like HEV, HMPV binding and entry 
could be promoted by interactions with a single HSPG (Figure 20B) (161). A better 
understanding of how HSPGs are utilized in HMPV pathogenesis as well as the discovery of 
higher affinity receptors or coreceptors will significantly advance our knowledge of the lifecycle 
of this virus, paving the way for the development of therapeutics that will block the attachment 
of HMPV to cells. 
 
Results 
HMPV Colocalizes with HSPGs and this Interaction is Required for HMPV Infection in BEAS-2B 
Cells  
Our previous studies showed that CHO-K1 mutants lacking the ability to synthesize HS 
were protected from HMPV infection. Furthermore, treatment of parental CHO-K1 cells with 
heparinase I and III dramatically decreased HMPV infectivity (65). We therefore attempted to 
visualize the interaction between HMPV and HSPGs. Imaging analysis of HMPV bound to Vero 
cells showed some colocalization between viral particles and cell surface HS (Figure 21A). 
However, a large proportion of the staining from the HMPV F polyclonal antibody (red) did not 
colocalize with the staining from HS (green). This could be due to incomplete staining of the 
anti-HS antibody, as it recognizes only a specific epitope in the glycan chain (epitope 10E4) that 
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may or may not be present in all HSPGs (350, 356). Nonetheless, these results provide visual 
evidence that at least some HMPV particles localize near cell surface HSPGs. 
While these studies provide evidence of the proximity between HMPV and HSPGs and 
support our hypothesis that HMPV binding to HSPGs are important for cell infection, CHO-K1 
cells are murine cells of ovarian origin and Vero cells are monkey kidney cells. Thus, to test the 
involvement of HSPGs in HMPV infection in a more relevant model, immortalized, non-
cancerous human bronchial epithelial cells were treated with heparinases and then tested for 
HMPV infection. As expected, BEAS-2B cells were permissive to infection by HMPV. However, 
HMPV infection was reduced by more than 95% when BEAS-2B cells were pretreated with either 
heparinase I or heparinase III (Figure 21B). As seen with CHO-K1 cells, treatment with 
chondroitinase ABC did not protect BEAS-2B cells from infection by HMPV. This indicates that 
HMPV infection is also mediated largely by HSPGs in this more physiologically relevant cell line. 
 
Syndecan-4, Betaglycan, and Glypicans 
To test whether a specific cell surface HSPG serves as a receptor for HMPV, 
permissiveness of HMPV infection was assessed in cells where expression of specific HSPGs were 
knocked down by RNA interference. Due to the ubiquitous nature of syndecan-4 and betaglycan, 
these two proteins were chosen initially as potential candidates. A549 cells, a human lung 
carcinoma cell line, were treated with siRNAs against syndecan-4 (sdc4) and betaglycan to 
decrease the expression of these proteins. Briefly, 3 x 106 cells were resuspended in 400 µL 
RPMI media without additives, electroporated with 200mM siRNA, and incubated for 72 hours 
at 37˚C. Transfected cells were then infected with equal amounts of GFP-expressing HMPV, RSV, 
or control PIV5 and VSV for four hours and infectivity was assessed by detecting GFP expression 
by flow cytometry the following day. Our data suggest that infectivity of HMPV, PIV5, VSV, or 
RSV was unaffected by siRNA-mediated knockdown of sdc4 or betaglycan (Figure 22A) 
suggesting that these HSPGs do not serve as receptors for HMPV. However, we have been 
unable to confirm knockdown of these proteins at the protein level as all the antibodies 
obtained thus far failed to detect sdc4 and betaglycan. Experiments to measure RNA levels of 
transfected cells will be performed to determine the knockdown efficiency of these siRNAs.  
To test whether glypicans are involved in HMPV binding and infection, the 
permissiveness of HMPV infection in A549 cells treated with phospholipase C (PLC) was 
determined. Treatment of cells with PLC should remove cell surface glypicans as these proteins 
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are anchored to the cell surface by glycophosphatidylinositol (GPI). As shown in Figure 22B, 
pretreatment of A549, Vero, CHO-K1, or BEAS-2B cells with PLC had a modest effect on HMPV 
infectivity, decreasing the overall number of infected cells by less than 20%. This suggests that 
HMPV interaction with glypicans is not required for HMPV infection. Experiments to determine 
the efficiency of PLC treatment to remove surface GPI-anchored proteins, however, are required 
and will be performed to ensure that PLC activity efficiently removes glypicans from A549 cells. 
 
HMPV Binding and Infection are Significantly Impaired in HeLa Cells 
For receptor binding studies, it is important to identify cell lines which bind virus to 
different extents. We have previously shown that HMPV binding to CHO pgsA745 and pgsD677 
mutant cell lines was significantly impaired due to the lack of HS in their cell surface (65). 
However, the identification of a parental cell line that lacks the ability to bind HMPV would be a 
valuable tool for future studies aimed at identifying high affinity receptors as this cell line would 
serve as an important negative control. Thus, I tested HMPV infectivity in several cell lines and 
identified HeLa cells as poorly permissive to HMPV binding and infection (Figure 23). Despite 
expressing some HSPGs (237, 263, 378) and normal amounts of β1 integrin (155) at the cell 
surface, binding of HMPV to HeLa cells decreased by up to 95% compared to control Vero cells 
(Figure 23A). In the same way, HMPV infectivity was reduced by up to 98% of that of Vero cells 
(Figure 23B). Importantly, HeLa cells were permissible to PIV5 infection to the same degree as 
Vero cells. Surprisingly, A549 cells were also less permissive to HMPV binding and infection as 
binding and infection decreased by 30 to 40% compared to Vero cells. However, PIV5 infection 
in A549 cells was also lower compared to Vero and HeLa cells, suggesting that these cells are 
less permissive to infection by paramyxoviruses. Thus, A549 cells appear to bind HMPV with less 
affinity whereas HeLa cells appear to express very low to no levels of HMPV binding proteins 
and are largely protected from HMPV binding and infection. 
 
Virus Overlay Protein Binding Assay (VOPBA) 
A recent study published by Tayyari, et. al. identified nucleolin, a protein primarily 
present in the nucleolus but also at the cell surface, as a receptor for RSV using a technique to 
identify virus-receptor interactions using SDS-PAGe electrophoresis and mass spectrometry 
(342). Briefly, surface proteins from different cell types are biotinylated and pulled down using 
neutravidin beads. Cell surface proteins were released from the beads by incubation in SDS 
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loading buffer containing DTT and the samples were resolved in a 4 – 12% Bis-Tris gel. Two 
samples per cell line were loaded symmetrically on the gel. After electrophoresis, one sample 
was transferred to a PDVF membrane while the other sample was fixed in 50% methanol, 10% 
acetic acid and stored at 4 ˚C. The membrane was then incubated in the presence of virus and 
then blotted with an antibody that recognizes the fusion protein. The resulting western blot 
image was superimposed with the fixed gel and the VOPBA bands were excised and analyzed by 
mass spectrometry to identify the surface proteins present in the sample. We attempted to 
adapt this protocol to identify a high affinity receptor for HMPV. Thus, cell surface proteins of 
Vero, A549, HeLa, CHO-K1, and pgsA745 cells were isolated as described and resolved by SDS-
PAGE. Successful isolation of cell surface proteins was demonstrated by determining the amount 
of protein in the sample using the Nanodrop and a BCA assay followed by blotting for the 
presence of EGF receptor (data not shown). Samples transferred to the PDVF membrane 
incubated in the presence of 1.6 x 107 pfu of rgHMPV. Because our HMPV F and N antibodies 
epitopes are located inside the viral membrane, the PDVF membrane was washed with t-TBS 
after viral incubation to permeabilize the viral particles. No signal was detected in the 
membrane using the anti-HMPV N monoclonal antibody (data not shown). Multiple bands were 
seen after blotting with our anti-HMPV F polyclonal antibody (Figure 24A). However, all these 
bands were also present in PDVF membranes that were not incubated with HMPV (Figure 24A, 
overlay), suggesting that the amount of background signal is too high for this antibody to be 
used in this technique. 
Because the initial mass spectrometry analysis of one of the bands seen after blotting 
with anti-HMPV F antibody showed the presence of nucleolin, and RSV, which has been shown 
to use nucleolin as a receptor (342), belongs to the same subfamily of paramyxoviruses, we 
tested whether nucleolin is required for HMPV infection. For this, A549 cells were pretreated 
with an antibody against nucleolin and then infected with rgHMPV. The percent of infected cells 
was determined by FACS as described in materials and methods. While it has been shown that 
pretreating cells with an antibody against nucleolin blocked RSV infection (342), pretreatment 
with this antibody did not abolish HMPV infectivity in A549 cells (Figure 24B), providing evidence 
that HMPV infection does not require cell surface nucleolin. Interestingly, RSV infectivity was 
not reduced after cell treatment with the antibody against nucleolin (Data not shown). The 
reason for the difference between my results and that of Tayyari and coworkers (342) is unclear 
but it is possible that different strains of RSV use different receptors or coreceptors for cell 
93 
 
binding. Pretreatment with antibodies against syndecan-4 and betaglycan did not alter HMPV 
infectivity (Figure 24B), suggesting that these HSPGs are not required for HMPV infection. 
However, because we were unable to detect syndecan-4 and betaglycan in western blot 
samples using these antibodies, further testing are needed to determine whether these 
antibodies bind to their target proteins. Interestingly, HMPV infection decreased by more than 
30% in cells pretreated with anti-cathepsin B antibody (Figure 24B). Anti-cathepsin B antibody 
was initially chosen as a negative control due to availability and because cathepsin B are 
localized to the endosomal pathway. The role for cathepsin B in HMPV infection, however, is still 
unknown. 
 
Discussion 
The preliminary results shown in this chapter provides important insights into the crucial 
process of viral attachment. First, we demonstrated that HMPV infection of BEAS-2B cells also 
depends on cell surface HS. Furthermore, we have preliminary data that two ubiquitously 
expressed HSPGs do not play a role in HMPV infection. In addition, we showed that, unlike 
previously published for RSV (342), cell surface nucleolin does not mediate HMPV attachment. 
Importantly, we identified a human cell line that is poorly permissive to HMPV infection that can 
serve as a negative control for future studies and we began the development of new techniques 
that can be used to identify potential high affinity receptors for HMPV. 
We have recently reported that cellular attachment of HMPV is mediated by HSPGs (65). 
Even though this work was done primarily in murine cells, we hypothesized that a similar HS-
dependent mechanism is required for infection in human bronchial epithelial cells. Here we 
confirm that cell surface HS is required for HMPV infection of BEAS-2B cells (Figure 22), which 
are immortalized cells derived from non-cancerous human bronchial epithelium and therefore 
represent a more physiologically relevant model than CHO-K1 cells. While some studies suggest 
that most of the cell surface HS is located primarily on the basolateral side of differentiated 
ciliated airway epithelial cells (11, 40, 72), the small amount of HSPG present on the apical side 
(11, 14) could be enough for HMPV to establish an initial infection in the upper respiratory tract. 
Upon tissue injury, apical levels of HSPG are upregulated and basolateral HSPGs can be exposed 
as it occurs during tissue regeneration, increasing the accessibility of HMPV to HSPGs (11). 
Furthermore, as seen for some papillomaviruses (168), HMPV infection could occur through the 
basolateral side after binding to HSPGs. 
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As mentioned previously, there are many ways in which HMPV could use HSPGs for cell 
entry (Figure 20). Our studies with syndecan-4, betaglycan, and glypicans favor a model similar 
to HSV-1 and HEV (72, 161, 308), where an interaction with one or more specific HSPGs is 
required for HMPV infection. Conversely, our preliminary results disfavors a model where HSPGs 
serve as generic, low affinity attachment sites as treatments to remove these proteoglycans, 
which would decrease the total amount of HS at the cell surface, did not alter HMPV infectivity. 
While it is possible that removal of one type of HSPG results in the overexpression of other 
HSPGs, it would be highly unlikely as these proteins regulate different cellular pathways. It is 
also possible that HSPGs are in such excess that removal of one does not alter HMPV binding. 
However, this is less likely because of the limited number of proteins modified by HS and the 
fact that we targeted the most common ones. Furthermore, HeLa cells, which express some 
HSPGs were unable to bind to HMPV. It is therefore possible that HeLa cells do not express a 
specific HSPG that is required for HMPV binding. Therefore, further experiments are needed to 
determine whether the surface concentration of these HSPGs was indeed reduced in the 
abovementioned experiments and to determine whether these HSPGs are present in HeLa cells. 
Whether the HMPV F protein recognizes a specific modification of HS or a site that also depends 
on the proteinaceous nature of the HSPG remains unknown. 
The studies described in this chapter represent initial steps at elucidating the 
attachment factors required for HMPV infection. We determined that HeLa cells expresses 
HSPGs but is largely protected from HMPV infection and we provide evidence that the inability 
of HMPV to infect these cells are primarily due to the failure of the virus to bind these cells 
(Figure 23). Importantly, PIV5 infectivity in HeLa cells was comparable to that in Vero cells. Since 
HeLa cells are not protected from infection by all paramyxoviruses, it is likely that HeLa cells do 
not express protein that serves specifically as a receptor for HMPV. While previous studies have 
shown that HeLa cells express HSPGs at their surface (237, 263, 378), it is possible that the 
HSPGs expressed by HeLa cells do not support HMPV binding, suggesting that one or more 
specific HSPGs are required for the binding of the virus. Interestingly, HMPV binding and 
infection was slightly reduced in A549 cells, a human lung carcinoma cell line, compared to Vero 
cells, which are monkey kidney cells. The decrease in both binding and infection suggest that the 
binding of HMPV to A549 cell is weaker than HMPV binding to Vero cells. This could be due to 
different expression levels of the HMPV receptor(s) or due to higher expression of other 
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glycoproteins that shield the viral binding site in A549 cells. This would also explain why HMPV 
binding was not significantly increased when higher amounts of virus was used (Figure 23B).  
In addition to establishing a negative control for receptor and entry studies of HMPV, 
the studies described in this chapter also provides foundational work for the development of 
new techniques to identify high affinity receptors for HMPV. The results shown in by Tayyari, et. 
al. (342) and the promising data described in this chapter warrants further exploration of the 
use of the VOPBA as a method for detecting cellular binding partners for HMPV. For this 
technique to work, however, the use of a higher affinity and more specific antibody is needed as 
background bands decrease the possibility to identify specific ones. Furthermore, the use of 
different types of PAGE gels may be needed to identify very high molecular weight complexes 
that may be interacting with HMPV. The development and use of non-denaturing screening 
techniques may also be required to identify proteins that only bind to HMPV under native 
conditions. 
Even though great progress has been made in the understanding of HMPV entry, most 
of the cellular factors that the virus hijacks to gain access to the cell are still unknown. The 
preliminary studies described in this chapter suggests that HMPV binding occurs through specific 
HSPGs that are not sdc4, betaglycan, or members of the glypican family of proteins. In addition, 
unlike RSV, HMPV binding does not occur through nucleolin. We have also identified a parental 
cell line that can be used with techniques like VOPBA to screen for factors that are important for 
HMPV cellular attachment. More work is therefore warranted to get a better understanding of 
the initial steps of the lifecycle of this virus. 
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Figure 21. HMPV colocalizes with HSPGs and BEAS-2B cells are protected from HMPV infection 
after treatment with heparinases.  
A. representative image of HMPV bound to Vero cells at 4˚C and stained with an anti-HS (green) 
monoclonal and an anti-HMPV F (red) polyclonal antibody. Purple = wheat germ agglutinin 
labeling plasma membrane proteins. B. Infectivity of rgHMPV was assessed in BEAS-2B cells 
after treatment with heparinase I, heparinase III, chondroitinase ABC, or PLC. GFP expression of 
at least 10,000 cells was determined by FACS the following day. Results shown are normalized to 
infection in BEAS-2B cells in the absence of treatment and are average of one experiment done 
in duplicate. 
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Figure 22. Syndecan-4, betaglycan, and glypicans do not play a significant role in HMPV 
infection. 
A. siRNA-mediated knockdown of syndecan-4 and betaglycan does not alter HMPV infectivity in 
A549 cells. Cells electroporated with siRNA were incubated for 72 hours and exposed to HMPV 
and control PIV5, VSV, and RSV for four hours. HMPV infectivity was assessed by GFP expression 
of at least 10,000 cells 24 hours post infection by FACS. Results shown are normalized to 
infectivity of A549 cells electroporated in the absence of siRNA and represents the average of 3 
independent experiments done in duplicate (n=3). Error bars = mean ± standard error of the 
mean. B. Vero, A549, BEAS-2B, and CHO-K1 cells pretreated with PLC were exposed to HMPV. 
Infectivity of at least 10,000 cells was assessed by GFP expression at 24 hours post infection by 
FACS. Data shown are normalized to HMPV infectivity in control cells not treated with PLC (n=1 
or 2). Error bars = mean ± standard error of the mean.  
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Figure 23. HeLa cells are poorly permissive to HMPV binding and infection.  
A. Representative western blot used for quantification in B. Red depicts signal from anti-HMPV 
polyclonal antibody and green shows actin loading control. B. HMPV binding to Vero, A549, and 
HeLa cells at an MOI of 10 and 15 was assessed and quantified as described previously. Data 
were normalized to WT Vero binding efficiency (n=4). Error bars = mean ± standard error of the 
mean. C. HMPV infection in Vero, A549, and HeLa cells was assessed at an MOI o f 1. Results 
shown are normalized to infection in Vero cells and represents the average of up to 3 
independent experiments done in duplicate (n=3 for HMPV and n=1 for PIV5). Error bars = mean 
± standard error of the mean. 
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Figure 24. Virus overlay protein binding assay (VOPBA) optimization and the role of nucleolin 
in HMPV infection.  
A. Cell surface proteins of Vero, A549, HeLa, CHO-K1, and pgsA745 cells were isolated, resolved 
by SDS-PAGE, transferred to a PDVF membrane, and blotted with 1.6 x 107 pfu/mL of HMPV for 
four hours. The location of the HMPV F protein in the membrane was detected using the 
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Odyssey system after labeling the HMPV F protein with an anti-HMPV F antibody. A control gel 
not exposed to HMPV and the overlay between the two gels (green = +HMPV, red = - HMPV) are 
also shown. B. Infection by rgHMPV of at least 10,000 A549 cells was assessed by FACS following 
incubation with antibodies targeted against syndecan-4, betaglycan, nucleolin, or control 
antibodies targeting cathepsin B and myc. Results shown are normalized against infection in the 
absence of antibodies and represents the average of up to 3 independent experiments done in 
duplicate (n=3 except for cathepsin B – n=1 – and myc – n=2). Error bars = mean ± standard 
error of the mean. 
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Chapter 6: Examination of the Entry Pathway for HMPV 
 
Introduction 
It has long been thought that viruses with a pH-independent fusion protein, including 
members of the paramyxovirus family, enter cells at the plasma membrane (180). This 
hypothesis is substantiated by the ability of their fusion proteins to promote cell-to-cell fusion 
under neutral pH conditions when expressed at the cell surface and the failure to inhibit viral 
infection in the presence of chemicals that raise endosomal pH. However, direct evidence of 
viral entry at the cell surface has not been obtained (203, 320). Low pH does not block fusion 
mediated by F proteins from PIV5 (35), HeV (63), RSV (320), NDV (54, 292), and pH-independent 
strains of HMPV (203), suggesting that the fusion protein could be active either on the surface 
or in endosomes. Furthermore, RSV and NDV fusion has been shown to be enhanced with low 
pH (54, 292, 320). Therefore, the pH requirement for fusion does not necessarily clarify the 
location of the fusion reaction.  
Earlier studies performed by Dr. Rachel Schowalter which I completed provided initial 
evidence that HMPV strain CAN97-83, which expresses a fusion protein that can be triggered by 
low pH (143, 299), could enter cells through endocytosis, as agents that raise endosomal pH and 
chemicals that block clathrin and dynamin-dependent endocytic pathways all blocked infection 
by HMPV (298). Thus, the fusion protein of HMPV CAN97-83 could use the low pH environment 
in the endocytic pathway to promote membrane fusion.  
Even though viruses with fusion proteins that are triggered by low pH enter cells 
through endocytosis, a low pH-triggering fusion protein is not a requirement for viruses to use 
endocytic pathways. Indeed, studies have shown that some viruses with pH-independent fusion 
proteins such as HIV can enter cells through endocytosis (218). Additionally, it has been 
reported that some members of the paramyxovirus family could enter cells through different 
endocytic mechanisms (54, 171, 262). Since we obtained initial evidence that HMPV uses 
endocytosis for cell entry ((298) and Figure 25), we performed studies to characterize its entry 
pathway. Additionally, we engineered GFP-tagged viral proteins with the ultimate goal of 
creating fluorescently label viral particles to perform live cell studies on the entry pathway of 
the virus. 
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Results 
HMPV and PIV5 Infection is Partially Inhibited by Methyl-β-cyclodextrin and is Likely Independent 
of Caveolin-mediated Endocytosis 
Our initial results using inhibitors of different endocytic pathways, including the 
dynamin inhibitor dynasore, suggested that HMPV could be using endocytosis for entry. 
Interestingly, treatment with dynasore, an inhibitor of dynamin, also decreased PIV5 infection. 
HMPV and PIV5 infection decreased significantly after cells were treated with dynasore in a 
dose-dependent manner, though inhibition of PIV5 infection was only partial (Figure 25A and 
(298)). We have previously shown that chlorpromazine, which promotes misassembly of clathrin 
at the cell surface and inhibits clathrin-mediated endocytosis (364), partially inhibits HMPV 
infection in Vero cells. Infectivity of PIV5, however, was not affected by treatment with 
chlorpromazine (298). Our data therefore suggests that HMPV and PIV5 use different pathways 
for cell entry although both require the activity of dynamin. The unexpected data suggesting 
that two paramyxoviruses are using different endocytic pathways for entry prompted us to 
examine the entry pathways of the two viruses. To date, clathrin- and caveolin-mediated 
endocytosis are the two endocytic pathways that are best understood. To examine whether 
caveolin-mediated endocytosis plays a role in infection by these viruses, we performed initial 
studies examining the effects of nystatin and methyl-β-cyclodextrin (mβCD) on viral infectivity. 
Nystatin is an antifungal that disrupts lipid rafts by binding to and sequestering sterols. Methyl-
β-cyclodextrin (mβCD) is a cyclic glucose oligomer that primarily binds to and extracts 
cholesterol but can also extract other lipids from the plasma membrane (23). It was previously 
shown that cholesterol is important for caveolae maintenance and dynamics and that depletion 
of cholesterol inhibits caveolae-mediated endocytosis (204). Even though disruptions in plasma 
membrane cholesterol can affect the formation of clathrin-coated vesicles (283, 333), it has 
been determined that mβCD and nystatin do not affect clathrin-mediated endocytosis (274). 
HMPV infection was not affected by pretreatment of Vero cells with nystatin or when 
nystatin was present at the time of infection (Figure 25B), suggesting that disruption of lipid 
rafts are not important for viral infectivity and providing initial evidence that HMPV does not use 
caveolae-mediated endocytosis. However, HMPV infection was reduced by more than 60% after 
treatment with 5 mM mβCD. Furthermore, PIV5 infectivity was reduced by at least 40% when 
infection was conducted in the presence of mβCD. VSV infection was almost abolished despite 
being internalized primarily by clathrin-mediated endocytosis (156), suggesting that treatment 
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with mβCD is also affecting clathrin-mediated entry (Figure 25C). Interestingly, the effect of 
mβCD on viral infection was significantly less pronounced when infection took place after 
pretreatment with but in the absence of mβCD (Figure 25C, white bars). The discrepancy in the 
effectiveness of mβCD inhibition could be due to a rapid replenishment of certain plasma 
membrane lipids or due to a deleterious effect caused by extraction of certain lipids in the viral 
envelope. Taken together, our data thus far show evidence that both HMPV and PIV5 can enter 
cells through a dynamin-dependent endocytic process. Nonetheless, control experiments 
assessing the efficiency of nystatin at disrupting lipid rafts and the changes that occur after 
treatment with mβCD are needed and will be performed. While more studies are clearly needed 
to elucidate the entry pathway for these viruses, our data provides evidence that clathrin-
mediated endocytosis is an entry pathway for HMPV entry whereas PIV5 takes advantage of a 
clathrin- and caveolin-independent pathway but dependent on dynamin. 
 
HMPV and PIV5 Infection can Occur in the Presence of DN Dynamin and CA Rab5 
Unlike viral entry at the plasma membrane, entry by endocytosis is a much more 
complex pathway that invokes the activity of many cellular proteins in order to carry the viral 
particle to the site of fusion. While there are several pathways for viral internalization by 
endocytosis (reviewed in (213)), it appears that in most cases, the cargo in primary vesicles are 
transported into early endosomes, where the cargo is subsequently sorted through the 
endosomal system (213, 259). To test whether HMPV and PIV5 entry occurs through the 
endosomal system, access to early endosomes through clathrin and caveolin-mediated 
endocytosis was blocked by overexpressing the dominant negative mutant of dynamin K44A 
(DN), which is defective in its GTP-binding activity (82) and prevents vesicle budding at the 
plasma membrane. HMPV or PIV5 were then added to transfected cells and, as previously 
reported, the cellular morphology of cells overexpressing the DN dynamin changed from having 
a polygonal shaped to a more round-edged appearance ((82) and Figure 26). Surprisingly, our 
data shows that cells overexpressing of DN dynamin can be infected by HMPV and PIV5 as GFP 
expression, which indicates translation of the viral genomic RNA, was observed in cells 
transfected with WT or DN dynamin (Figure 26, red cells express dynamin, green cells are 
infected with virus, yellow are areas with dynamin and GFP). Interestingly, the GFP expression 
pattern in cells expressing WT and DN dynamin that were infected by HMPV differed. Most cells 
accumulate GFP at very distinct locations in the cytoplasm after infection with rgHMPV 
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(presumably near the plasma membrane) while only a small subpopulation of cells express GFP 
in the nucleus. However, a higher proportion of rgHMPV-infected cells transfected with DN 
dymanin showed a diffused GFP-expression pattern in the cytoplasm and expressed GFP in the 
nucleus. GFP distribution after PIV5 infection, nonetheless, appears to be unaffected by the 
overexpression of either WT or DN dynamin (Figure 26). While this data suggest that HMPV and 
PIV5 can infect cells expressing DN dynamin, more studies with higher populations of 
transfected cells are needed to quantify changes in infectivity between cells expressing WT and 
DN dynamin. Furthermore, control experiments testing the efficacy of DN dynamin at blocking 
endocytosis need to be performed. 
HMPV and PIV5 infection was also tested after transfection with WT Rab5 and the 
constitutively active (CA), GTP-bound Rab5 Q79L mutant (327) as infectivity of cells 
overexpressing these proteins should be high. Cells overexpressing Rab5 WT or CA were 
permissive to HMPV and PIV5 infection and no changes in GFP localization after infection was 
seen in these cells (Figure 26). Experiments testing the effect of dominant negative Rab5 will be 
performed to determine if these cells can be infected by HMPV and PIV5. Additionally, studies 
with higher populations of transfected cells will be performed to quantify differences between 
infectivity of cells expressing WT, DN, and CA Rab5. 
 
HMPV Entry Colocalizes with Rab7 but not with Rab5 
The results shown in Figure 26 indicate that HMPV and PIV5 infection can occur in the 
presence of WT and DN dynamin as well as WT and CA Rab5. This is surprising given that both 
clathrin and caveolin-mediated endocytosis require the activity of dynamin for the formation of 
the endocytic vesicle and our results using chemical inhibitors suggest that these viruses use 
endocytosis for entry. Thus, we attempted to track viral entry at different time points to 
determine whether these viruses colocalize with endosomes. Initial studies were performed 
using HMPV and VSV as control. Briefly, HMPV and VSV were bound to Vero cells at 4˚C for one 
hour and then allowed to internalize for 5 to 15 mins at 37˚C. Viral internalization was stopped 
by washing extensively with PBS chilled to 4˚C followed by fixation with 4% paraformaldehyde. 
Cells were washed and fixed immediately after viral binding for the t = 0 mins as control. After 
the samples were permeabilized with 1% Triton X-100 and blocked with normal goat serum, 
HMPV was labeled with an antibody against its nucleoprotein and VSV was labeled with an 
antibody against its matrix protein followed by incubation with a secondary antibody conjugated 
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to the fluorophore Dylight488. Endogenous cellular EEA-1, Rab5, and Rab7 were labeled at the 
same time to determine whether viral particles colocalize with these proteins. Furthermore, cell 
surface sialic acid and N-acetylglucosamine were labeled with wheat germ agglutinin conjugated 
with Alexa Fluor647 to determine the location of the plasma membrane. 
As expected, HMPV particles were found at the plasma membrane immediately after 
the binding step and did not colocalize with EEA-1 or Rab5, both markers of the early 
endosomes. However, a small number of HMPV particles colocalized initially with Rab7, a 
marker of the late endosome and lysosome (Figure 27). This colocalization was also observed 
after five minutes but colocalization with EEA-1 and Rab5 was still not observed. No 
colocalization was observed between VSV and EEA-1, Rab5, or Rab7 at the same time point. 
Experiments with longer time points were also performed but they provided inconclusive results 
(data not shown). It has been shown that VSV enters primarily through clathrin-mediated 
endocytosis particles reached the early endosomes but not the late endosomes (8). However, 
VSV internalization has been shown to be synchronized and occur very rapidly, with some 
estimates as fast as two minutes (156). Thus, it is possible that colocalization of VSV with early 
endosomal markers were not seen because the viral particles had already fused with the cell. It 
is unclear why we observed colocalization between HMPV and Rab7 at both time points. It is 
possible that a subpopulation of Rab7 molecules is localized near the plasma membrane at a site 
very near to the binding site of HMPV but not near the binding site of VSV. More experiments 
will be required to determine whether HMPV attachment occurs in distinct areas of the cell 
surface and whether Rab7 are localized near that area. Experiments involving live-cell imaging 
will greatly help elucidate the entry pathway of HMPV but these experiments required the 
availability of a fluorescently-tagged viral particle. 
 
GFP-tagged HMPV G Protein is Expressed at the Cell Surface 
The availability of fluorescently tagged viral particles would facilitate the study of viral 
entry as it would allow direct visualization of the entry process. Thus, to generate a fluorescent 
viral particle, we engineered the GFP-tagged HMPV G and HMPV M proteins and attempted to 
incorporated into the viral particles in trans. Briefly, DNA fragments bearing the genetic 
sequence for HMPV G and HMPV M and flanked by restriction sites were ligated onto the 
pEGFP-C1 or pEGFP-N1 mammalian expression vectors. Because HMPV G is a type II 
transmembrane glycoprotein and possess an N-terminal cytoplasmic tail, ligation into the 
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pEGFP-C1 vector resulted in a GFP tag located inside the viral and cellular membranes (GFP-
HMPV G) whereas ligation into the pEGFP-N1 vector produced a HMPV G protein with the GFP 
tag in the ectodomain (HMPV G-GFP). Because the HMPV G protein is dispensable for the HMPV 
lifecycle in vitro, a GFP tag in this protein is less likely to induce deleterious effects to the virus. 
The resulting plasmids were sequenced to confirm the presence of the fused protein and were 
then transfected into Vero cells. Our preliminary studies showed that both the HMPV G-GFP and 
GFP-HMPV G plasmids were expressed at the surface of Vero cells (Figure 28). Experiments are 
currently under way to determine whether the proteins expressed from these plasmids can be 
incorporated into the viral particle. Due to the abundance of HMPV M protein inside viral 
particles, we decided to tag this protein in addition to HMPV G. We are currently determining 
whether the GFP-tagged HMPV M protein is expressed in Vero cells. 
 
Discussion 
The preliminary results presented in this chapter provide useful information about the 
entry process of HMPV and PIV5. We showed evidence that infectivity of both these viruses 
could be blocked by inhibiting the activity of dynamin with the compound dynasore. 
Furthermore, we provide evidence against a role of caveolin-mediated endocytosis in HMPV and 
PIV5 entry, as nystatin has been shown to inhibit endocytosis mediated by caveolin and not by 
clathrin (274). Additionally, we performed initial studies assessing viral infectivity in the 
presence of dominant negative dynamin as well as a constitutively active Rab5 mutant and we 
carried initial colocalization studies to identify the spatial location of viral particles over time. 
Finally, we have tagged the HMPV G and HMPV M proteins with GFP and are continuing to work 
on creating a fluorescent labeled viral particle. 
Even though our initial evidence suggest that HMPV and PIV5 use an entry pathway that 
depends on dynamin and that HMPV infection can also be inhibited by chlorpromazine (Figure 
25 and (298)), the data obtained using dominant negative dynamin shows that cells expressing 
this mutant protein are still susceptible to HMPV and PIV5 infection (Figure26). Dominant 
negative mutant proteins act by outcompeting endogenous wild type proteins and preventing 
them from acting on the substrate. Thus, the apparent discrepancy could be due to incomplete 
inhibition of vesicle scission by DN dynamin, as only one viral particle needs to reach the 
cytoplasm for infection to take place and GFP to be produced. Furthermore, our studies with 
dynasore indicate that PIV5 infection is only partially dependent on dynamin and still a small 
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population of cells was infected by HMPV after treatment with dynasore, suggesting that 
alternative pathways for infection exist for both of these viruses. Due to the lack of a highly 
efficient transfection method, cells were infected with a much higher MOI to minimize the 
chance that an insufficient number of viruses in the sample result in large numbers of 
noninfected cells. Exposure to more viruses and imaging of a limited number of cells could 
therefore result in imaging of cells infected by alternative entry pathways. 
We have also shown that HMPV and PIV5 infectivity is decreased when cells were 
treated with mβCD but not after treatment with nystatin. While both chemicals bind to 
cholesterol with high affinity, their overall mechanism of action and the effect on cells differs. 
Nystatin usually binds to sterols (including cholesterol and ergosterol) at the cell surface and 
causes an increased in membrane permeability by forming pores (173). Compounds like mβCD, 
on the other hand, extract cholesterol and other lipids from the plasma membrane without 
perturbing the bilayer (23). It is possible that the differences in inhibition of viral infectivity be 
due to the differences in the mechanism of action of these compounds. Additionally, it has been 
shown that mβCD also extracts lipids like sphingomyelin (274). It has been shown that the lipid 
composition of viral and cellular membranes play an important role in HCV infectivity (6, 362). It 
is possible that extraction of lipids like sphingomyelin from viral and cellular membranes explain 
the effect of mβCD on viral infection. Thus, it would be of interest to determine whether 
differences in viral and plasma membrane lipid composition have an effect on paramyxovirus 
infectivity. 
Elucidating the entry pathway of HMPV is of great importance as it will provide 
information that could be used in the development of therapeutics. With the data presented in 
this chapter, we have only begun to dissect the entry pathway of HMPV. Many more studies are 
therefore required to clearly elucidate the route of entry of HMPV as well as the viral and 
cellular compounds, including proteins and lipids, that are responsible for viral invasion. 
Important experiments that are currently underway include testing the effect of overexpression 
of dominant negative Eps15 and caveolin as well as colocalization studies with molecules 
involved in the clathrin and caveolin endocytic pathways. Furthermore, the availability of a 
fluorescently labeled virus would help in colocalization studies using live microscopy. 
Confirmation that viral entry of HMPV and PIV5 occur through endocytosis would represent an 
important step forward in our understanding of paramyxovirus entry, as these viruses belonged 
to different subfamilies and PIV5 has long been used as a model for paramyxoviruses.  
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Figure 25. HMPV and PIV5 infection likely occurs through endocytosis.  
A. HMPV, PIV5, and control VSV entry in Vero cells treated with dynasore. Cells in 24-well plates 
pretreated with dynasore or vehicle control diluted at 80 µM (black) or 120 µM (white) were 
infected in the presence of drug for 2 hrs. For analysis of the effects of dynasore postinfection, 
drug or vehicle control was added for 2.5 hrs after infection. Cells were analyzed by FACS for 
GFP expression the following day. Data shown represent the number of GFP-expressing cells as 
a percentage of control (infectivity of cells treated with vehicle control) and are the average of 3 
independent experiments done in duplicate. Error bars = mean ± standard error of the mean. B. 
Infectivity of HMPV was determined in Vero cells after pretreatment (black) and/or in the 
presence of nystatin (gray = pretreatment + coinfection, white = coinfection only). The 
fluorescence intensity of at least 10,000 cells was determined by FACS the following day. Results 
shown are normalized to infection in no nystatin control and represents the average of 4 
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independent experiments done in duplicate (n=4). Error bars = mean ± standard error of the 
mean. C. Vero cells were infected with HMPV, PIV5, or VSV after (black) or during (white) 
treatment with 5mM mβCD. Cells were analyzed by FACS for GFP expression the following day. 
Data shown represent the number of GFP-expressing cells as a percentage of control (infectivity 
of cells treated with vehicle control) and are the average of 3 independent experiments done in 
duplicate. Error bars = mean ± standard error of the mean. 
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Figure 26. HMPV and PIV5 can infect cells expressing dominant negative dymanin and 
constitutively active Rab5.  
Vero cells grown in coverslips and transfected with either WT dynamin or dynamin K44A mutant 
or either Rab5 WT or Rab5 Q79L mutant fused with mCherry and mRFP respectively (red) were 
infected with either GFP-expressing HMPV or PIV5 (green) for three hours. Following an 
overnight incubation, cells were fixed, mounted on a slide, and imaged using a Nikon A1 
confocal microscope. Images shown are representative of four images taken from a single 
experiment (n=1). Arrows indicate cells expressing the transfected protein that have been 
infected. 
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Figure 27. HMPV entry colocalizes with endogenous Rab7 but not with endogenous Rab5. 
HMPV or VSV were bound to Vero cells grown in coverslips at 4˚C. After extensive washing, cells 
were either incubated in media prewarmed to 37˚C for 5 mins to allow viral entry before fixing 
or fixed right away (t = 0 mins). Samples were permeabilized, stained with antibodies against 
HMPV N or VSV M (green) and Rab5, Rab7, or EEA-1 (red), and mounted on a slide for imaging. 
Plasma membrane proteins were stained using wheat germ agglutinin conjugated with Alexa 
Fluor647 (purple). Images shown are representative of images taken from four independent 
experiments (n=4). 
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Figure 28. Cellular expression of HMPV G – GFP and GFP – HMPV G. 
The gene sequence of the HMPV G protein was placed into the pEGFP-C1 and pEGFP-N1 
plasmids in frame with the sequence of EGFP to tag the HMPV G protein with GFP at the N- and 
C- terminus (GFP-HMPV G and HMPV G-GFP respectively). Plasmids were purified and 
transfected into Vero cells and expression was observed using a Nikon A1 confocal microscope. 
High expression levels were seen with both constructs. 
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Chapter 7: Discussion and Future Directions 
 
Studies performed on HMPV since its discovery in 2001 (352) have shown that HMPV 
differs from other paramyxoviruses in several aspects of the entry cycle. Despite expressing 
three surface glycoproteins, only the F protein is required for viral infection (27, 31, 65), which 
demonstrates that the F protein possesses receptor-binding activity and that, unlike most 
paramyxoviruses, its triggering is not dependent on nor enhanced by the homotypic attachment 
protein (180, 299). Moreover, the HMPV F protein is proteolytically cleaved by exogenous 
proteases (299, 352) and some strains of HMPV have F proteins that can be triggered by low pH 
(143, 180, 298, 299). The results presented here increase our understanding of some of these 
unique characteristics of HMPV and elucidate some key aspects in the entry pathway of this 
important human pathogen. We confirmed that HMPV binding to cells does not depend on 
expression of the HMPV G protein as we showed that the F protein of HMPV specifically binds to 
HSPGs and that this interaction is enough for viral binding to the cell ((65) and Chapter 4). We 
also confirmed the observation made by Cseke and coworkers that integrins play a role in HMPV 
infection (80) though the specific step at which these cellular proteins act remains unknown 
((65) and Chapter 4). Furthermore, we explored mechanistically the regulatory role of the 
histidine residue at position 435 for low pH triggering of HMPV F and identified new areas in the 
F protein where potential electrostatic interactions function to stabilize the F protein and allow 
proper local folding (Chang, et. al., manuscript submitted, Chapter 3). Finally, we provided 
preliminary evidence on potential candidate receptors for HMPV binding (Chapter 5) and the 
potential role of different endocytic pathways on viral entry (Chapter 6). The studies presented 
here therefore represent important steps forward in our understanding on the entry cycle of 
HMPV and could potentially serve as the basis for the development of therapeutic agents. 
 
The Triggering of HMPV F 
Most studies to date have provided strong evidence that paramyxovirus F proteins were 
able to efficiently promote membrane fusion at neutral pH and that fusion activity could not be 
promoted by low pH. This holds true for most paramyxoviruses (180) as prior to the studies 
carried by Dr. Schowalter in our laboratory (299), there was only one study that showed some 
increase in RSV fusion at lower pH values (320) and another one implicating low pH triggering 
for the paramyxovirus SER (302). In the latter study, cells expressing the SER F protein after 
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infection with a vaccinia virus vector were able to efficiently form syncytia after treatment with 
low pH and SER virus was unable to infect cells after treatment with lysosomotropic agents 
(302). These studies, however, remain controversial as they were not able to be replicated in 
cells expressing SER F after transfection (35). Since Dr. Schowalter’s finding on low pH triggering 
of HMPV F (299), others have shown that the F protein of other strains of HMPV can also be 
triggered by low pH (143, 203).Thus, the studies on HMPV from our laboratory represent the 
first confirmed example of a paramyxovirus F protein whose membrane fusion activity can be 
significantly promoted by low pH. 
The ability of HMPV F to be triggered by low pH poses interesting questions about the 
differences between the F protein of HMPV and the rest of paramyxoviruses. Previous studies 
from our laboratory showed that histidine residues, particularly one at position 435 (H435), 
have an important role in the regulation of low pH triggering (298). With a pKa of 6.4, histidine 
residues are important physiological regulators of pH-dependent processes as changes in the 
protonation state of these residues can occur under physiological conditions and translate into 
drastic changes in protein conformation. In the case of viruses, it has been shown that 
protonation of histidine residues at low pH are involved in the activation of all three classes of 
membrane fusion proteins including the fusion proteins of influenza (HA protein, also a class I 
fusion protein), dengue virus (E protein, a class II fusion protein), and VSV (G protein, a class III 
fusion protein)(56, 162, 348). Mutations of histidine residues in influenza HA destabilize the 
protein leading to triggering at higher pH values (348). Our initial studies suggested that the 
protonation of the histidine residue H435 is important for triggering of HMPV F by low pH (298). 
The studies presented in Chapter 3 and those of Mas, et. al. (203) have confirmed the 
requirement of a positive charge at this position for the triggering of HMPV F. 
Despite the dramatic reduction in cell-to-cell fusion observed when the charged 
residues around HMPV F H435 were removed (298), we were able to rescue infectious HMPV 
particles after introducing these mutations into the viral genome (Figure 8). Interestingly, while 
viral titers from all mutant viruses were reduced by three or more logarithmic units compared to 
WT, titers from recombinant viruses expressing the H435A and H435N mutations were 
significantly higher than viruses bearing the K295A and R396A mutations (Figure 8). The reason 
why the HMPV F mutations R396A and K295A appear to be more deleterious to the viral 
lifecycle compared to mutations in H435 is still unclear. Our homology model of the HMPV F 
protein in its prefusion conformation predicts K295 and R396 to be freely exposed at the surface 
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of the protein (Figure 6). It is possible that these residues have other important roles in the 
lifecycle of the virus and thereby increasing the selective pressure and making these mutations 
more difficult to overcome. We have shown that HMPV entry is initially mediated by 
interactions between the F protein and heparan sulfate ((65) and Chapter 4). Therefore, one 
possibility is that the positively charged residues K295 and R396 are needed for interactions 
with the negatively charged heparan sulfate during virus entry. While H435 and its surrounding 
residues are located at the base of the head domain, interactions between HS and this region 
could take place at an intermediate step in the fusion process or with longer branches of 
heparan sulfate. 
Based on our data from fusion assays, it was remarkable that we were able to recover 
infectious particles carrying these mutations in their F proteins. Moreover, our preliminary 
studies indicate that the efficiency of viral growth is significantly enhanced in subsequent 
passages (data not shown). The ability to recover recombinant viruses bearing these mutations 
and for them to replicate more efficiently over time suggest that the initial mutations did not 
abolish fusion completely and provided a selective pressure for these viruses to evolve 
mechanisms to bypass the requirement for protonation of H435 to trigger the F protein. 
Interestingly, conventional sequencing data, which presents the average sequence in a sample 
population, provided no evidence of compensating mutations in the F protein of these viruses 
(data not shown). Studies have shown that RNA viruses are capable of generating a very diverse 
population of ‘quasispecies’ that act cooperatively to evolve and adapt to new environments 
(359). Thus, the presence of a heterogenous population in which subset of viruses harbor 
mutations that together provide the adaptive changes that allow viruses with mutations at or 
around H435 to grow is possible. Because these quasispecies represent a fraction of the viral 
population, they cannot be detected by traditional sequencing methods. Identification of these 
quasispecies by deep sequencing the viral genomes is therefore of great interest as they would 
provide information on the adaptive changes in the viral population that allowed it to overcome 
the mutations around the H435 region. Deep sequencing data could also provide information on 
compensatory mutations in the surface glycoproteins, especially in F, increasing our 
understanding on the different regions that are important for triggering at low pH. Mapping the 
regions important for HMPV F will in turn allow us to determine if those regions are also 
important in other paramyxovirus F proteins and will give us a better understanding of this key 
step in the viral lifecycle. 
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Additional Roles for Potential Electrostatic Interactions in HMPV F 
While our experiments and those of others (203) indicate that protonation of HMPV F 
H435 is essential for low pH mediated membrane fusion, it is also clear that changes in the 
protonation state of H435 alone is not sufficient for F triggering at low pH. Further analysis of 
the amino acid sequence of HMPV F revealed another region where potential electrostatic 
interactions could play an important role in the trigger of the protein. Interestingly, this region, 
which is a three-stranded β-sheet domain made up from residues that are part of HRA and F2, 
has been shown to modulate fusion in PIV5 (121). While there is very little sequence similarity in 
this region between PIV5 and HMPV, as non-polar residues predominate in PIV5, the importance 
of this region in the stability of the protein and the triggering process remains.  
Our studies showed that mutations of residues D54 and E56 produced hyperfusogenic F 
proteins while mutation at position E51 abolished fusion activity. Despite the proximity of these 
residues, it is clear that charges in the region between F2 and HRA control different aspects of 
the F protein. We showed that mutation of residue E51 exposes a cleavage site that is normally 
hidden from endogenous proteases. While the exact location of this cleavage site is still 
unknown, it must be near the usual cleavage site as cleaved mutant proteins were similar in size 
compared to WT F1. The HMPV F sequence contains an arginine residue two residues upstream 
of the predicted WT cleavage site (RQSR/F, / = predicted cleavage site) that could become 
accessible to endogenous trypsin-like proteases after mutation of E51. If proteolytic cleavage 
occurs at this residue, it would result in an F1 protein with polar and charged residues (QSR) at 
the N-terminus upstream of the hydrophobic fusion peptide. It would not be surprising that F 
protein mutants with polar and charged residues at the N-terminus of the F1 subunit cannot 
promote membrane fusion. Our homology model predicts E51 to be in close proximity to 
residues K138 and K142. It would be interesting to know if these residues are also important for 
proper cleavage of the F protein. Replacement of these residues with alanine or negatively 
charged residues (which should produce a phenotype similar to E51K) as well as experiments 
identifying the novel cleavage site should provide useful information on how electrostatic 
interactions promote proper cleavage activation. 
It is possible that the sequence differences in this region between HMPV and PIV5 are 
related to the requirements for their homotypic attachment proteins. While PIV5 HN is essential 
for viral-cell binding and fusion (180), the G protein of HMPV is not required for neither step (31, 
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65, 299). Therefore, the presence of charged residues in this region of HMPV F could help 
supplant the need for interactions with G for the regulation of triggering. The electrostatic 
interactions in this region could help stabilize the metastable prefusion conformation until 
binding of HMPV F to negatively-charged HSPGs forces conformational changes that disrupts 
this interaction and primes F for triggering at low pH. 
 
HMPV – Receptor Interactions 
Initial studies by Biacchesi and coworkers showed that the HMPV F protein alone can 
promote virus-cell binding and infection (31), indicating that the F protein must have receptor 
binding abilities. The studies detailed in the preceding chapters have confirmed this hypothesis 
and show that HMPV F binds to HSPGs and that this interaction is sufficient for cell infection 
(Chapter 4 and (65)). Carbohydrates play an important role in entry for many viruses including 
several members of the paramyxovirus family. It is well known that paramyxoviruses that 
express HN attachment proteins like PIV5 bind to cell surface sialic acid. Furthermore, RSV and 
BRSV binding to HSPGs has also been reported (115, 163, 174, 176). The crystal structures of 
several HN proteins have been solved and indicate that the binding site for sialic acid is located 
at the top of the head domain (184, 385, 386). The binding site for SLAM, however, is located at 
the side of the MeV H protein (135). While structures of pneumovirus F proteins in the prefusion 
form are unavailable to date, our homology model indicates that positively charged residues are 
more concentrated at the top of the head domain of HMPV F (data not shown). Therefore, the 
binding site for negatively-charged HSPGs could also be located at the top of the head region. 
Nonetheless, more experiments are needed to determine the exact location of the binding site 
for HSPGs. 
Even though the prevailing hypothesis for many viruses is that binding to GAGs is a 
nonspecific event that serves only to concentrate viral particles at the surface of the cell to 
facilitate subsequent interactions with higher affinity receptors, we believe that the interaction 
between HMPV F and HSPGs is specific, as interactions between paramyxoviruses and HSPGs 
has only been documented for members of the pneumovirinae subfamily and our experiments 
show significant impairment in viral binding and infection in the absence of HSPGs. Moreover, 
our preliminary data suggest that not all HSPGs interact with HMPV F for virus binding (Chapter 
5). Therefore, it is possible that only a few specific proteoglycans can serve as platforms for 
HMPV F anchoring though the identity of these HSPGs are still unknown. It has been shown that 
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HSPGs can promote particle internalization (237, 378). Thus, binding to HSPGs alone could 
directly promote viral internalization as has been reported for HSV-1 and HEV (161, 241, 308, 
349) or could allow interaction with higher affinity receptors or coreceptors. Whether 
interactions with one or a few specific HSPGs alone can directly lead to viral internalization 
alone still needs to be determined.  
Cell surface nucleolin has been recently proposed to be a functional receptor for RSV 
(342). Previous studies have shown that RSV infection is facilitated by interactions between RSV 
G and GAGs (174). While RSV F has also been shown to interact with GAGs (115), a more recent 
study showed that a virus with a truncated RSV G protein showed decrease binding to GAGs, 
suggesting that the G protein is the primary binding partner for GAGs in RSV (176). Binding of 
RSV F to nucleolin is thought to occur after interactions between RSV G and GAGs. Despite 
belonging to the same subfamily of viruses, our preliminary results indicate that cell surface 
nucleolin does not play a significant role in HMPV infection (Figure 24). Moreover, HMPV 
binding to cells was not enhanced in the presence of HMPV G, suggesting that the G protein 
does not play a role in viral binding at least in vitro. The observation that any potential cellular 
interactions mediated by HMPV G are not essential for viral attachment further underscores the 
importance of the interaction between HMPV F and specific HSPGs and suggests that this 
interaction could directly mediate viral entry. It would be interesting and extremely valuable, 
however, to learn whether HMPV F binds to other cell surface proteins and the role those 
binding events play in viral infectivity. Techniques such as the VOPBA (Chapter 5) should prove 
to be useful in the search for those surface proteins. 
It was suggested that interactions between RSV and HSPGs are likely irrelevant in vivo as 
immunofluorescence studies using an antibody against epitope 10E4 suggested that HS is 
located primarily on the basolateral side of differentiated ciliated airway epithelial cells (52, 226, 
389). While 10E4 is the most commonly used monoclonal antibody against HS, the specificity of 
10E4 varies between different HS (350, 356). It is possible that HSPGs recognized by 10E4 locate 
preferentially to the basolateral side while other HSPGs are present in the apical side of 
polarized cells. Indeed, some studies show HSPG expression, including glypicans, on the apical 
side of polarized cells (52, 75, 199, 214). The amount of HSPGs present on the apical side of cells 
could allow HMPV to establish an initial infection in the upper respiratory tract. It has been 
shown that, after viral infection, the morphology of cells that make up human airway epithelium 
changes resulting in increased mucin production and a loss of ciliated epithelial cells due to 
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shedding (389). Additionally, tissue injury and disruptions of cell layers cause an increase in 
apical levels of HSPG and exposure of basolateral HSPGs (52). Initial infection by HMPV 
therefore could in turn increase the accessibility of HSPGs to the virus. Furthermore, while it is 
commonly believed that viral infections occur initially at the apical surface of polarized cells, 
infection through the basolateral side after binding to HSPGs has been documented for some 
papillomaviruses (168). Detailed studies with polarized human airway epithelial cells would be 
essential to identify the physiological location of viral attachment and entry during HMPV 
infection. 
 
Potential Roles for the HMPV G Protein 
The evidence that cellular attachment of HMPV is mediated by the fusion protein forces 
the field to reconsider the role of HMPV G in viral entry. Interestingly, RSV, BRSV, and AMPV 
have also been shown to be infectious in the absence of their attachment proteins in vitro (163, 
164, 231) and very little sequence homology is seen between the attachment proteins of the 
two subfamilies of paramyxoviruses (351). Therefore, it appears that there is a difference in the 
requirement for the homotypic attachment protein for viral attachment and fusion between the 
members of the paramyxovirinae and pneumovirinae subfamilies. However, even though 
pneumoviruses can grow in the absence of the attachment protein, in vivo studies show that 
viruses devoid of this protein either cannot replicate, as in the case of RSV (346), or are 
significantly attenuated, as BRSV and HMPV (27, 295). Therefore, while the role of the G protein 
is still unknown, it appears that this protein confers an advantage for the virus in vivo though it 
is not essential for viral growth in vitro. Studies have shown that RSV G improves the efficiency 
of cell fusion (139), packaging, and particle formation (345). It has been shown that infectious 
particles lacking the HMPV G protein can be recovered (31, 65) and our laboratory has 
demonstrated that cell-to-cell fusion mediated by HMPV F is not enhanced by the presence of 
the HMPV G protein (299). Furthermore, in vivo studies show that infectivity of HMPV ΔG virus 
is attenuated in the lower respiratory tract of nonhuman primates but not in the upper 
respiratory tract (27). Therefore, it is likely that HMPV G is not required for fusion and/or viral 
packaging though we cannot rule out the possibility that it is required for fusion and/or viral 
packaging the environment of the lower respiratory tract. 
Pneumovirus G proteins are highly glycosylated and, in the case of RSV, can exist as a 
soluble form that is about half in size and is secreted from infected cells (141). Interestingly, 
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Teng and coworkers showed that the infectivity in mice of recombinant RSV expressing only the 
soluble form of G was only mildly reduced compared to WT whereas a drastic reduction was 
seen in viruses that did not express G at all (346), suggesting that the ectodomain alone is 
largely responsible for most of the G activity. Therefore, it appears that the primary role of 
pneumovirus G proteins is something other than mediating viral attachment. Several studies 
have shown that paramyxovirus attachment proteins are major targets for antigenic response 
though the antibodies produced are many times poorly neutralizing (71). In addition, the 
secreted form of RSV G interferes with antibody-mediated neutralization and plays a role in 
modulating the immune response (71, 158). Interestingly, the HMPV G gene presents the largest 
sequence variability in the viral genome, resulting in less than 50% homology between the G 
proteins of the two subgroups of HMPV (18). It has been shown that protective neutralizing 
antibodies were not produced in hamsters after immunization with HMPV G expressed in a 
HPIV1 vector (312). Moreover, Bao and coworkers showed that the HMPV G protein inhibits 
innate immune responses (14). Therefore, while a soluble form of HMPV G has not been 
characterized, the high degree of glycosylation and sequence variability could be essential for 
immune evasion. 
Previous studies have demonstrated that the G proteins of both RSV and HMPV also 
bind to GAGs (304, 347). While our studies indicate that the HMPV F protein is the primary 
attachment factor and no significant differences in viral binding to cells in vitro was observed 
between WT and viruses lacking the G protein (65), the HMPV ΔG mutant virus was less efficient 
at infecting the lower respiratory tract of animals (31). Therefore, it is still possible that the 
HMPV G protein could confer a selective advantage for viral attachment in some tissues either 
by recognizing a specific GAG or a higher affinity receptor. Even though the exact function of 
HMPV G in the viral lifecycle is still unknown, the gene encoding HMPV G is present in all clinical 
isolates sequenced so far (27, 31) and therefore must serve an important function in the viral 
lifecycle. More studies are clearly warranted to get a better understanding on the function of 
this viral protein. 
 
HMPV Entry Into Cells 
The finding that the HMPV F protein mediates the initial viral attachment step (65), that 
it can be triggered by low pH (299), and that inhibitors of endocytosis and agents that raise 
endosomal pH can reduce HMPV infectivity (298) all suggest an entry mechanism that is 
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significantly different from the entry pathway hypothesized for most paramyxoviruses. While it 
has long been thought that paramyxoviruses gain access to the cell at the plasma membrane 
after cell binding mediated by the attachment protein (180), our data suggest that HMPV entry 
occurs through endocytosis and is independent of the activity of the attachment protein. In 
addition, our preliminary data also suggest a role for endocytosis on entry of PIV5, questioning 
the general belief that entry of paramyxoviruses with F proteins that can be triggered by neutral 
pH occurs at the plasma membrane. 
Even though most members of the paramyxovirus family express F proteins that can be 
triggered at neutral pH and inhibitors of endosomal acidification do not block infectivity in most 
cases, there is evidence that, in addition to HMPV, at least some other paramyxoviruses could 
also enter cells through endocytic pathways. Kolokoltsov and coworkers showed that RNAi-
mediated knockdown of proteins involved in clathrin-mediated endocytosis significantly 
reduced RSV infectivity (171). Pernet, et. al. showed that NiV entry can occur by 
macropinocytosis after binding to its receptor EphrinB2 and low endosomal pH was not required 
for NiV to exit the vesicle (262). Furthermore, studies with chemical inhibitors suggest that NDV 
may infect cells through caveolin-mediated endocytosis (54). In addition to our work with 
HMPV, we also showed that inhibition of dynamin decreases PIV5 infectivity (Figure 25). The 
microenvironment in endosomes can be significantly different to that of the cell surface, from 
the membrane lipid composition to the protein content inside the vesicles. Infection by tick-
borne encephalitis virus, Semliki Forest virus, and dengue virus require different lipid membrane 
compositions in endosomes (166, 236, 329, 388) while other viruses like SARS coronavirus and 
Ebola virus require proteolytic cleavage by endosomal proteases for infection to occur (62, 296, 
310). Interestingly, cleavage of Ebola virus GP1 protein reveals a binding domain for the 
endosomal/lysosomal cholesterol transporter Niemann-Pick C1 (NPC1) (55, 77). Binding to NPC1 
is essential for Ebola infection and is therefore considered a postendocytic intracellular receptor 
required for viral fusion. Even though intracellular receptors have not been characterized for 
paramyxoviruses, infection by members of this family could take place via endocytosis 
regardless of the ability on their F proteins to be triggered by low pH. 
Numerous studies have shown that viral entry pathways are largely defined by the cell 
surface receptors being used by the virus (reviewed in (129)). Even though influenza virus can 
bind to a wide range of sialic acid-containing molecules, cell entry occurs through different 
endocytic pathways depending on viral interactions with other cellular proteins (67, 86). Since 
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many paramyxoviruses also bind to sialic acid, the entry pathways of these viruses could be 
similar to that of influenza. Interestingly, while HMPV does not bind to sialic acid, there appears 
to be a significant resemblance between the entry of HMPV and influenza as both viruses 
express a class I membrane fusion protein that is also responsible for viral binding to cell surface 
carbohydrates and must be proteolytically cleaved to be active (hemaglutinin, HA for influenza 
and HMPV F)(311). Like some sialylated proteins, some HSPGs also have sorting capabilities 
(187, 275) and, like most cell surface proteins, are endocytosed after ligand binding for recycling 
or degradation (273). Thus, the pathway of internalization of some syndecans is thought to be 
clathrin-independent (118) while some glypicans use caveolin-mediated endocytosis (198) to get 
to endosomes. The exact pathway of internalization for other HSPGs is still largely unknown. 
However, it remains possible that the HSPG receptor of HMPV dictates the entry pathway of the 
virus. 
Our laboratory and others have shown that β1 integrins play an important role in 
promoting HMPV infection (65, 80). While the results from Cseke, et. al. were initially 
interpreted by many to mean that αvβ1 integrins was the initial attachment receptor for HMPV, 
our studies indicate that integrins have an important role after binding to HSPGs (65). It is 
unclear what role of β1 integrins have in HMPV entry. It has been shown that integrins have an 
important role in the regulation of a complex set of signaling pathways that are responsible for 
many aspects of cell behavior including endocytosis. Integrins signal through many pathways 
including those mediated by PI3-kinase (PI3K), protein kinase C (PKC), Src-family protein tyrosine 
kinases, and ERK (124, 151). Because the activity of many of these signaling pathways promotes 
endocytosis (94), it is not surprising that integrins can dictate the route of viral entry (123). 
Indeed, internalization and proper endocytic sorting of mammalian orthoreoviruses depend on 
β1 integrin and Src kinases even though their initial attachment receptor is JAM-A (84, 197). In 
addition, it has recently been shown that activation of the PI3K/Akt pathway by β1 integrin 
promotes the internalization of mature vaccinia virus (153). Interestingly, vaccinia viruses also 
bind to cell surface GAGs and enter cells mainly through endocytosis (59, 212) even though viral-
cell membrane fusion can occur at the plasma membrane (59). Thus, it is possible that proper 
signaling through β1 integrin is required for efficient internalization and proper sorting of HMPV 
in the endosomal pathway. 
In addition to regulating endocytic processes, integrins are also internalized and 
recycled through these endocytic pathways (61). The internalization of integrins themselves can 
123 
 
occur through clathrin-dependent and clathrin-independent endocytosis, and their 
internalization is often accompanied by internalization of the bound ligand (61, 305). The 
internalization and recycling of integrins bound to their ligands allows them remain active 
intracellularly and to direct receptor and cargo trafficking through different compartments 
(309). Indeed, integrin signaling through endocytic compartments could be responsible for the 
regulation of endosomal cathepsins, which has been shown to influence Ebola virus entry (297). 
If HMPV binds directly to β1 integrin, the entry pathway viral particle could be the same as the 
route of internalization of β1 integrin. Furthermore, integrins could be required for the proper 
expression and localization of an unknown endosomal factor that is required for HMPV entry. 
Our studies and those performed in other viral systems allow us to propose a model for 
HMPV entry. Initial attachment of HMPV to the surface of the cell is mediated by interactions 
between HMPV F and HSPGs (65) at the apical or basolateral side of polarized cells in vivo. 
Attachment of HMPV to HSGPs would then allow the virus to interact with other cell surface 
proteins including β1 integrin to promote viral internalization through endocytosis. While HMPV 
entry could occur through more than one pathway of endocytosis, our results suggest that at 
least a subpopulation of HMPV use clathrin-mediated endocytosis for cell entry. Because the 
optimal pH for triggering of HMPV appears to be less than 5 (299), we hypothesize that the viral 
cell-membrane fusion step would occur in a late endosomal/endolysosomal compartment. 
Studies using live-cell imaging and polarized cells are clearly needed to confirm this model as 
these studies would determine the site of cell attachment and the entry pathway the virus takes 
to establish a productive infection. Furthermore, expanding these studies to other 
paramyxoviruses like PIV5 will provide valuable information that could change our hypothesis of 
how paramyxovirus infection occurs. 
 
Remaining Questions in Paramyxovirus Fusion and Entry and Potential Applications to 
Medicine 
Despite the wealth of information that has been gathered about paramyxovirus F 
protein-mediated membrane fusion and viral entry, many important questions remain to be 
answered. Foremost among these is the identification of the triggering signal(s) that are 
transmitted from the attachment protein to the F protein upon receptor binding. What kinds of 
conformational changes occur in the attachment protein that signal the F protein to trigger? 
Where are the interactive sites between the attachment and the F proteins? Are conformational 
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changes and/or interactive sites different between paramyxoviruses so that a homotypic 
attachment protein is required? While current data suggest that, for some paramyxoviruses, this 
interaction is between the stalk domain of the attachment protein and the head domain of the F 
protein (43, 89, 185, 209), the exact location in the F protein remains unknown. Furthermore, 
the F protein of members of the pneumovirinae subfamily can be triggered in the absence of the 
homotypic attachment protein, suggesting that the triggering mechanism differs significantly 
between the two subfamilies.  
Important questions also remain on the process of fusion itself. What are the structural 
intermediates of F in the fusion process? While recent biophysical data have provided us with 
evidence of the prehairpin intermediate of PIV5 F (167), structural information about the 
prehairpin intermediate as well as the conformational changes leading to it and after the 
formation of it remain to be elucidated. Furthermore, the precise role of the attachment protein 
as an active participant of the refolding of the F protein during fusion beyond the prehairpin 
intermediate state (268) is still unknown. Are interactions with the attachment protein needed 
for the F protein to achieve certain intermediate states? If so, what replaces this function of the 
attachment protein in members of the pneumovirinae subfamily? 
Another significant area of study is to clarify the role of different cellular pathways in 
the viral entry process. Increasing amount of data suggest a more complex mechanism of entry 
that, in many cases, may involve the endocytic machinery of the cell. There are advantages for a 
virus to enter through an endocytic pathway, as endosomes protect viruses from the host 
immune system and provide a unique environment for fusion to occur, therefore potentially 
decreasing the probability of triggering the fusion protein prematurely. However, data to date 
do not rule out the possibility that paramyxoviruses enter at the plasma membrane or have 
more than one entry pathway. Lipid mixing and particle uptake do not necessarily correlate with 
productive infection (218), and thus determining the route of entry for productive infection 
remains an important goal. 
While a remarkable wealth of information has been gathered since the discovery of 
HMPV a little over a decade ago (352), a lot of basic questions about the lifecycle of the virus 
and the cellular factors involved in infection remain to be answered. The work presented here 
represents an important step forward in our understanding of the physiology of HMPV infection. 
We provided evidence that the viral attachment step is mediated by HSPGs and that entry likely 
occurs through endocytosis. Furthermore, we identified important regions where potential 
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electrostatic interactions could play a role in the triggering of HMPV F at low pH. A better 
understanding of the triggering of HMPV F, the conformational changes that take place, and a 
more comprehensive understanding of the roles of HSPGs in the context of HMPV pathogenesis 
as well as the discovery of higher affinity receptors or coreceptors will significantly advance our 
knowledge of the lifecycle of this virus, paving the way for the development of therapeutics that 
will block the attachment of HMPV to cells. 
Recent studies on membrane fusion and entry of paramyxoviruses have provided 
significant advancements in our understanding of these processes, paving the way for the 
exploration of potential therapeutic targets using small molecules (335) and peptide inhibitors 
against the fusion protein (186, 324). While there are indeed conserved regions in the surface 
glycoproteins that translate into similarities in overall mechanisms of binding and entry, there is 
a significant degree of diversity in this family that provides for unique aspects of receptor 
binding, triggering, membrane fusion, and viral entry. Given the importance of this family of 
viruses to human health and global economy, more studies are clearly needed to better 
understand both the conserved mechanisms and the unique aspects of paramyxovirus 
glycoprotein function. 
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Appendix I: Abbreviations Used in this Document 
6-HB Six-helix bundle 
CA Constitutively active 
DN Dominant negative 
ER Endoplasmic Reticulum 
F Fusion 
FBS Fetal Bovine Serum 
FP Fusion peptide 
GAG Glycosaminoglycan 
GFP Green fluorescent protein 
GPI Glycophosphatidylinositol 
HeV Hendra virus 
HEV Hepatitis E virus 
HIV Human immunodeficiency virus 
HMPV Human metapneumovirus 
HN/G/H Paramyxovirus attachment protein 
HPIV1 Human parainfluenza virus 1 
HRA Heptad repeat A 
HRB Heptad repeat B 
HS Heparan sulfate 
HSPG Heparan sulfate proteoglycans 
HSV-1 Herpes simplex virus 1 
HTLV-1 Human T-cell leukemia virus 1 
MeV Measles virus 
mβCD Methyl-β-cyclodextrin 
NiV Nipah virus 
P/S Penicillin/Streptomycin 
PAGE Polyacrylamide gel electrophoresis 
PI3K Phosphoinositide 3 – kinase 
PIV3 Parainfluenza virus 3 
PIV5 Parainfluenza virus 5 
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PKC Protein kinase C 
RSV Respiratory Syncytial virus 
Sdc4 Syndecan-4 
SeV Sendai virus 
TM Transmembrane domain 
VOPBA Virus overlay protein binding assay 
VSV Vesicular stomatitis virus 
WT Wild type 
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